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YHTEENVETO 
Haimasyöpä on yksi huonoennusteisimpia syöpiä, johon sairastuu ja kuolee 
Suomessa vuosittain lähes 900 ihmistä. Nykyiset syöpälääkkeet tehoavat 
haimasyöpään heikosti ja taudin ennuste on erittäin huono. Duktaalinen 
adenokarsinooma on haimasyövän yleisin muoto ja termi ’haimasyöpä’ viittaa tässä 
työssä nimenomaan duktaaliseen alatyyppiin. Tässä tutkimuksessa pyrittiin 
kartoittamaan haimasyövän molekyylitason muutoksia ja löytämään uusia geenejä, 
joita voitaisiin tulevaisuudessa hyödyntää taudin diagnostiikassa ja hoidossa. 
Tutkimus keskittyi erityisesti kromosomissa 19 sijaitsevaan 19q13-monistuma-
alueeseen, tässä lokuksessa geenimonistuman kautta aktivoituvien geenien 
tunnistamiseen ja niiden toiminnalliseen karakterisointiin.  
Työn ensimmäisessä vaiheessa hyödynnettiin fluoresenssi in situ hybridisaatio -
menetelmää, jonka avulla kartoitettiin 19q13 alueen kopiolukumuutoksia 
haimasyöpäsolulinjoissa. Tämän tutkimuksen avulla pystyttiin rajaamaan 1,1 Mb:n 
suuruinen monistuma-alue. Rajatun alueen sisältä löytyi vielä 600 kb:n kokoinen 
ydinalue, jossa monistuman taso oli huomattavan suuri. Seuraavaksi monistuman 
yleisyys määritettiin primaareissa haimakasvaimissa, ja sen sen mahdollista yhteyttä 
kliinis-patologisiin tekijöihin tutkittiin laajassa yli 500 potilaan aineistossa. 
Monistuman havaittiin esiintyvän yli 10%:ssa haiman adenokarsinoomia, ja mikä 
tärkeintä, sen huomattiin korreloivan kasvaimen huonon erilaistumisasteen ja taudin 
levinnäisyyden kanssa. Monistuma ei suoranaisesti ollut yhteydessä potilaiden 
eloonjäämiseen, mutta potilaiden, joilla esiintyi korkea-asteista 19q13 monistumaa, 
keskimääräinen elinaika oli selvästi lyhyempi kuin niiden, joilla kyseistä 
monistumaa ei ollut.  
Monistuma-alueella sijaitsevat geenit tunnistettiin julkisten tietokantojen ja 
ihmisen genomikartoituksen tarjoaman tiedon avulla, ja niiden ilmentymistasot 
määritettiin kvantitatiivista reaaliaikaista PCR-tekniikkaa hyödyntäen. Tämä 
analyysi osoitti, että useat alueella sijaitsevat geenit ilmentyivät voimakkaammin 
monistuman myötä. Seuraavaksi tutkittiin näiden geenien hiljentämisen vaikutusta 
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haimasyöpäsolujen elinvoimaisuuteen RNA-inhibitio (RNAi) -menetelmän avulla. 
Geenit, joiden hiljentäminen heikensi solujen elinkykyä, luokiteltiin mahdollisiksi 
monistuman kohdegeeneiksi. MED29-geeni (IXL) osoittautui näissä kokeissa 
vahvimmaksi kandidaatiksi ja oli myös voimakkaasti yli-ilmentynyt monistuman 
omaavissa soluissa, joten jatkotutkimukset keskittyivät siihen.  
RNA-inhibitioon perustuvaa geenin hiljentämistä hyödynnettiin 
haimasyöpäsoluissa, joissa MED29:n ilmentymistaso oli sisäsyntyisesti korkea. 
Hiljentäminen johti useiden syöpäsoluille tyypillisten ominaisuuksien, kuten 
solukasvun ja solujen migraatio- ja invaasiokyvyn, heikentymiseen. Lentivirus-
pohjainen MED29-geenin yli-ilmentäminen haimasyöpäsoluissa, joissa se ei 
luonnollisesti ilmentynyt, johti yllättäen myös kasvun hidastumiseen. Merkittävin 
löydös oli kuitenkin se, että näiden solujen istutus immuunipuutteiseen hiireen johti 
dramaattiseen kasvainten määrän ja koon pienenemiseen kontrollisoluihin 
verrattuna, viitaten selvästi kasvua rajoittavaan ominaisuuteen.  
Mikrosirupohjaista genominlaajuista tutkimusmenetelmää käytettiin hyväksi 
selvittämään mekanismeja, jotka aiheuttivat kasvuerot MED29- ja kontrollisolujen 
välillä. Tutkimus toi esiin suuren joukon erilaisesti ilmentyviä geenejä, jotka 
geeniontologiatutkimuksen perusteella osallistuvat mm. solusyklin ja 
solunjakautumisen säätelyyn. Yleisesti ottaen mikrosirututkimus paljasti, että 
MED29 vaikuttaa useiden solusykliä säätelevien geenien toimintaan tavalla, joka 
johtaa solujakautumisen pysähtymiseen.  
Yhteenvetona voidaan todeta, että 19q13-kromosomialueen monistuma on 
kliinisesti merkittävä ja se korreloi kasvaimen erilaistumis- ja levinnäisyysasteeseen 
haimasyövässä. Korkea-asteinen 19q13 monistuma johtaa useiden geenien 
ilmentymisen lisääntymiseen, mutta MED29 vaikuttaa tällä hetkellä olevan yksi 
biologisesti merkittävimmistä monistuman kohdegeeneistä. MED29-geenin 
hiljentäminen rajoitti solun kasvua, elinkykyä ja muita syöpäsolulle tunnusomaisia 
piirteitä haimasyöpäsoluissa, joissa se oli monistunut. Soluissa, joissa MED29- 
geenin monistumaa ei ollut, johti sen ilmentäminen myös heikentyneeseen 
solukasvuun ja rajoitti huomattavasti tuumorikasvua hiireen istutetuissa 
siirrännäisissä. MED29 on osa transkription säätelyyn osallistuvaa 
mediaattorikompleksia, jonka on hiljattain osoitettu olevan osallisena useassa 
syövässä. Tämä tutkimus osoittaa nyt ensimmäistä kertaa, että MED29:llä on 
merkittävä, mutta kompleksinen rooli haimasyövän patogeneesissä. 
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ABSTRACT 
Pancreatic cancer is one of the most aggressive malignancies with high mortality. In 
Finland, it affects about approximately 900 people annually and nearly the same 
number of people die of it. The current treatment strategies for pancreatic cancer are 
ineffective, and the prognosis is very poor. Ductal adenocarcinoma is the most 
common form of pancreatic cancer and the term ’pancreatic cancer’ refers here to 
the ductal subtype. This study aimed to characterize the molecular aberrations in 
pancreatic cancer and to highlight putative target genes that may serve as novel 
diagnostic markers or targets for therapy. More specifically, it concentrated on the 
characterization of the amplified region at chromosome 19q13 and functional 
studies of putative target genes within this locus.  
The first study explored DNA copy number changes at the 19q13 locus in 
pancreatic cancer cell lines using fluorescence in situ hybridization (FISH). A 1.1 
Mb amplicon with a 660-kb core region of high-level amplification was delineated. 
The prevalence of the 19q13 amplification and its possible correlation with 
clinicopathological features was investigated in over 500 primary pancreatic tumors. 
19q13 copy number changes were found in more than 10% of ductal 
adenocarcinomas. Importantly, these changes correlated with advanced tumor stage 
and grade. In addition, the median survival time of patients with 19q13 
amplification was considerably shorter than that of patients with a normal copy 
number.  
Genes located within the amplified region were identified using public genomic 
databases, and their expression levels were defined by quantitative real-time PCR 
(qRT-PCR). Interestingly, a number of genes within the amplicon were 
overexpressed through amplification. To select functionally important targets, an 
RNA inhibition (RNAi)-based viability screen was applied to identify genes for 
which downregulation attenuated cell viability. The expression screen and RNAi 
profiling results identified MED29 (IXL) as the most promising candidate target in 
the 19q13 amplicon.  
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Subsequent functional studies concentrated on MED29. RNAi-mediated 
downregulation of MED29 in cells with high endogenous MED29 expression led to 
inhibition of several cancer cell-associated characteristics, such as cell growth, 
migration, invasion, and colony formation on soft agar. Unexpectedly, the lentiviral-
based induction of MED29 expression in pancreatic cancer cells with low 
endogenous MED29 levels also led to growth inhibition. More important, when 
MED29-overexpressing pancreatic cancer cells were inoculated into nude mice, a 
dramatic reduction in tumor incidence and tumor growth was observed compared to 
mice inoculated with control cells.  
A genome-wide microarray-based gene expression analysis was utilized to 
uncover the mechanisms involved in the growth differences between the MED29 
and the control cells. This analysis identified a large group of differentially 
expressed genes, and subsequent ontology analyses revealed their association with 
cell cycle- and cell division-related processes. Overall, the microarray data show 
that several cell cycle regulatory genes were affected by MED29 expression in a 
way that led to cell cycle inhibition.  
To conclude, amplification of the 19q13 chromosomal locus has clinical 
significance and correlates with tumor stage and grade in pancreatic cancer. 
Amplification of 19q13 leads to the upregulation of multiple genes, of which 
MED29 represents a putative target gene. Silencing of MED29 in pancreatic cancer 
cells with a high MED29 expression level resulted in reduced cell growth and 
survival and inhibited several cancer cell-associated characteristics. In contrast, 
induced MED29 overexpression in pancreatic cancer cells with low endogenous 
levels of the protein led to reduced growth and, importantly, inhibited tumor 
formation in a mouse xenograft model. MED29 is part of a large, multisubunit 
complex that is involved in the regulation of transcription and has recently been 
linked to the pathogenesis of several cancers. This study shows for the first time that 
MED29 possesses an important but complex role in pancreatic cancer pathogenesis. 
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INTRODUCTION 
The pancreas is a glandular organ located in the abdominal cavity behind the 
stomach. It is an important regulator of protein and carbohydrate digestion and 
glucose homeostasis. The exocrine component of the pancreas is composed of 
acinar and ductal cells that produce and deliver pancreatic juice containing digestive 
enzymes into the gastrointestinal tract to facilitate the breakdown of carbohydrates, 
proteins and fats (Bardeesy & DePinho, 2002; Hezel et al., 2006). The endocrine 
component of the pancreas is composed of four specialized cell types that form 
clusters called Islets of Langerhans. It is responsible for the regulation of 
metabolism and glucose homeostasis through the secretion of hormones, including 
insulin, glucagon and somatostatin (Bardeesy & DePinho, 2002; Hezel et al., 2006). 
Typical diseases of the pancreas include diabetes, pancreatitis and pancreatic cancer. 
Pancreatic cancer affects approximately 230,000 people every year worldwide 
and is the eighth most common cause of cancer-related death (Parkin et al., 2005). 
In Finland, pancreatic cancer accounts for approximately 900 cases per year and is 
slightly more common among men than women (The Finnish Cancer Registry). The 
median survival of patients with pancreatic cancer is less than six months, and the 
five-year survival rate is less than 5% (Hezel et al., 2006; Jemal et al., 2009). The 
poor prognosis of this malignancy results from its ability to rapidly invade the 
lymphatic system and surrounding tissues and to metastasize to distant sites before 
diagnosis (Hezel et al., 2006). The aggressive biology of pancreatic cancer and its 
resistance to available therapies generally preclude curative treatment at the time of 
diagnosis. Less than 20% of pancreatic carcinomas are localized to the pancreas and 
are resectable when diagnosed (Freitas et al., 2009; Hidalgo, 2010).  
Pancreatic cancer evolves through sequential genetic and epigenetic changes in 
the ductal epithelium over a prolonged period (Bardeesy & DePinho, 2002; Maitra 
& Hruban, 2008). Pancreatic cancer seldom affects young people; it is a disease of 
the elderly caused by the gradual accumulation of genetic and epigenetic changes 
that eventually provide tumor cells with a growth advantage and positive selection 
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over non-cancerous cells. The histopathological picture of pancreatic carcinoma and 
its precursor lesions, together with the accompanying molecular profiles, have 
formed the framework for current research on pancreatic cancer (Hruban et al., 
2000; Bardeesy & DePinho, 2002). In addition, recent methodological achievements 
as well as the sequencing of the human genome have revolutionized cancer research 
and provided excellent tools for the exploration of the molecular events that take 
place in the development of cancer (Bell, 2010). High-throughput profiling 
technologies have produced a wealth of data pertaining to somatic alterations in 
pancreatic cancer, including mutations, deletions, and amplifications (Jones et al., 
2008), thus increasing our knowledge of the molecular events that take place in 
pancreatic cancer tumorigenesis. However, a number of cancer-associated genes 
remain to be discovered and functionally characterized within the altered regions 
(Buchholz & Gress, 2009).  
This study aims to investigate specific molecular alterations in pancreatic 
cancer and explore their clinical importance, identify putative new amplification 
target genes, and finally, characterize the function of the most promising candidates. 
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REVIEW OF THE LITERATURE 
1. Molecular alterations in cancer  
Cancer is thought to evolve through the accumulation of genetic and epigenetic 
changes that confer cancerous cells a selective advantage over the non-cancerous 
cell population (reviewed by Ponder, 2001). It is seen as a stepwise evolutionary 
process where a single mutation provides an initial growth or survival advantage to 
one cell and is then followed by additional changes, finally leading to the clonal 
expansion of cells with multiple genetic changes and unlimited growth potential 
(reviewed by Kinzler & Vogelstein, 1996). During tumor development, a cancer cell 
must acquire certain characteristics to become malignant: self-sufficiency in growth 
signals, insensitivity to growth regulatory signals, a means to escape from apoptosis, 
unlimited replication potential, sustained angiogenesis, and the ability to invade 
tissue and metastasize, the features generally known as the hallmarks of cancer 
(reviewed by Hanahan & Weinberg, 2000).  
Cancer cells obtain these characteristics through diverse mechanisms that lead 
to changes in gene sequence, structure, copy number, and expression (Albertson, 
2006; Bell, 2010). These changes can affect the target protein in a way that allows 
tumor cells a growth advantage or prolonged survival. Aberrations are brought 
about at the genomic level by various mechanisms, including altered karyotypes, 
mutations and epigenetic regulation (Bell, 2010). Mutations, defined as permanent 
changes in the DNA sequence, are generally divided into small and large-scale 
aberrations. Small-scale mutations include small deletions, insertions, and point 
mutations that can lead to a truncated, altered, or unaffected protein product 
(Vogelstein & Kinzler, 2004). A point mutation causes a single nucleotide exchange 
that can be silent (does not change the amino acid), cause a change in the amino acid 
sequence and possibly altered protein structure (missense mutation) or introduce a 
premature stop codon and result in a truncated protein (nonsense mutation) 
(Vogelstein & Kinzler, 2004). Deletions and insertions typically result in frameshift 
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changes (i.e., a shift in the reading frame of the nucleotide codon during translation) 
that usually lead to an altered amino acid sequence and changed protein. They can 
also result in splice site mutations if the insertion or deletion of nucleotides occurs at 
the site of splicing (removement of introns) during the RNA processing. Large-scale 
mutations or chromosome-level alterations involve gains and losses of chromosomal 
loci (i.e., amplifications and deletions) and chromosomal rearrangements, such as 
inversions and translocations (Albertson et al., 2003). Amplifications (see detailed 
discussion in the following chapter) and deletions cause changes in gene dosage and 
are commonly observed in human cancers. Inversion is a chromosomal 
rearrangement in which a segment of a chromosome is reversed within a single 
chromosome. Translocation involves the rearrangement of two chromosomes. 
Translocations may lead to the formation of chimeric proteins when two genes are 
joined together (Croce, 2008). Genes can also be translocated to sites at which their 
transcription is affected. Chromosomal abnormalities also include aberrations in 
chromosome number, referred to as aneuploidy, which are characteristic of several 
human cancers.  
1.1 Tumor suppressor genes and oncogenes 
Acquired or inherited aberrations typically affect two major classes of cancer genes: 
tumor suppressor genes and oncogenes (reviewed by Vogelstein & Kinzler, 2004). 
Tumor suppressor genes can be divided into three classes: gatekeepers, caretakers, 
and landscapers. Gatekeepers are growth regulatory genes that control important 
cellular processes such as proliferation, cell cycle and DNA repair (Sherr, 2004; 
Stratton, 2009). They usually become inactivated during tumor development 
through allelic loss, an inactivating mutation or epigenetic silencing (Vogelstein & 
Kinzler, 2004). These inactivating events are generally referred to as loss-of-
function aberrations. According to the Knudson two-hit hypothesis (Knudson, 
1971), two hits are needed to inactivate both alleles of a tumor suppressor gene. If 
only one allele is affected, the remaining allele can produce a functional protein. 
However, in the case of haploinsufficiency, the loss of a single allele is sufficient to 
abolish the function of the gene (Fero et al., 1998). The first identified tumor 
suppressor gene was RB1 (retinoblastoma 1), which is recognized as a causative 
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affected gene in retinoblastoma patients (Knudson, 1971). Another well-known 
example of a tumor suppressor gene that is commonly silenced during tumor 
development is TP53 (Sherr, 2004). TP53 encodes the p53 protein, which plays a 
fundamental role in the control of the cell cycle and the induction of apoptosis. 
Another class of tumor suppressor genes includes the caretakers that sustain 
genomic integrity and thus indirectly control cancer progression by maintaining a 
low mutation rate (Kinzler & Vogelstein, 1997). This subclass of tumor suppressors 
includes mismatch repair (MMR) genes, nucleotide-excision repair (NER) genes, 
and base-excision repair (BER) genes, which are all responsible for correcting 
mistakes that arise in DNA during replication (Vogelstein & Kinzler, 2004). Some 
stability genes, for example, BRCA1 and BRCA2, control large genome-related 
processes such as recombination and chromosomal segregation (Vogelstein & 
Kinzler, 2004). Mutations in caretakers commonly lead to genomic instability. The 
third subclass of tumor suppressor genes, called landscapers, includes genes that 
modulate the microenvironment in which the cells grow (Kinzler & Vogelstein, 
1998). The growth of tumor cells is highly dependent on their interactions with 
stromal cells and the extracellular matrix (Bissell & Radisky, 2001). Faulty 
landscaper genes could contribute to the growth of tumor cells by causing 
abnormalities in the tumor microenvironment (Macleod, 2000). PTEN and SMAD4 
have been indicated as potential landscaper genes (Kinzler & Vogelstein, 1998; 
Macleod, 2000). 
Proto-oncogenes are normal cellular genes that can turn into oncogenes when 
abnormally activated, most commonly by mutation, amplification, or chromosomal 
rearrangement (Figure 1). Accordingly, alterations leading to the activation of an 
oncogene are called gain-of-function mutations. They cause changes in the DNA 
that affect the protein product in a way that leads to abnormal activity or loss of 
regulation, thus providing the tumor cell with a growth advantage (Todd & Wong, 
1999; Vogelstein & Kinzler, 2004). A point mutation in a proto-oncogene can 
change the protein structure in a way that alters its normal function, such as by 
constitutive activation. Translocations, which are caused by chromosomal 
rearrangements, may give rise to novel fusion proteins with altered function and 
capability. A classical example of such an oncogenic fusion gene is ABL-BCR 
generated by a t(9;22) translocation. The resulting chromosome is known as the 
Philadelphia chromosome in chronic myelogenous leukemia (Shtivelman et al., 
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1985). Alternatively, a gene can be translocated to a new location that is under the 
control of a strong promoter, leading to induced expression. Translocations are more 
common in lymphomas and leukemias, but they are also found in solid tumors 
(Nambiar et al., 2008). As an example, fusion of the TMPRSS2 gene with ETS 
transcription factor genes has been observed in prostate cancer (Tomlins et al., 
2005). Amplification refers to a selective increase in gene dosage, which often leads 
to increased messenger RNA (mRNA) and protein expression (Albertson, 2006). It 
is a typical mechanism of oncogene activation and will be discussed later in more 
detail (see below). In contrast to tumor suppressor genes, oncogenes act in a 
dominant fashion, meaning that a single altered allele provides a tumor cell with a 
growth advantage and may lead to uncontrolled growth (Todd & Wong, 1999). 
Oncogenes typically encode growth factors (e.g., PDGF), growth factor receptors 
(e.g., ERBB2), transcription factors (e.g., MYC), chromatin remodelers (e.g., ALL1), 
signal transducers (e.g., RAF1), and apoptosis regulators (e.g., BCL2) (Croce, 2008). 
 
 
 
 
Figure 1. Common oncogene activation mechanisms. 
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1.2 Gene amplification in cancer  
Gene amplification, defined as a selective increase of DNA copy number in a 
specific chromosomal region, is a common mechanism used by solid tumors to 
activate genes that contribute to tumor development (Albertson et al, 2003). 
Increased DNA copy number of an otherwise normal gene is expected to lead to 
increased levels of mRNA and protein, thus giving rise to increased activity or 
function of the protein.  
1.2.1 Manifestation and mechanisms 
Amplified DNA can be organized in different ways in mammalian nuclei: as 
extrachromosomal units, consisting of sub-microscopic episomes and 
cytogenetically visible double minutes (DMs); as repeated elements at a single 
locus, seen as homogenously staining regions (HSRs); or scattered at various sites 
throughout the genome (Schwab, 1999; Albertson, 2003). HSRs, DMs, and 
episomes may contain genetic material from different chromosomal origins 
(Myllykangas & Knuutila, 2006). DMs are acentric, atelomeric, and autonomously 
replicating circular segments of DNA (Hahn, 1993; Albertson, 2006) that are 
thought to arise via episome excision (Wahl et al., 1989). They can also be formed 
through HSR breakdown and subsequent circularization (Singer et al., 2000). 
Similarly, DMs can relocate into the genome after a double-stranded DNA break to 
form an HSR (Coquelle et al., 1998). According to the breakage-fusion-bridge 
(BFB) model, which was originally proposed by McClintock based on her studies of 
maize, amplification evolves from repeated cycles of fusion and breakage of 
chromosomes (McClintock, 1942). This cycle begins with the formation of a 
dicentric chromosome resulting from a chromosomal break or telomere dysfunction. 
At anaphase, the centromeres are pulled in opposite directions and form a bridge. A 
breakage generates sticky ends that fuse after replication, generating a chromosome 
with inverted duplicated terminal sequences (Savelyeva & Schwab, 2001). This 
cycle goes on until the chromosomal ends are stabilized. The sequential events in 
the BFB cycle, including amplification due to telomere loss (Murnane & Sabatier, 
2004) or chromosomal breakage (Coquelle et al., 1997), formation of fused sister 
chromatids and anaphase bridges (Shimizu et al., 2005), formation of inverted 
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repeats (Toledo et al., 1992), and intra-tumor heterogeneity (Gisselsson et al., 2000), 
have been observed in vivo, providing further support for this model. Additional 
amplification mechanisms have been proposed, including over-replication and 
unequal exchange (Windle & Wahl., 1992; Smith, 1990). The over-replication 
model is based on multiple initiations of replication during a single cell cycle, 
giving rise to onion skin-like structures (Windle & Wahl, 1992), whereas unequal 
exchange is based on unequal recombination of either homologous or non-
homologous chromatids, leading to duplication in one chromatid and deletion in the 
other (Smith, 1990). Common chromosomal fragile sites, defects in DNA 
replication and telomere dysfunction are thought to promote amplification events 
(Myllykangas & Knuutila, 2006).  
1.2.2 Clinical implications 
Gene amplification in mammals is an unscheduled event that occurs in response to 
cytotoxic drugs and during tumorigenesis (Schwab, 1999). It has been associated 
with aggressive tumors and decreased survival (Savelyeva & Schwab, 2001). 
Therefore, it may be useful as a diagnostic and prognostic marker in the prediction 
of therapeutic response and as a target for drug design (Albertson et al., 2003). 
Amplified targets with clinical significance as prognostic markers include the 
MYCN oncogene in neuroblastoma (Savelyeva & Schwab, 2001) and MYC and 
ERBB2 in breast cancer (Slamon et al., 1987; Al-Kuraya et al., 2004). Amplification 
of the ERBB2 oncogene is assessed to predict the therapeutic response and select 
appropriate treatment strategies for breast cancer (Masood et al., 2002; Mass et al., 
2005). In addition, amplified oncogenes can be excellent targets for specific 
therapies because tumors can become dependent on their increased expression, a 
phenomenon known as “oncogene addiction” (Weistein et al., 2002). A well-known 
example of an anti-cancer agent targeting a specific amplified oncogene is 
trastuzumab (Herceptin), which targets ERBB2 (Carter et al, 1992).  
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1.2.3 Target identification  
Amplifications and other copy number variations (gains and losses) can be detected 
at the genomic level by several methods, most commonly by microarray-based 
approaches. The development of new microarray technologies and high-throughput 
screening methods has boosted the mapping of tumor genomes and eased the 
identification of tumor-associated genes. Conventional comparative genomic 
hybridization (CGH) (Kallioniemi et al., 1992), which is based on competitive 
hybridization of tumor and reference DNA to metaphase chromosomes, has 
provided the basis for the methods currently used for the detection of unbalanced 
variants in tumor genomes. CGH can be applied to obtain copy number data at the 
chromosome band-level, whereas spotted arrays provide much better resolution. 
CGH arrays with different platforms, such as BAC clones (Cai et al., 2002), cDNA 
clones (Pollack et al., 1999), and oligonucleotides (Barrett et al., 2004), have been 
developed. In addition, microarrays designed for single nucleotide polymorphism 
(SNP) detection can be applied to detect DNA copy number changes. 
It is necessary to confirm the results of an array-CGH (aCGH) experiment once 
a copy number increase is found. Confirmation is usually achieved by fluorescence 
in situ hybridization (FISH) or quantitative PCR (qPCR). FISH can also be applied 
to further resolve amplification profiles and to redefine the boundaries of an 
amplicon (Feuk et al., 2006). Briefly, molecularly cloned genomic DNA sequences 
(typically BAC clones) are chosen to cover the region of interest, followed by 
fluorescent labeling and hybridization to interphase chromosomes of the 
investigated material. Detection of copy number signals can be laborious by this 
approach, but it can be applied to tissue samples and utilized at a large scale if the 
sample material is printed on a single slide, for example, tissue microarrays (TMAs) 
(Kononen et al., 1998).  
Delineation of the amplicon is followed by the identification of genes within the 
amplified region and expression analysis by quantitative RT-PCR. Expression 
analysis is performed because amplification target genes are expected to be 
overexpressed (Albertson, 2006). Identification of the so-called driver genes (genes 
that promote tumor development) for specific amplicons remains challenging 
because several genes can be amplified and overexpressed within a single amplicon 
(Bärlund et al., 2000; Kauraniemi et al., 2001; Hyman et al., 2002; Heidenblad et al, 
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2005; Pärssinen et al., 2007). Amplicons often contain so-called passenger genes 
that are amplified and overexpressed along with the driver genes but do not promote 
tumor formation. Therefore, functional validation of putative targets is required. 
Efficient methods to obtain biological confirmation of the causal role of putative 
targets include the RNA interference (RNAi)-mediated knockdown of amplified 
genes in overexpressing cells and ectopic expression of target genes in a model 
lacking the amplification (Santarius et al., 2010). At this time, 77 amplified human 
genes with sufficient evidence for a causal role in cancer have been identified 
(Santarius et al., 2010).  
1.2.4 The 19q13 amplicon  
A genome-wide aCGH profiling (Mahlamäki et al., 2004) revealed a high-level 
amplification at 19q13 in pancreatic cancer, which was subsequently confirmed by 
other aCGH studies (Aguirre et al., 2004; Heidenblad et al., 2004; Holzmann et al., 
2004; Bashyam et al., 2005; Gysin et al., 2005, Nowak et al., 2005). The high-
amplification peak in the aCGH profile suggests that this amplicon might be 
biologically important. During the past few years, the 19q13 amplicon has gained 
attention in pancreatic cancer, and several putative target genes have been reported, 
including DYRK1B (Moniaux et al., 2006), PAF1 (Deng et al., 2006) and PAK4 
(Chen et al., 2008). AKT2, a putative oncogene in ovarian cancer, encodes for a 
serine/threonine protein kinase and is also located within this amplicon (Cheng et 
al., 1992). 
In addition to pancreatic carcinomas, 19q13 amplification has been observed in 
a subset of other cancers, including ovarian cancer (Cheng et al., 1992; Bellacosa et 
al., 1995; Thompson et al., 1996; Tang et al., 2002), breast cancer (Kallioniemi et 
al., 1994; Bellacosa et al., 1995; Yu et al., 2009), cervical cancer (Rao et al., 2004; 
Narayan et al., 2007), gastric cancer (Vauhkonen et al., 2007), non-small cell lung 
cancer (Kim et al., 2005), small cell lung cancer (Ried et al., 1994; Petersen et al., 
1997), and urinary bladder cancer (Richter et al., 2000). Table 1 provides examples 
of studies showing 19q13 amplification in several cancers. Only relatively common 
cancers with adequate sample size and a mention of the 19q13 amplification are 
included in Table 1. The 19q13 aberration is a fairly rare event, but it often 
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manifests as a high-level amplification (over 10 copies per cell), suggesting 
biological significance. Importantly, the exact size and location of the amplifications 
in different studies may vary due to the fact that different methods have been used. 
Therefore, one cannot be certain that these amplicons represent the same locus. It is 
possible that several regions of amplification may exist within the 19q13 locus. 
 
Table 1. Examples of studies showing 19q13 amplification in various tumors. 
Reference Tumor type No. of samples Method 
Dohna et al., 2000 Adenocortical carcinoma 22 primary tumors CGH 
Kallioniemi et al., 1994 Breast cancer 33 carcinomas CGH 
Bellacosa et al., 1995 Breast cancer 106 carcinomas Southern 
Yu et al., 2009 Breast cancer 16 carcinomas aCGH 
Rao et al., 2004 Cervical cancer 77 carcinomas CGH 
Narayan et al., 2007 Cervical cancer 21 primary tumors, 8 cell lines aCGH 
Larramendy et al., 1997 Chondrosarcoma 19 tumors CGH 
Knösel et al., 2004 Colorectal cancer 54 carcinomas CGH 
Sniders et al., 2003 Fallopian tube cancer 14 carcinomas aCGH 
van Dekken et al., 2001 Gastric cancer 20 carcinomas aCGH 
Vauhkonen et al., 2007 Gastric cancer 15 carcinomas aCGH 
Huntsman et al., 1999 Glioblastoma 5 cell lines FISH 
Marchio et al., 1997 Hepatocellular cancer 50 carcinomas CGH 
Medina et al., 2009 Lung cancer 25 primary tumors aCGH, FISH 
Terris et al., 1998 Neuroendocrine tumors of digestive 
system 
20 tumors CGH 
Balsara et al., 1997 Non-small cell lung cancer 10 carcinomas, 10 cell lines CGH 
Kim et al., 2005 Non-small cell lung cancer 50 carcinomas aCGH 
Atiye et al., 2005 Osteosarcoma 22 sarcomas aCGH 
Bellacosa et al., 1995 Ovarian cancer 132 carcinomas Southern 
Yamamoto et al., 2009 Ovarian cancer 136 carcinomas FISH 
Mahlamäki et al., 2004 Pancreatic cancer 16 cell lines aCGH 
Kikuchi et al., 2008 Pancreatic cancer 29 carcinomas FISH 
Chen et al., 2008 Pancreatic cancer 42 carcinomas, 27 cell lines ROMA 
Ganguly et al., 2009 Retinoblastoma 25 blastomas SNP genotyping 
Ried et al., 1994 Small cell lung cancer 13 primary tumors aCGH 
Richter et al., 2000 Urinary bladder cancer 1561 carcinomas FISH 
aCGH, array comparative genomic hybridization; CGH, comparative genomic hybridization; FISH, fluorescence in situ 
hybridization; ROMA, representational oligonucleotide microarray analysis; SNP, single nucleotide polymorphism 
1.3 Epigenetics  
In addition to genetic alterations, it has become apparent that epigenetic 
mechanisms play an important role in the evolution and progression of cancer 
(Omura & Goggins, 2009; Feinberg et al., 2006; Ting et al., 2006; Jones & Baylin, 
2007; Esteller, 2007). Epigenetics is defined as hereditable changes in gene 
expression that are not caused by changes in DNA sequence. These events are 
typically mediated by two mechanisms: DNA methylation and histone modification.  
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DNA methylation involves the covalent addition of a methyl group to the 5’ 
position of cytosine pyrimidine, most often at CpG dinucleotides (Omura & 
Goggins, 2009). This modification is brought about and maintained by DNA 
methyltransferases (DNMTs) (Yen et al., 1992; Okano et al., 1998). DNA 
methylation is crucial for normal mammalian development (Okano et a, 1999) but is 
also a key regulator of gene expression in various cancers (Omura & Goggins, 
2009). Several tumor suppressor genes are silenced through promoter 
hypermethylation in cancer but even hypomethylation has been observed in the 
context of gene overexpression (Sato et al., 2003a).  
Histones are the backbone proteins of chromatin, which package DNA into 
structural units called nucleosomes. A nucleosome is a hetero-octamer composed of 
core histone proteins and tightly wound DNA around it. Long, protruding N-
terminal tails of histones on the surface of nucleosomes serve as the main sites of 
biochemical modification, including acetylation, methylation, phosphorylation, 
ubiquitination, SUMOylation, and ADP-ribosylation (Esteller, 2007; Kouzarides, 
2007). Acetylation of lysine residues by histone acetyl transferases (HATs) 
neutralizes the charge between the histone tails and the negatively charged DNA, 
making chromatin more accessible for active transcription. Correspondingly, histone 
deacetylation is mediated by another group of specific enzymes called histone 
deacetylases (HDAs). Histone deacetylation serves as an alternative and 
combinatory route for epigenetic silencing of tumor suppressor genes. 
1.4 Micro-RNAs 
Micro-RNAs (miRNAs) are single-stranded, non-coding RNA molecules of ~22 
nucleotides that function as negative regulators of gene expression in various 
biological processes, such as proliferation, differentiation, and apoptosis (reviewed 
by Esquela-Kerscher & Slack, 2006). Most human miRNAs are located within 
introns of protein-coding or non-coding mRNAs and are transcribed by RNA 
polymerase II. MiRNAs are often only partially complementary to their target 
mRNA sequence and can exert silencing either by translational repression or mRNA 
degradation, depending on the degree of complementarity (Elbashir et al., 2001; 
Brennecke et al., 2005). Perfect or nearly perfect complementarity to target mRNA 
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induces RNA interference (RNAi), leading to the complete degradation of target 
mRNA, whereas imperfect complementarity leads to translational repression. A 
single miRNA can control hundreds of target genes (Lim et al, 2005; Barbato et al., 
2009) and approximately 30% of human genes are estimated to be targeted by 
miRNAs (Lewis et al., 2005; Xie et al., 2005). Aberrant miRNA expression in 
cancer was first observed a few years ago as two miRNAs, miR-15a and miR-16-1, 
were shown to be downregulated or deleted in chronic lymphocytic leukemia (CLL) 
(Calin et al, 2002). Subsequently, several miRNA profiles of various cancers have 
shown aberrant regulation and expression of multiple miRNAs (Calin et al, 2006; 
Zhang et al., 2006; Lee et al., 2007; Porkka et al., 2007). Moreover, recent miRNA 
expression profiling containing multiple cancers clustered different tumor types 
more accurately than mRNA expression profiling (Lu et al., 2005). MiRNAs are 
thought to function in cancer as tumor suppressor genes and oncogenes (Esquela-
Kersher & Slack, 2006). 
2. Pancreatic cancer 
2.1. Epidemiology and risk factors  
Pancreatic cancer is an aggressive disease and one of the deadliest malignancies. In 
2007, age-adjusted incidence rates in Finland were 9.3 per 100,000 among men and 
6.6 per 100,000 among women, whereas mortality rates climbed to 9.0 and 6.9 per 
100,000, respectively (Finnish Cancer Registry, http://www.cancerregistry.fi). Late 
diagnosis and ineffective treatment strategies make pancreatic cancer the third most 
common cause of cancer-related death in Finland. These rates are similar to those 
observed in the Western world (Finnish Cancer Registry, Jemal et al., 2009; Thun et 
al., 2010). Prognosis in pancreatic cancer is poor because of the aggressiveness of 
the disease, lack of early diagnostic tools and profound resistance to treatment. 
Median survival for patients with locally advanced disease is somewhat better than 
for those with metastatic disease, but the overall five-year survival rate among 
pancreatic cancer patients is less than 5% (Jemal et al., 2009; Thun et al., 2010).  
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The causes of pancreatic cancer have been widely explored, but they remain 
largely unknown (reviewed by Hidalgo, 2010). Only a few demographic and 
environmental risk factors and some autosomal dominant genetic disorders have 
been linked to pancreatic cancer (Hezel et al., 2006, Raimondi, 2009). Involvement 
of various environmental risk factors has been implicated, but clear evidence of a 
causative role exists only for smoking (Fuchs et al., 1996; Schuller, 2002; Hezel et 
al., 2006; Raimondi, 2009). Smoking doubles the risk of pancreatic cancer (Maitra 
& Hruban, 2008) and approximately 25% of pancreatic cancer cases are related to 
smoking (Raimondi, 2009). The association between pancreatic cancer and dietary 
factors has been continuously investigated, but no strong or consistent correlation 
has been confirmed (Raimondi, 2009). Obesity and a diet high in meats and fat are 
reported to increase the risk of pancreatic cancer (Michaud et al., 2001; Larsson et 
al., 2007), whereas a so-called healthy lifestyle appears to decrease the risk (Jiao et 
al., 2009). Alcohol consumption does not appear to be a causal factor for pancreatic 
cancer unless it leads to chronic pancreatitis, which has been linked to an increased 
risk (Lowenfels et al., 1993; Lowenfels & Maisonneuve, 2005; Maitra & Hruban, 
2008; Raimondi, 2009). Other known risk factors include advanced age, a family 
history of pancreatic cancer (Klein et al., 2004), and a hereditary predisposition 
(discussed below). Long-standing diabetes confers an increased risk of developing 
pancreatic cancer, but it can also be an early manifestation of the disease (Everhart 
& Wright, 1995; Huxley et al., 2005).  
Approximately 10% of pancreatic cancer patients have an underlying germline 
disorder, while the rest of the cases result from somatic changes (Lynch et al., 1996; 
Schenk et al., 2001; Hezel et al., 2006; Lochan et al., 2008). Hereditary diseases and 
cancer syndromes associated with pancreatic cancer include familial pancreatitis 
(Lowenfels et al., 1997), familial breast and ovarian cancer (Goggins et al; 1996; 
Lynch et al., 2005), familial atypical multiple mole melanoma (FAMMM) (Bartsch 
et al., 2002; Goldstein et al., 2004), Peutz-Jeghers syndrome (Giardiello et al., 
2000), Li-Fraumeni syndrome (Kleihues et al., 1997), hereditary nonpolyposis 
colorectal cancer (HNPCC) syndrome (Yamamoto et al., 2001; Geary et al., 2008), 
familial adenomatous polyposis (FAP) (Giardiello et al., 1993), and cystic fibrosis 
(Maisonneuve et al., 2007). Germline mutations associated with an increased risk 
for pancreatic cancer include among others those targeting the tumor suppressor 
genes APC, BRCA2, CDKN2A/p16, and STK11/LKB1, the DNA mismatch repair 
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gene MLH1, and the trypsinogen gene PRSS1 (Hezel et al., 2006). Germline 
mutations in CDKN2A are primarily linked to FAMMM, but they confer up to a 22-
fold increased risk for pancreatic cancer (Goldstein et al, 2004). BRCA1 and BRCA2 
mutations are responsible for familial breast and ovarian cancers, but they are also 
associated with increased susceptibility to pancreatic cancer. BRCA1 is associated 
with a lower relative risk than BRCA2 (Goggins et al; 1996; Lynch et al., 2005). 
Silencing of STK11/LKB1 is characteristic of Peutz-Jeghers syndrome and confers a 
substantially increased risk of developing pancreatic cancer. Inherited mutations in 
DNA mismatch repair genes, including MLH1 and MSH2, are typically found in 
HNPCC, but they are also linked to pancreatic cancer susceptibility (Yamamoto et 
al., 2001; Geary et al., 2008). Further, patients with familial pancreatitis caused by 
germline mutations in PRSS1 have an over 50-fold increase in the incidence of 
pancreatic cancer (Lowenfels et al., 1997). FAP is an autosomal dominant disease of 
the colon caused by mutated APC, which confers an intermediate risk for pancreatic 
cancer (Giardiello et al., 1993). The germline mutations discussed here account for 
less than 20% of pancreatic cancer prone familial cases, implying that additional 
predisposing genes and loci exist (Hezel at el., 2006). One such susceptibility locus 
showing autosomal dominant inheritance has been identified at the 4q32-43 locus 
(Eberle et al., 2002). 
2.2. Pancreatic cancer pathology  
The pancreas is composed of two compartments: the exocrine and the endocrine 
pancreas. The endocrine pancreas contains four special cell types gathered together 
into clusters called Islets of Langerhans that are embedded between the exocrine 
units of the pancreas (Figure 2) (Bardeesy & DePinho, 2002; Hezel et al., 2006). 
The endocrine pancreas regulates glucose homeostasis through the secretion of 
hormones such as insulin and glucagon. The exocrine compartment of the pancreas 
accounts for 80% of the tissue mass and is composed of three types of cells: ductal, 
acinar and centroacinar cells (Hezel et al., 2006). Ductal cells are cubically shaped 
cells that form the ductal network of the pancreas. The acinar cells are organized 
into functional units at the end of the ducts (Figure 2). The centroacinar cells are 
located in the acinar units between the acinar and the ductal cells (Hezel et al., 
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2006). The exocrine pancreas is involved in digestion and secretes digestive 
enzymes into the duodenum.  
 
 
 
Figure 2. Anatomy of the pancreas illustrating its gross anatomy (upper left), the 
exocrine compartment (upper right), a single acinus (lower left) and a pancreatic 
islet surrounded by the exocrine tissue (lower right) (Bardeesy & DePinho, 2002. 
Reprinted with permission). 
 
Tumors of the pancreas are roughly divided into endocrine and exocrine 
tumors. This study focuses on exocrine tumors, and more specifically, on pancreatic 
ductal adenocarcinoma (PDAC), which is the most common form of pancreatic 
cancer, accounting for approximately 85% of all cases (Mihaljevic et al., 2010). 
According to the WHO (World Health Organization) classification system, 
pancreatic exocrine tumors are divided into benign, borderline, and malign tumors 
according to their biological behavior. They are histologically graded as well, 
moderately, and poorly differentiated (Klöppel et al., 1996). The most widely 
recognized staging of pancreatic cancer relies on TNM classification from 1987, 
which is based on the extent of the primary tumor (T), regional lymph node status 
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(N), and metastatic status (M). Pancreatic exocrine carcinomas encompass ductal 
adenocarcinomas, osteoclast-like giant cell tumors, serous cystadenocarcinomas, 
mucinous cystadenocarcinomas, intraductal papillary-mucinous carcinomas, acinar 
cell carcinomas, pancreatoblastomas, solid-pseudopapillary carcinomas, and 
miscellaneous carcinomas including other extremely rare forms of epithelial 
carcinomas not mentioned above (Klöppel et al., 1996).   
Ductal adenocarcinomas commonly arise in the head of the pancreas and are 
characterized by infiltrating neoplastic epithelium and intense desmoplastic reaction 
(Hezel et al., 2006; Hidalgo, 2010). This dense, poorly vascularized tumor stroma 
forms a microenvironment that actively interacts with tumor cells, promoting 
tumorigenesis (Chu et al., 2007; Mahadevan et al., 2007; Olive et al., 2009). The 
pancreatic stellate cells or myofibroblasts are essential players in the formation and 
turnover of the tumor stroma along with fibroblasts, endothelial cells and 
inflammatory cells (Hildalgo, 2010). For example, pancreatic stellate cells secrete 
collagen and other matrix components in response to various growth factors 
(Masamune et al., 2009). The importance of the interplay between tumor cells and 
the surrounding microenvironment was not understood until recently (reviewed by 
Polyak et al., 2009). The tumor stroma serves not only as a mechanical barrier but 
also as a dynamic compartment that is involved in the whole process of tumor 
formation from initiation to metastasis (Chu et al., 2007; Mahadevan et al., 2007). 
The role of the tumor stroma in chemoresistance of PDAC was convincingly 
demonstrated by Olive et al. (2009) in a work where they reduced the tumor stroma 
in a mouse model by treatment with a hedgehog inhibitor, which led to improved 
delivery of gemcitabine and extended overall survival. Vascular, lymphatic, and 
perineural invasion along with infiltration of the spleen and peritoneal cavity are 
characteristic of pancreatic cancer (Hansel et al, 2003; Hezel et al., 2006). 
Pancreatic tumors typically metastasize to the liver and lungs (Hansel et al, 2003; 
Hezel et al., 2006).  
PDAC is generally thought to originate from pancreatic ductal cells because of 
their morphological similarity, although the cell of origin is currently not known 
(Bardeesy & DePinho, 2002; Hezel et al., 2006). PDAC typically manifests as duct-
like structures with varying degrees of cellular atypia (Baumgart et al., 2005; Hezel 
et al., 2006). Valuable information pertaining to disease pathogenesis has emerged 
from morphological examinations of proliferative precursor lesions and mouse 
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models of PDAC, supporting the hypothesis of a ductal origin (Mihaljevic et al., 
2010). However, other pancreatic cell types, such as acinar cells, can also 
transdifferentiate into ductal-like tumor cells, providing an alternative route to 
PDAC (Parsa et al., 1985; Mihaljevic et al., 2010). This hypothesis has been further 
strengthened by studies in transgenic mice (Sandgren et al., 1990; Wagner et al., 
1998). In addition, a small subgroup of pancreatic cancer cells (less than 5%) has 
been found to have cancer stem cell (CSC)-like properties that render them capable 
of asymmetric cell division, thus enabling them to generate both mature cells and 
cancer stem cells (Li et al., 2007; Hermann et al., 2007). The question arises 
whether these cells can give rise to pancreatic cancer. The idea of cancer stem cells 
arose about a decade ago as minor subpopulations of cells within tumors were 
observed to drive tumorigenesis and possess some characteristics of stem cells 
(Reya et al., 2001). Recently, pancreatic cancer stem cells were reported to express 
stem cell-specific surface markers, exert properties of self-renewal and multilineage 
differentiation, and show upregulation of developmental genes such as Sonic 
hedgehog (SHH) and BMI-1 (Lee et al., 2008). The ongoing debate about cancer 
stem cells may also pertain to pancreatic cancer.  
Pancreatic cancer has been suggested to follow a genetic progression model 
(Figure 3) according to which it evolves from benign epithelium to fully invasive 
cancer via premalignant lesions called pancreatic intraepithelial neoplasms 
(PanINs), in parallel with successive accumulation of genetic aberrations (Hruban et 
al., 2000). PanINs exert a spectrum of distinctive morphological changes compared 
to normal ductal epithelium that are suggested to represent gradual stages of 
dysplastic growth (Hruban et al., 2000). This progression model has recently been 
augmented with accompanying desmoplastic changes in the surrounding stroma that 
contribute to malignant transformation (Morris et al., 2010). PanINs are the most 
common and well-studied precursor lesions of the pancreas; other precursor lesions 
include mucinous cystic neoplasms (MCN) and intraductal papillary mucinous 
neoplasms (IPMN) (Brugge et al., 2004; Maitra et al., 2005; Hezel et al., 2006). 
MCNs are large, mucin-producing cystic lesions with a distinctive ovarian-type 
stroma and variable degree of epithelial dysplasia (Brugge et al., 2004; Maitra et al., 
2005; Maitra & Hruban, 2008), whereas IPMNs resemble PanINs morphologically 
but grow into larger cystic structures (Hezel et al., 2006; Maitra & Hruban, 2008). 
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Figure 3. Progression model for pancreatic cancer (Hruban et al., 2000). The 
tumor progression from normal epithelium towards carcinoma in situ occurs 
through precursor lesions called pancreatic intraepithelial neoplasias (PanINs), 
which are linked to specific genetic alterations. Adapted from Am J Pathol 2000, 
156:1821-1825 with permission from the American Society for Investigative 
Pathology.  
2.3. Genetic alterations in pancreatic cancer 
Pancreatic cancer is a disease of germline and somatic genetic alterations. Given 
that approximately 10% of pancreatic cancers are estimated to derive from inherited 
predisposition (Lynch et al., 1996), the vast majority of alterations are sporadic. 
Data suggest stepwise accumulation of specific genetic changes in ductal epithelium 
together with evolving morphological stages (Figure 3) (Hruban, 2000). Alterations 
targeting specific genes along with increasing cellular atypia include activation of 
HER-2/neu (also known as ERBB2) and KRAS oncogenes and inactivation of 
CDKN2A/p16, TP53, BRCA2, and SMAD4/DPC4 tumor suppressor genes (Bardeesy 
& DePinho, 2002; Baumgart et al., 2005; Maitra & Hruban 2008; Hezel et al., 
2006). The HER-2 oncogene is amplified and overexpressed in a variety of solid 
tumors, including pancreatic cancer (Day et al., 1996; Apple et al., 1999; 
Mahlamäki et al. 2002), but this aberration is not the most typical alteration in 
PDAC. Instead, activating point mutations of the KRAS oncogene are among the 
most common genetic changes in pancreatic cancer, occurring in about 90% of cases 
(Maitra & Hruban, 2008; Hidalgo, 2010). KRAS mutations arise in an early low-
grade PanIN lesion (PanIN-1) (Figure 3), leading to constitutively activated Ras 
protein and activation of several proliferative and survival signaling pathways. 
Similarly, 95% of pancreatic tumors have inactivating mutations in the CDKN2A 
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tumor suppressor gene, resulting in the loss of the growth regulatory protein p16 and 
the subsequent loss of cell cycle control (Maitra & Hruban, 2008). CDKN2A 
mutations occur in intermediate lesions (PanIN-2) and are followed by inactivating 
mutations in SMAD4, TP53, and BRCA2 in late lesions (PanIN-3) (Figure 3). 
SMAD4 or DPC4 (deleted in pancreatic cancer) is inactivated in 50% of pancreatic 
tumors by homozygous deletion or intragenic mutation. SMAD4 is involved in 
TGFβ signaling and provides tumor cells with a selective growth advantage when 
abrogated (Siegel et al., 2003). TP53 is inactivated in 50-75% of pancreatic cancers, 
leading to abnormal cell division and survival with further accumulation of genetic 
defects (Vogelstein & Kinzler, 2004). Loss of BRCA2 affects approximately 10% of 
pancreatic carcinomas, giving rise to increased genomic instability, which is 
characteristic of PDAC. Telomere shortening is also a typical feature of pancreatic 
cancer, occurring at the early stages of progression (van Heek et al., 2002; 
Ranganathan et al., 2009). In addition, developmental pathways, including 
Hedgehog, Notch, and Wnt-β-catenin signaling pathways, are reported to become 
re-activated during PDAC tumorigenesis (Berman et al., 2003; Miyamoto et al., 
2003; Zeng et al., 2006; Pasca di Magliano et al., 2007).  
Several genetically engineered mouse models have been created to study 
pancreatic cancer progression, most of which are based on activated KRAS 
(reviewed by Morris et al., 2010). KRAS belongs to the RAS superfamily of 
GTPases and mediates a number of cellular functions from proliferation to 
differentiation and survival (Malumbres & Barbacid, 2003). It is nearly universally 
mutated in advanced PDACs and carries activating mutations at early premalignant 
stages. A conditional, genetically engineered, KRAS-driven mouse model has been 
shown to recapitulate the progression observed in humans from PanIN lesions to 
invasive PDAC (Hingorani et al., 2003). This process is further accelerated if the 
model is combined with the inactivation of appropriate tumor suppressors, such as 
CDKN2A (Aguirre et al., 2003), TP53 (Hingorani 2005) and SMAD4 (Bardeesy et 
al., 2006). The role of different developmental pathways in PDAC development has 
been actively studied using transgenic mice (reviewed by Morris et al., 2010). These 
KRAS-driven models have provided valuable knowledge about the initiation and 
progression of PDAC.  
Genomic changes in pancreatic cancer include multiple types of aberrations 
from losses and gains of whole chromosomes to changes at selected chromosomal 
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loci (Baumgart; 2005). Alterations are often frequent and heterogenous. Cytogenetic 
analysis of primary pancreatic tumors and cell lines have revealed multiple, 
nonrandom numerical and structural chromosomal abnormalities (Johansson et al., 
1992; Bardi et al., 1993; Griffin et al., 1995; Höglund et al., 1998) including 
translocations, chromosomal breaks, and amplifications. Highly complex karyotypes 
with various aberrations and large intratumoral heterogeneity are often observed 
(Griffin et al., 1995; Gorunova et al., 1998). Studies using conventional CGH as 
well as recent array-based CGH methods have revealed several chromosomal 
regions of recurrent losses and gains in pancreatic cancer including losses of 3p, 4q, 
6q, 8p, 9p, 13q, 18q, and 22q and gains of 5p, 7p, 7q, 8q, 11q, 12p, 17q, 19q and 
20q (Mahlamäki et al., 1997, 2004, Gorunova et al., 1998; Schleger et al., 2000; 
Harada et al., 2002; Aguirre et al., 2004; Heidenblad et al., 2004; Gysin et al., 2005; 
Nowak et al., 2005). Amplification of AKT2 (a known oncogene in ovarian cancer) 
on chromosome 19q has been reported in 10%–15% of pancreatic cancers (Cheng et 
al., 1996; Miwa et al, 1996) and amplification of oncogenic CMYC on chromosome 
8q has been reported in 20%–30% of cases (Nowak et al., 2005; Schleger, 2002). 
Other amplified and overexpressed putative oncogenes in pancreatic cancer, which 
play a significant role in tumor development based upon clinical or biological 
evidence (according to criteria presented by Santarius et al., 2010), include ARPC1A 
(Laurila et al., 2009) and SMURF1 (Suzuki et al., 2008).  
In addition to genetic and genomic aberrations in pancreatic cancer, gene 
expression patterns are also modulated by epigenetic events and miRNAs (as 
discussed earlier). Tumor suppressor genes are frequently inactivated by aberrant 
promoter hypermethylation in multiple cancers. Many of them, including CDKN2A, 
MLH1, and CDKN1C, have been reported to be silenced by hypermethylation in 
pancreatic cancer (Ueki et al., 2000; Omura & Goggins, 2009). Recent miRNA 
profiling by Lee and colleagues identified unique miRNA profiles in normal, benign 
and malignant pancreatic tissues (Lee et al., 2007). Another miRNA profiling in 
pancreatic cancer was able to differentiate normal pancreas, chronic pancreatitis and 
PDAC based on their miRNA profiles (Bloomston et al., 2007).  
As already described, pancreatic cancer is known to be a multifaceted disease 
with mixed genetic background. This finding was recently confirmed by a 
comprehensive genetic analysis, which profiled somatic mutations of 20,661 
protein-coding genes in 24 pancreatic ductal adenocarcinomas (Jones et al., 2008). 
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This detailed genetic profiling firmly indicated pancreatic cancer to be an extremely 
complex and heterogenous malignancy, harboring an average of 63 genetic 
abnormalities per tumor. However, this complexity was considerably reduced when 
the alterations were organized into processes and pathways. Despite the large 
number of identified changes and case-to-case variation, each of the aberrations 
seemed to fall into one of 12 common pathways (Figure 4). This pattern simplifies 
the complexity of pancreatic cancer and guides us towards a pathway-oriented 
strategy instead of focusing on individual genes and proteins. 
 
 
 
Figure 4. Signaling pathways and processes involved in pancreatic cancer 
(modified with permission from Jones et al., 2008). The genetically altered genes in 
pancreatic carcinomas typically fall into these twelve pathways and processes 
presented here. 
2.4. Clinical presentation, diagnosis and treatment 
Pancreatic cancer remains a substantial therapeutic challenge due to the lack of a 
means for early detection and resistance to current treatment strategies. Symptoms 
arise late and less than 20% of patients are diagnosed with a localized, potentially 
curable tumor (Freitas et al., 2009; Hidalgo, 2010). Symptoms are often broad and 
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depend on the location of the tumor and the stage of the disease. Vague abdominal 
pain and nausea are common non-specific symptoms. Tumors that develop in the 
head of the pancreas can cause obstructive cholestasis, leading to painless jaundice. 
Systemic manifestations of the disease include asthenia, anorexia, and weight loss 
(Freitas et al., 2009; Hidalgo, 2010). Physical examination may provide additional 
information, but results from routine blood tests are generally non-specific. Mild 
abnormalities in liver function tests, hyperglycemia and anemia may be found 
(Hidalgo, 2010). 
The initial evaluation of pancreatic cancer is often done using multidetector 
computed tomography (CT) or magnetic resonance imaging (MRI) with or without 
fine needle biopsy to visualize the primary tumor and to outline an initial 
management plan (Freitas et al., 2009; Hidalgo, 2010). Endoscopic ultrasonography, 
or, more rarely, endoscopic retrograde cholangiopancreatography (ERCP) may be 
used if the tumor is not identifiable on CT or if a tissue biopsy is needed (Hidalgo, 
2010). ERCP is associated with an increased risk of complications and is now rarely 
used without a therapeutic intent. There are many potential serum biomarkers to 
ease diagnosis, but only carbohydrate antigen CA 19-9 has demonstrated clinical 
usefulness (Harsha et al., 2009). Nevertheless, even CA 19-9 has its limitations, 
such as a lack of precision and, more rarely, false negative results.  
Operative procedures include cephalic pancreatoduodenectomy, distal 
pancreatectomy, and total pancreatectomy. Gemcitabine alone or in combination is 
considered the standard post-operative treatment (Freitas et al., 2009; Hidalgo, 
2010). According to recent data, one out of eight patients who undergoes surgical 
resection lives for longer than ten years (Schnelldorfer et al., 2008). In addition, the 
three-year survival rate for patients with resectable PDAC in Finland during the 
years 2000-2006 was 29% (Kiviluoto, 2008). Treatment of patients with locally 
advanced or metastatic disease is mainly palliative. Possible treatment strategies 
include chemotherapy or combined chemoradiation therapy (Hidalgo, 2010). In 
addition, there is on-going clinical development of new targeted agents, including 
small molecule inhibitors, monoclonal antibodies, nanotechnology, and adenoviral 
agents. We should nevertheless keep in mind the importance of early diagnosis and 
detection of neoplastic precursors as the most effective means to reduce cancer-
related mortality, as has been shown with other malignancies (Andriole et al., 2005; 
Saslow et al., 2007; Levin et al., 2008).  
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3. Transcriptional regulation 
3.1 Mechanisms of transcription  
The regulation of transcription is a key step in maintaining cellular homeostasis and 
controlling cellular growth, differentiation, and development (Hahn, 2004; Koch et 
al., 2008). This level of regulation is mediated by a number of transcription factors 
and coregulators that activate or repress transcription in response to numerous 
signals originating from inside or outside the cell (Conaway et al., 2005b). Three 
main RNA polymerases (pol) are responsible for nuclear transcription in eukaryotes: 
RNA polymerases I and III transcribe noncoding genes, such as those encoding 
transfer RNAs or ribosomal RNAs, whereas RNA polymerase II transcribes coding 
mRNAs and some noncoding RNA species (Koch et al., 2008).  
Eukaryotic mRNA synthesis is a stepwise process driven by RNA polymerase 
II and regulated by specific activator and repressor proteins, general transcription 
factors, and a coregulatory multiprotein complex, Mediator, which mediates 
regulatory signals from specific regulators to pol II and the general transcription 
factors at the core promoter (Conaway et al., 2005b; Kornberg, 2005). The core 
promoter is the DNA sequence where pol II and the general transcription factors 
assemble. The general transcription factors involved in pol II-mediated transcription 
include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. They help to position the 
polymerase at the promoter and facilitate transcription (Figure 5). The assembly 
starts with TFIID recognizing a specific binding site in the DNA, such as the 
TATA-box, a TA-rich region at the promoter, usually located 25 base pairs 
upstream of the transcription start site. TFIIA stabilizes TBP (a TATA-box binding 
protein, a part of the TFIID complex) and TFIID binding to DNA (Weideman et al., 
1997) and blocks some transcription inhibitors from binding to DNA (Kokubo et al., 
1998; Hahn, 2004). TFIIB binds to DNA-bound TBP and later to pol II, facilitating 
formation of the preinitiation complex (PIC) (Hahn & Roberts, 2000), which is an 
inactive state of Pol II and associated factors assembled at the core promoter just 
before transcription initiation. TFIIF binds to Pol II, facilitating its recruitment to 
the promoter and PIC formation. TFIIE and TFIIH function primarily during the 
steps after PIC formation. TFIIH melts the DNA, thus allowing pol II access to the 
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DNA template. TFIIH has both kinase and helicase activities, and TFIIE is thought 
to support TFIIH in its function (Ohkuma, 1997).  
Pol II recruitment to DNA is the most important step in transcriptional 
regulation that can be facilitated or repressed by specific activators or repressors, 
respectively. Specific activator or repressor proteins typically bind distant from the 
transcriptional start site and mediate their signals via coregulatory complexes such 
as the Mediator complex (Koch et al., 2008; Ansari et al., 2009). The regulatory 
sequences or elements (RE), for example, upstream activating sequences (UAS), 
serve as binding sites for specific regulatory proteins and can locate adjacent to the 
promoter but also further upstream or downstream of it (Taatjes et al., 2004; Malik 
& Roeder, 2005). The accessibility of these binding locations is regulated by a wide 
spectrum of post-translational histone modifications, making the regulation even 
more complex (Taatjes et al., 2004). Histone acetyltransferases (HAT) are enzymes 
that acetylate lysine residues on histones, diminishing the interaction between 
histones and the DNA and rendering the DNA more accessible to transcription 
factors. The composition of the involved proteins and protein complexes and their 
interactions during PIC formation are illustrated in Figure 5.   
 
 
 
Figure 5. Model for PIC formation and activated transcription. Transcriptional 
activators bind to their target sites (upstream activated sequence, UAS), recruiting 
Mediator, which in turn facilitates the pol II recruitment to the core promoter and 
the PIC formation, leading finally to initiation of transcription. Mediator acts here 
as a bridge between activators and the general pol II transcription machinery 
including pol II and the general transcription factors (IIA-IIH). (Reprinted with 
permission from Malik & Roeder, 2005). 
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3.2 Mediator in transcription 
Mediator plays a fundamental role in the activation and repression of eukaryotic 
mRNA synthesis and is presumed to be an important component of the RNA 
polymerase II general transcription machinery (Kim et al., 1994; Thompson et al., 
1995; Takagi et al., 2006; Conaway et al., 2005a). It bridges the signals between 
specific transcriptional regulators and the general transcription apparatus (Taatjes et 
al., 2004), but the actual mechanism of action of mammalian Mediator has not been 
firmly established (Conaway et al., 2005a).  
Mediator was originally identified in Saccharomyces cerevisiae through the 
discovery that purified activators and the general transcription machinery alone 
were incapable of active transcription in vitro (Flanagan et al., 1991). Later, the 
yeast Mediator was purified to homogeneity and found to stimulate transcription in 
the absence of an activator (Kim et al., 1994). Further functional studies on 
Mediator have reported both stimulatory and inhibitory functions in vitro (Conaway 
et al., 2005a). In vivo, Mediator seems to be a direct target of activators and is 
recruited to gene promoters at the preinitiation stage of transcription to facilitate pol 
II recruitment and PIC formation (Figure 3) (Bhaumik et al., 2004; Bryant & 
Ptashne, 2003; Govind et al., 2005; Kuras et al., 2003).  
Mediator is structurally and functionally highly conserved across eukaryotes, 
comprising 25-30 subunits (Myers et al., 2000; Boube et al., 2002; Sato et al., 2004) 
that are organized into three distinct modules: head, middle and tail (Dotson et al., 
2000; Chadick et al., 2005). Although the mechanism by which Mediator interacts 
with pol II is not fully understood, the yeast Mediator appears to bind to the C-
terminal domain (CTD) of the polymerase (Kim et al., 1994; Thompson et al., 
1993). Furthermore, it is now well documented that yeast Mediator interacts directly 
with transcriptional activation domains of several DNA binding regulatory proteins 
(Myers et al., 2000; Kim et al., 1994; Malik & Roeder, 2000). Of note, different 
subunits of Mediator appear to interact with different transcriptional activators 
(Conaway et al., 2005b), and Mediator complexes with distinct kinase modules may 
regulate different sets of genes (Sato et al., 2004). These findings suggest a complex 
and multidimensional role for Mediator in transcriptional regulation. 
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3.3 The MED29 subunit  
Human MED29 (previously known as Intersex-like, IXL) encodes a protein of 221 
amino acids, which is a subunit located in the head module of the Mediator complex 
(Sato et al., 2003b). Mammalian MED29 was identified as a novel, previously 
uncharacterized subunit of the Mediator complex by tandem mass spectrometry 
analysis of highly enriched Mediator fractions of rat liver nuclei (Sato et al., 2003b). 
The same subunit was identified and characterized from a human embryonic heart 
cDNA library and called Intersex-like (IXL) due to its close homology to 
Drosophila melanogaster intersex protein (Wang et al., 2004). After these initial 
discoveries of mammalian MED29, no further studies on its functional role have 
been published. The role and mechanism of action of MED29 in transcriptional 
regulation remain elusive.   
MED29 is widely expressed during different stages of embryonic development 
and in various human adult tissues (Wang et al., 2004). Sequence analysis shows 
high evolutionary conservation across species, with over 90% identity with mouse 
Ixl and 36% identity with Drosophila melanogaster Intersex (Wang et al., 2004). 
Drosophila melanogaster intersex is an important transcriptional coregulator that 
interacts with a DNA-binding transcriptional activator doublesex and is involved in 
female somatic sex determination (Garrett-Engele, 2002). Similarly, MED29 may 
be a coregulatory target of some DNA-binding transcriptional regulators. MED29 
contains a consensus Src homology 3 (SH3) binding site for the Nck adaptor 
protein, which suggests a role in downstream signaling cascades, such as Pak and 
mitogen-activated protein kinase (MAPK) pathways (Wang et al., 2004). MAPK 
pathways are main signaling cascades through which cells transduce signals outside 
of the cell into intracellular responses involving growth, differentiation, damage 
repair, and cell death.  
In COS-7 cells, MED29 is predominantly localized in the nucleus, but it is also 
found in the cytoplasm (Wang et al., 2004). The role of MED29 in transcriptional 
regulation fits well with its nuclear localization. MED29 was reported to act as a 
transcriptional suppressor when fused with a Gal4-DNA-binding domain and 
cotransfected with VP-16 into COS-7 cells (Wang et al., 2004). Overexpression of 
MED29 was shown to significantly inhibit the transcriptional activities of SRE and 
AP-1, the main downstream targets of MAPK signaling, suggesting a 
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downregulatory role of MED29 in the MAPK signaling cascade in COS-7 cells 
(Wang et al., 2004). MAPK signaling affects four different subtypes of MAPKs: 
extracellular signal-related kinases (ERK1/2), Jun amino-terminal kinases (JNK1-3), 
p38 proteins, and ERK5 proteins, being thus in an essential and broad role in the 
control of cellular growth and differentiation (Chang et al., 2001). These initial 
discoveries suggest that MED29 could play a role in the regulation of cell growth 
and development, but further studies are needed to confirm these findings and to 
define the mechanisms of action.     
42 
AIMS OF THE STUDY 
The aims of this study are to characterize the recurrently amplified chromosomal 
region at 19q13 in pancreatic cancer, to identify putative novel targets in this region 
and to evaluate their clinical significance. The specific aims are as follows. 
 
1. To define the core region of the 19q13 amplification in pancreatic cancer 
and to identify putative novel target genes within the core amplicon. 
2. To evaluate the clinical significance of the 19q13 core amplicon in large 
patient material. 
3. To characterize the functional role of the putative amplification target genes 
using gene silencing and gene transfer techniques. 
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MATERIALS & METHODS 
1. Cell lines (I, III) 
A total of 16 pancreatic cancer cell lines were included in the study. AsPC-1, BxPC-
3, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF-II, Hs 700T, Hs 766T, MIA PaCa-2, 
PANC-1, SU.86.86, and SW1990 were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). DAN-G, HUP-T3, and HUP-T4, were obtained 
from the German Collection of Microorganisms and Cell Cultures (Brunswick, 
Germany). The breast cancer cell lines BT-474 and MCF7, the human embryonic 
kidney cells (HEK 293T/17), and the mouse embryonic fibroblast cell line 
(NIH/3T3) were obtained from the ATCC. Bacterial TOP10 Escherichia coli cells 
were obtained from Invitrogen (Carlsbad, CA). All cell lines were grown under 
recommended conditions. 
2. Tumor samples (II) 
The primary pancreatic tumor samples and the corresponding metastases were 
obtained from 356 pancreatic surgery patients at the Department of General- 
Visceral- and Thoracic Surgery, the University Medical Center Hamburg-Eppendorf 
during the years 1993-2005. The samples were fixed with formalin and embedded in 
paraffin. All tumors were reviewed by two pathologists who determined the 
histological type and grade of the samples (G1 = highly differentiated, G2 = 
moderately differentiated, G3 = poorly differentiated). The pathologic stage, nodal 
status and metastasis information were included as well as the follow-up and 
survival data. The standard TNM classification for pancreatic cancer was used: pT 
stage T1 = tumor size ≤ 2 cm, T2 = tumor size > 2 cm, T3 = tumor growth into 
surrounding tissues, T4 = tumor growth into the stomach, spleen, large bowel or 
nearby large blood vessels; pN stage N0 = no lymph node metastases, N1 = 
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metastases in local lymph nodes; and pM stage M0 = no distant metastases, M1 = 
distant metastases. The median age of the patients was 62.8 years (range 21-88 
years) and the mean follow-up time for ductal adenocarcinomas was 18.52 months 
(range 1-74 month). Informed consent had been obtained from all patients upon 
admission to hospital.  
3. Tissue microarrays (I, II) 
Two different pancreatic cancer tissue microarrays (TMAs) and one cell line 
microarray were used for the DNA copy number analysis in this study. The first 
TMA was a commercial array obtained from Petagen Incorporation (Seoul, Korea) 
and contained 33 pancreatic cancer samples and four non-neoplastic pancreatic 
tissue specimens. The other TMA was build from the patient material described 
above and contained a total of 600 samples, including 357 primary tumors of the 
pancreas (213 ductal adenocarcinomas, 54 adenocarcinomas of the ampulla of 
Vater, 40 pancreatic endocrine tumors, 33 intraductal papillary mucinous neoplasms 
(IPMNs), 15 benign cystic tumors, one malignant cystic tumor, and one acinar cell 
carcinoma), 129 corresponding lymph node metastases, 22 distant metastases, 24 
local recurrences, and a standard control area containing 40 tumors from other 
organs, 10 healthy pancreatic tissue samples, and 18 healthy tissue samples of other 
sites. The cell line microarray contained in total 120 cancer cell lines representing 
various tissue types and nine cell lines of non-neoplastic origin. The content of the 
smaller pancreatic tissue array used in the Study I is described in Table 2.  
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Table 2. Clinicopathological data of the tumor specimens on the TMA in the Study I. 
 
No Sex Age Histology  Grade TNM Stage 
1 M 66 Non-neoplastic region    
2 M 71 Non-neoplastic region    
3 M 85 Non-neoplastic region    
4 M 71 Non-neoplastic   
5 M 49 Ductal adenocarcinoma G1  T4N3M0 (III) 
6 M 61 Ductal adenocarcinoma G3  T3N1M1 (IV) 
7 M 65 Ductal adenocarcinoma G3  T2N4M1 (IV) 
8 M 66 Ductal adenocarcinoma G1-G2  T3N1M0 (IIB) 
9 M 55 Ductal adenocarcinoma G1-G2  T2N1M0 (IIB) 
10 M 71 Ductal adenocarcinoma G1-G2  T1N1M0 (IIB) 
11 M 59 Ductal adenocarcinoma G3  T3N0M0 (IIA) 
12 M 60 Ductal adenocarcinoma G3  T3NXM0 (IIA) 
13 M 71 Ductal adenocarcinoma G2  T3N1M0 (IIB) 
14 M 85 Ductal adenocarcinoma G2  T3N0M0 (IIA) 
15 M 55 Ductal adenocarcinoma G2  T3N0M0 (IIA) 
16 F 69 Ductal adenocarcinoma G3  T4N1M1 (IV) 
17 M 66 Ductal adenocarcinoma G3  T3N0MX (IIA) 
18 F 78 Ductal adenocarcinoma G2  T3N1M0 (IIB) 
19 M 47 Ductal adenocarcinoma G2  T3N1M1 (IV) 
20 M 65 Ductal adenocarcinoma G2  T2N0M1 (IV) 
21 M 61 Ductal adenocarcinoma _ T2N1M1 (IV) 
22 M 69 Ductal adenocarcinoma _ T3N0M0 (IIA) 
23 F 78 Ductal adenocarcinoma G2  T2N0M0 (IB) 
24 M 66 Ductal adenocarcinoma G2  T3N1M1 (IV) 
25 M 64 Ductal adenocarcinoma G2  T3N1M0 (IIB) 
26 M 69 Ductal adenocarcinoma _  T3N0M1 (IV) 
27 F 66 Ductal adenocarcinoma _ T3N0M0 (IIA) 
28 M 64 Ductal adenocarcinoma G2  T3NXM1 (IV) 
29 M 60 Ductal adenocarcinoma G2  T3N1M0 (IIB) 
30 M 63 Ductal adenocarcinoma G2  T3N1M0(IIB) 
31 M 74 Ductal adenocarcinoma _  T3N0M0 (IIA) 
32 M 43 Endocrine carcinoma  _   
33 M 60 Ductal adenocarcinoma G2  T3N0M0 (IIA) 
34 M 75 Ductal adenocarcinoma G2-G3  T2N1MX (IIB) 
35 F 46 Ductal adenocarcinoma G2-G3  T3N1M1 (IV) 
36 F 65 Endocrine carcinoma  
37 F 60 Ductal adenocarcinoma G4 T3N1M1 (IV) 
4. Genomic clones (I, II) 
Fifteen evenly distributed bacterial artificial chromosome (BAC) clones over the 
entire 2.9 Mb amplicon at 19q13 were selected for the copy number analysis using 
public genome databases (National Center for Biotechnology Information: 
http://www.ncbi.nlm.nih.gov and University of California Santa Cruz Genome 
Bioinformatics: http://www.genome.ucsc.edu). The BAC clones were purchased 
from Invitrogen (Carlsbad, CA), whereas the pericentromeric reference clone RP11-
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345J21 was a kind gift from Mariano Rocchi (the University of Bari, Bari, Italy). 
The list of all BAC clones is shown in Table 3.  
 
Table 3. Genomic BAC clones used in the copy number analysis by FISH. 
Localization is based on UCSC Genome Browser assembly May 2004. 
 
Clone name GenBank accession Size (kb) Start (bp)  End (bp)  
CTB-186G2 AC008649 127 43772845 43893312 
CTD-2540F13 AC022144 149 43893313 43987758 
CTC-360G5 AC011455 149 44037170 44178197 
CTC-218B8 AC011443 157 44244816 44401384 
RP11-67A5 AC018477 172 44461580 44633655 
RP11-256O9 AC016381 76 44600000 44700000 
CTC-488F21 AC139454 191 44934122 45124860 
RP11-746O9 AQ450800, AQ453825 a 183 45113627 45297066 
RP11-246P10 AQ488066, AQ488067 a 170 45304261 45473822 
CTC-425O23 AC118344 178 45390096 45568430 
CTC-492K19 AC010271 161 45566202 45663017 
CTD-2223D2 AC020929 120 45661273 45780841 
CTC-490E21 AC008537 169 45975835 46143755 
CTD-2356P16 AC008962 154 46227483 46373579 
CTD-2195B23 AC011510 129 46373580 46498596 
RP11-345J21 b AQ540013, AQ540014 a 196 34827676 35023872 
 
a BAC end sequences, b pericentromeric control clone 
5. Fluorescence in situ hybridization (I, II) 
Fluorescence in situ hybridization (FISH) was used for copy the number analysis of 
the 19q13 locus in pancreatic cancer cell lines and three different TMAs described 
above. All the 19q13 BAC clone DNA probes were labeled with SpectrumOrange-
dUTP (Vysis, Downers Grove, IL) and the pericentromeric reference probe (RP11-
345J21) was labeled with fluorescein-12-dUTP (Perkin-Elmer, Boston, MA) by 
random priming. Dual-color FISH was performed as previously described (Bärlund 
et al., 2000) and hybridization signals were evaluated using the Olympus BX50 
fluorescence microscope (Olympus, Tokyo, Japan). Forty intact nuclei were scored 
for each probe, and relative copy numbers were calculated as the ratios of mean 
absolute copy number of the test probe versus the reference probe.  
For the cell lines, each BAC clone was individually hybridized against the 
reference probe, whereas a contig of three overlapping BAC clones (RP11-67A5, 
RP11-256O9, and CTC-488F21), located in the core region of the 19q13 amplicon, 
was used for the TMAs and the cell line array. Control experiment on normal 
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lymphocytes verified that this probe combination gave a single hybridization signal. 
The RP11-345J21 probe was again used as a reference.  
FISH on tissue microarrays was carried out as described (Andersen et al., 2001) 
with slight modifications. Briefly, the slides were deparaffinized in three changes of 
hexane for 10 min each, dipped twice in 100% EtOH, treated with 0.3% NaBH4 for 
30 min, and rinsed with PBS. Then the slides were incubated in the Vysis 
Pretreatment Solution (Vysis, Downers Grove, IL) for 40 min at 80°C, rinsed with 
H2O, and treated with the Vysis Protease for 20 min at 37°C. This was followed by 
the Proteinase K treatment for 10 min at 37°C. Finally the slides were washed in the 
increasing series of EtOH (70%, 85%, 100%), dehydrated, denatured in 70% 
formamide/2X SSC for 3 min at 70°C, washed with EtOH, dehydrated, and 
hybridized with the denatured probes in a humidified chamber at 37°C for 24h. The 
nuclei were counterstained with DAPI in Vectashield antifade solution.  
The hybridization signals were scored and evaluated as described above. 
Relative copy numbers greater than or equal to 2 were considered as amplifications 
whereas copy numbers over 1.5 but less than 2 were considered as gains. Polysomy 
was defined as samples with the absolute copy number of the 19q13 locus over 5 but 
the relative copy number less than two. 
6. Quantitative RT-PCR (I, III) 
Gene expression analyses for all 23 known genes in the 1.1 Mb core amplicon that 
were expressed in PANC-1 cells were performed using Light Cycler equipment 
(Roche, Mannheim, Germany). Further gene expression validations were performed 
with the Light Cycler or the ABI 7900HT Fast Sequence Detection System (Applied 
Biosystems, Foster City, CA). Total RNA was isolated from cell lines using the 
RNeasy Mini kit (Qiagen) and transcribed into first-strand cDNA using Superscript 
III reverse transcriptase (Invitrogen) or the Script cDNA synthesis kit (Bio-Rad, 
Inc., Hercules, CA). Xenograft RNA was extracted by mechanical lysis using the 
MagNA Lyser instrument (Roche Diagnostics GmbH, Mannheim, Germany) and 
was further purified by use of the RNeasy Mini kit (Qiagen), similarly to RNA 
harvested from cell lines. Normal human pancreatic RNA was obtained from 
Ambion (Cambridgeshire, United Kingdom). For analyses using the Light Cycler 
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system, gene expression levels were normalized against house-keeping gene TBP 
(TATA-box binding protein) or GUSB (glucuronidase beta), and Light Cycler 
software (Roche) was used for data analysis. Primers and probe sets for the Light 
Cycler were obtained from TIB MolBio (Berlin, Germany), and the Universal 
ProbeLibrary assay for GUSB was obtained from Roche. TaqMan gene expression 
assays for the ABI system were obtained from Applied Biosystems, and ABI 
7900HT software (Applied Biosystems) was used for data analyses. Expression 
levels of the target genes in the ABI system were normalized against the 
housekeeping gene GAPDH (glyceraldehyde- 3-phosphate dehydrogenase).    
7. Sequencing (III) 
CDNA from PANC-1 and SU.86.86 cells was PCR amplified using primers from 
both ends of the MED29 coding sequence. The reaction contained 1 µl of cDNA, 5 
µl of 10x PCR Gold Buffer, 4 µl of 25µM MgCl2, 1 µl of dNTPs, 1 µl of each 10 
µM primer, and 0.3 µl of Amplitaq Gold DNA polymerase (Applied Biosystems, 
Foster City, CA). The cycling program included 35 cycles of denaturation at 95ºC 
for 30 seconds, annealing at 55ºC for 1 minute, and extension at 72º for 1 minute. 
The PCR products were purified using the Qiagen QIAquick PCR Purification Kit 
according to the manufacturer’s instructions (Qiagen Inc.). The sequencing reactions 
were carried out using the Big Dye Terminator chemistry (Applied Biosystems) 
according to the manufacturer’s protocol and the ABI 3100 sequencer (Applied 
Biosystems). 
8. Western blot (III) 
To collect total protein, cells were lysed into RIPA buffer (1% PBS, 1% nonidet P-
40, 0.5% sodium deoxycholate and 0.1% SDS) supplemented with a complete mini 
protease inhibitor cocktail (Roche Diagnostics GmbH). The protein content was 
quantified using Bradford reagent (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). Proteins were separated by SDS-PAGE and transferred onto PVDF 
membrane (Roche Diagnostics GmbH) with a Trans-blot® SD transfer apparatus 
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(Bio-Rad Laboratories, Hercules, CA). After blotting, the membrane was blocked 
overnight. Immunodetection was performed using a custom-made MED29-specific 
primary antibody (GenWayBiotech, San Diego, CA), and proteins were visualized 
by using a BM chemiluminescence western blotting kit (Roche Diagnostics GmbH). 
β-Tubulin 1 (Sigma-Aldrich Chemie GmbH) was used as a loading control.  
9. Loss-of-function RNA inhibition screen (I) 
Loss-of-function screening using high-throughput RNA inhibition (RNAi) 
technology was performed for all known genes in the 1.1 Mb core amplicon that 
were expressed in 19q13 amplified PANC-1 cells. A small interfering RNA 
(siRNA) library that targeted all known genes in the studied amplicon one by one, 
was utilized (Table 3). Two genes, SAMD4B and EID2B, were hypothetical proteins 
at the time of the experiment and were thus not included. Four siRNAs were 
designed for each gene according to previously described criteria (Meister et al., 
2004; Reynolds et al., 2004). All gene-specific siRNAs for the loss-of-function 
screen as well as a non-silencing control siRNA were obtained from Qiagen. 
Reverse siRNA transfection using Oligofectamine (Invitrogen) was applied on a 
384-well Costar microtiter plate (Fisher Scientific, Hampton, NH). After complex 
formation, suspensions of MIA PaCa-2 or PANC-1 cells were added. The total cell 
number was quantified using the Cell Titer Blue method (Promega, Madison WI) 
and an EnVision plate reader (Perkin- Elmer, Wellesley, MA). Reduced cell 
viability to 50% or less compared with non-silencing control siRNA-treated cells 
was regarded as a significant change.  
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10. siRNA-mediated gene silencing (I, III) 
Gene silencing by gene-specific siRNAs was used to study the functional role of 
MED29 in pancreatic cancer cell lines with MED29 amplification and subsequent 
overexpression. Silencing was obtained with the single siRNAs described above 
(Table 4) or by an ON-TARGETplus SMART siRNA pool containing a mixture of 
four gene-specific siRNAs specific for MED29 (Dharmacon, Lafayette, CO). An 
siRNA targeting the firefly luciferase gene (LUC) (Sigma, St. Louis, MO) was used 
as a control. Interferin transfection reagent was used for siRNA transfection 
according to the manufacturer’s instructions (Polyplus Transfection, San Marcos, 
CA). Transfections were performed in standard growth medium. The efficiency of 
MED29 silencing in each experiment was confirmed by quantitative RT-PCR.  
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Table 4. The siRNA sequences used in the study. 
Gene Gene Bank  siRNA 
ID 
Antisense Sense 
GMFG XM_290842 198 UGUAAACCACGAACCUGGGct CCCAGGUUCGUGGUUUAC
Att 
  243 ACAAAGGGUAGGACACUCGg
c 
CGAGUGUCCUACCCUUUG
Utt 
  27 UUAGCUCUGGGUCUACCUCg
c 
GAGGUAGACCCAGAGCUA
Att 
  207 ACUUGUAGCUGUAAACCACg
a 
GUGGUUUACAGCUACAAG
Utt 
LRFN1 NM_004877 2069 AUAAUUACACGAAUCUCCCat GGGAGAUUCGUGUAAUUA
Utt 
  188 AUACAAGUGAAGGUGCCACt
g 
GUGGCACCUUCACUUGUA
Utt 
  754 UAUAGCGGAUCAUGAGCAGa
a 
CUGCUCAUGAUCCGCUAU
Att 
  762 AUACACCUUAUAGCGGAUCat GAUCCGCUAUAAGGUGUA
Utt 
PD2 NM_019088 555 UCUUUCGCAUCCAUGGCACc
a 
GUGCCAUGGAUGCGAAAG
Att 
  1051 ACGUUCCAGUUGUACUCCCg
a 
GGGAGUACAACUGGAACG
Utt 
  267 UAUUGCAGUACUUGACUCGg
c 
CGAGUCAAGUACUGCAAU
Att 
  587 AUAACGGUUGAACUCAGUGg
a 
CACUGAGUUCAACCGUUA
Utt 
MED29 NM_017592 261 UAUAACGCUGCACAGGAUCg
a 
GAUCCUGUGCAGCGUUAU
Att 
  584 AAUCUGGGCUUUGAUGACCg
c 
GGUCAUCAAAGCCCAGAU
Utt 
  144 AACUAGGACCCGAUACACCa
g 
GGUGUAUCGGGUCCUAGU
Utt 
  264 UCUUAUAACGCUGCACAGGat CCUGUGCAGCGUUAUAAG
Att 
ZFP36 NM_003407 1524 UCGUCAUAAAUAAAGGGCCc
a 
GGCCCUUUAUUUAUGACG
Att 
  376 AGAAGGUCCGACAUAGCUCa
g 
GAGCUAUGUCGGACCUUC
Utt 
  890 UAUUCAUCAGGGUCGGAUCc
c 
GAUCCGACCCUGAUGAAU
Att 
  488 AACUUGUGACAGAGUUCCGt
c 
CGGAACUCUGUCACAAGU
Utt 
PLEKHG2 NM_022835 3463 AUAUUGGUUGGGCUCUCGCt
g 
GCGAGAGCCCAACCAAUA
Utt 
  3219 AAGUUGUAAGAGCCGGCACc
t 
GUGCCGGCUCUUACAACU
Utt 
  1774 ACAUAAGGGUCCUUCACCGg
c 
CGGUGAAGGACCCUUAUG
Utt 
  1677 UUCUAGCAUCUCGAGGUCGa
g 
CGACCUCGAGAUGCUAGA
Att 
RPS16 NM_001020 360 AUAUUUCUGGUAAUAGGCCa
c 
GGCCUAUUACCAGAAAUA
Utt 
  161 UUGAUGAGACCAUUGCCGCg
t 
GCGGCAAUGGUCUCAUCA
Att 
  3008 UAAAUCUGGGCCACGUGACc
a 
GUCACGUGGCCCAGAUUU
Att 
  313 UAGCAUAAAUCUGGGCCACg
t 
GUGGCCCAGAUUUAUGCU
Att 
SUPT5H NM_003169 2304 AUGAGUUCGUUGUCCCUCCg
g 
GGAGGGACAACGAACUCA
Utt 
  525 ACAUUAUCGAUAUUGGAGGc
t 
CCUCCAAUAUCGAUAAUG
Utt 
  2694 UAUUCUUCCUCAGCCCGUGa
c 
CACGGGCUGAGGAAGAAU
Att 
  3363 UCAAUGCUCAGUAGGACGCc
c 
GCGUCCUACUGAGCAUUG
Att 
TIMM50 NM_00100156
3 
964 AACAAGGUCUCGAUGCCUGg
g 
CAGGCAUCGAGACCUUGU
Utt 
  1099 AUGUAUCUUGUGGCGUCCCg
g 
GGGACGCCACAAGAUACA
Utt 
  1123 AUAUAGACGACGCUCACAGtc CUGUGAGCGUCGUCUAUA
Utt 
  117 AUAUCCUUUACAUGGUGUCc
a 
GACACCAUGUAAAGGAUA
Utt 
DLL3 NM_016941 117 AAGAGUGGAUCUGCAGCUCg
a 
GAGCUGCAGAUCCACUCU
Utt 
  1968 AGAAGAUGGCAGGUAGCUCa
a 
GAGCUACCUGCCAUCUUC
Utt 
  1862 UUUCACGGACAGAAUCGAGg
a 
CUCGAUUCUGUCCGUGAA
Att 
  2302 UAUAGGUGUUUCUAGAGAGa
t 
CUCUCUAGAAACACCUAU
Att 
CRI2 NM_153232 685 AUUCGGCAUCAAACGCUGCtt GCAGCGUUUGAUGCCGAA
Utt 
  780 AAGUUCUUCUAUCAGAGGGtt CCCUCUGAUAGAAGAACU
Utt 
  621 AAGCUCUUGUAUUCUGCCGg
g 
CGGCAGAAUACAAGAGCU
Utt 
  796 UAAACUUAUCGCAACCAAGtt CUUGGUUGCGAUAAGUUU
Att 
DYRK1B NM_004714 599 AAUUUCGUAGCGCUCCAGCc
a 
GCUGGAGCGCUACGAAAU
Utt 
  1607 AUAUCGGUUGCUGUAGCGGt
a 
CCGCUACAGCAACCGAUA
Utt 
  778 AUAUAGUACUUCAUCUCCGt
g 
CGGAGAUGAAGUACUAUA
Utt 
  1345 UCUUUCGUCCUUCGUAGGGtc CCCUACGAAGGACGAAAG
Att 
FBL NM_001436 644 UUAAUGAGGUCACGGCCAGa
g 
CUGGCCGUGACCUCAUUA
Att 
  948 UUCAUAUGGCUCAAGGGUCa
a 
GACCCUUGAGCCAUAUGA
Att 
  807 AUUACGCAGGAAGGUGUGGg
c 
CCACACCUUCCUGCGUAA
Utt 
  819 AAAGUGUCCUCCAUUACGCa
g 
GCGUAAUGGAGGACACUU
Utt 
FCGBP NM_003890 6395 AUUUGCAGGGUGACACUGCg
g 
GCAGUGUCACCCUGCAAA
Utt 
  5974 UUAACACGAAACCCGCGUCg
c 
GACGCGGGUUUCGUGUUA
Att 
  12000 AAUGAGGACUGUCUGCUCCg
g 
GGAGCAGACAGUCCUCAU
Utt 
  780 AUCAUAGCGAGAUUGGGAGg
c 
CUCCCAAUCUCGCUAUGA
Utt 
PSMC4 NM_006503 200 AAAUUGUCCGAUGACCAGCg
g 
GCUGGUCAUCGGACAAUU
Utt 
  260 AUAAUAGUUGGAGCCUGUGg
t 
CACAGGCUCCAACUAUUA
Utt 
  596 UGUUGUGUGAUGUGCCACCg
c 
GGUGGCACAUCACACAAC
Att 
  752 AUCGAAUCUCUUGGUGGCGa
t 
CGCCACCAAGAGAUUCGA
Utt 
ZNF546 NM_178544 192 AAAGUCAUUUGGAGGCCCGt
g 
CGGGCCUCCAAAUGACUU
Utt 
  2656 UUAUGCAUAGGACUUCCUCa
c 
GAGGAAGUCCUAUGCAUA
Att 
  743 AUUAGCAUUUGACUAACGCa
t 
GCGUUAGUCAAAUGCUAA
Utt 
  2279 AAUGUAAGUCGAUAACUGCa
a 
GCAGUUAUCGACUUACAU
Utt 
MAP3K10 NM_002446 1719 AUCUUAUGCUCAAAGCCAGa
g 
CUGGCUUUGAGCAUAAGA
Utt 
  1351 UUCGAUGACUUCAAGCCGCtt GCGGCUUGAAGUCAUCGA
Att 
  1326 AUGCUACCGAAAUCUGGCCg
c 
GGCCAGAUUUCGGUAGCA
Utt 
  2401 AAAGAAGAGGCCGUCGAGCc
a 
GCUCGACGGCCUCUUCUU
Utt 
AKT2 NM_001626 631 AUCUUAUGCUCAAAGCCAGa
g 
CUGGCUUUGAGCAUAAGA
Utt 
  1511 AAUUCAUCAUCGAAGUACCtt GGUACUUCGAUGAUGAAU
Utt 
  459 AGAAUCCACGUGGAAGGUCc
t 
GACCUUCCACGUGGAUUC
Utt 
  1012 UGAUGUCGCGGUAUACCACg
t 
GUGGUAUACCGCGACAUC
Att 
PLD3 NM_012268 706 UCAUUGUUGGUGAGGGUCCa
g 
GGACCCUCACCAACAAUG
Att 
  512 AAAGAGAUGCAAGUCGCCGt
a 
CGGCGACUUGCAUCUCUU
Utt 
  1279 ACGUAGAUGAAACUCCGGGc
a 
CCCGGAGUUUCAUCUACG
Utt 
  1051 AAGAUCUUGGUCAGGUCUCg
a 
GAGACCUGACCAAGAUCU
Utt 
LUCa M15077 siLUC AUUAAGACGACUCGAAAUCtt GAUUUCGAGUCGUCUUAA
Utt 
a A non-silencing control siRNA  
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11. Lentivirus-mediated gene overexpression (III)  
A lentiviral plasmid was used for gene transfer to create cell lines with stable 
MED29 overexpression. A MED29 cDNA clone was obtained in a pT-REx-DEST31 
plasmid (Invitrogen), grown in TOP10 E. coli cells (Invitrogen), and purified by use 
of a QIAfilter Plasmid Maxi Kit (Qiagen, Valencia, CA). The MED29 insert was 
isolated by PCR amplification using two pairs of restriction primers that produced 
863-bp (MED29-1) and 675-bp (MED29-2) PCR products. Both PCR products were 
confirmed to contain the entire MED29 coding region by sequence analysis. BamHI 
and NedI restriction sites were used to clone the inserts into the pWPI lentiviral 
vector. pWPI with no insert was used as a control. pWPI was co-transfected with 
Delta 8.9 and VSVG plasmids into HEK 293T/17 cells using CaCl2. The viral 
supernatant was harvested at 48 h after transfection, filtered, and concentrated by 
centrifugation. The viral concentrate was diluted in polybrene to infect NIH/3T3, Hs 
700T, and MIA PaCa-2 cells. A successful transduction was evaluated by 
visualizing GFP (encoded by the pWPI vector), and MED29 expression was 
confirmed by qRT-PCR and western blot analysis. 
12. Animals and tumor models (III) 
Six-week-old male athymic nu/nu mice (Harlan, the Netherlands) were used to 
follow tumor growth in vivo (n=40). MED29-expressing Hs 700T and MIA PaCa-2 
cells and their respective empty vector (mock) control cells were inoculated into the 
flanks of the mice subcutaneously, and tumor growth was followed for up to seven 
(Hs 700T) or eight (MIA PaCa-2) weeks. Animal welfare was monitored daily for 
clinical signs, and tumor measurements were performed twice per week. Tumor 
volume was calculated according to the formula V=(π/6)(d1xd2)3/2, where d1 and 
d2 are perpendicular tumor diameters. After sacrifice, the overlaying skin was 
removed, and the tumors were photographed. The final size of the tumors was 
measured with a caliper, and the volume was calculated as the length × width × 
depth × π/6 (Janik et al., 1975). The animal experiments were carried out according 
to the European Convention for the Protection of Vertebrate Animals used for 
Experimental and other Scientific Purposes, Statutes 1076/85 § and 1360/90 of The 
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Animal Protection Law in Finland, and EU Directive 86/609. The experimental 
procedures were reviewed by the local Ethics Committee on Animal 
Experimentation at the University of Turku and approved by the local Provincial 
State Office of Western Finland. 
13. Functional assays 
12.1 Cell proliferation and serum starvation (III) 
Cell proliferation and serum starvation assays were performed in 24-well plates and 
the cells were counted at 24-120 h after plating using the Coulter Counter (Beckman 
Coulter, Fullerton, CA). In serum starvation experiments, growth medium 
containing 1% FBS was used. In synchronized growth experiments, cells were 
grown in serum-free medium for 72 h, and their accumulation to the G1-phase of the 
cell cycle was confirmed by flow cytometry. Thereafter, the cells were grown in 
normal growth medium, and their growth was monitored for 96 h as indicated 
above. Each assay consisted of six replicates and was repeated at least twice. 
12.2 Cell cycle analysis (I) 
For the cell cycle analysis, cells were trypsinized and suspended in hypotonic 
staining buffer (0.1 mg/mL sodium citrate tribasic dehydrate, 0.03% Triton X-100, 
50 µg/mL propidium iodide, 2 µg/mL RNase A), and the amount of incorporated 
propidium iodide was determined by flow cytometry (Coulter EPICS XL-MCL, 
Beckman Coulter, Inc., Palo Alto, CA). Cell cycle distribution was analyzed using 
the Cylchred program. Each experiment was done in three replicates and repeated 
twice.  
12.3 Apoptosis assay (I) 
An Annexin V FITC Apoptosis Detection Kit (Calbiochem, La Jolla, CA) was used 
to detect apoptotic cells by flow cytometry (Beckman Coulter). EXPO32 ADC 
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version 1.2 analysis software (Beckman Coulter) was applied for the analysis. All 
experiments were performed in three replicates and repeated twice. 
12.4 Cell migration and invasion (III) 
Cell culture migration chambers (8.0 µm pore size, BD Biosciences, Bedford, MA) 
and equivalent matrigel-coated invasion chambers (BD Biosciences) were used to 
study cell migration and invasion, respectively. For both assays, 5 x 104 cells were 
seeded in the upper chamber while the lower chamber was filled with culture 
medium. After 22h post-plating, the cells that had migrated or invaded through the 
pores were fixed with methanol and stained with toluidine blue. Aperio ScanScope® 
XT (software version 9; Aperio Technologies, USA) was used to capture images of 
each membrane. The total area of migrated and invaded cells on a single membrane 
was determined from four images quantified by use of ImageJ software 
(http://rsb.info.nih.gov/ij/). Each assay was performed in six replicates and repeated 
at least twice. 
12.5 Soft agar colony formation (III) 
The ability of a cell to form colonies, which is characteristic to tumor cells, was 
studied by growing cells on soft agar. Cells (3-10 x 105 per well) were grown in 
0.3% agarose on a 6-well plate for 14 days. Images (six images per well) were 
captured with an Olympus IX71 microscope (Olympus Corporation, Tokyo, Japan) 
using the Capture Pro 6.0 program. The number and total area covered by colonies 
were quantified using ImageJ software. 
14. Microarrays (III) 
12.1 Microarray gene expression  
Total RNA was extracted from MED29-overexpressing MIA PaCa-2 and Hs 700T 
cells and their respective empty vector (mock)-transfected control cells by use of the 
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RNeasy Mini kit (Qiagen). The quantity and integrity of the RNA samples was 
assessed with a 2100 Bioanalyzer (Agilent, Santa Clara, CA). Sample (MED29) 
RNA was labeled with Cy5 and mock RNA with Cy3. The RNA pools were co-
hybridized onto 44K whole human genome oligonucleotide microarrays (Agilent) 
according to the manufacturer’s instructions. A total of six arrays (two biological 
replicates corresponding to the two ME29 constructs and three technical replicates) 
were prepared per cell line, and they were scanned by an Agilent microarray 
scanner. 
12.2 Microarray data analysis 
For the analysis, microarray images were transformed into spot intensity data using 
Agilent Feature Extraction software (version 10.5.1.1). The Limma package for the 
Bioconductor (Gentleman et al., 2004; Smyth, 2005) was used for preprocessing and 
analysis of the data. Preprocessing filtered out the spots flagged by the software as 
control spots, saturated, non-uniformity outliers or population outliers. Background 
correction was performed by the normexp method with an offset of 50 (Ritchie et 
al., 2007) and normalization by the LOESS normalization method (Smyth & Speed, 
2003).  The log ratio of normalized red (overexpression) and green (mock control) 
intensity values was used as the representative value for the given probe. Averages 
were taken for replicates representing the same mRNA. Differentially expressed 
genes were identified by means of empirical Bayes with Benjamini-Hochberg 
adjustment for P-values (Benjamini & Hochberg, 1995; Smyth, 2004). A fold 
change of 1.5 and an adjusted P-value of 0.05 were set for thresholds for differential 
expression. To examine the linkages between the samples, a hierarchical clustering 
method with correlation distance and average linkage was conducted. The cellular 
networks and canonical pathways involving the differentially expressed genes were 
generated through the use of Ingenuity Pathway Analysis (Ingenuity), and the 
enriched gene ontologies among the differentially expressed genes were obtained 
using DAVID bioinformatics resources (Dennis et al., 2003; Huang et al., 2009). 
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15. Human cell cycle RT-PCR array (III) 
Ready-to-use Profiler PCR plates (SA Biosciences, Frederick, MD) were used to 
validate the microarray data and the effects on MED29 expression on cell cycle 
regulation. The plates contained 84 cell cycle-related genes, five housekeeping 
genes, three RT controls, three PCR controls, and a genomic DNA control. Total 
RNA from the MED29-expressing and the mock Hs 700T and MIA PaCa-2 cells 
and mice xenografts was extracted as described above with an additional DNase 
treatment step. The RNA content was measured with the Bioanalyzer (Agilent) or 
NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA). One microgram 
of total RNA was transcribed into cDNA and PCR-amplified according to the 
manufacturer’s instructions. PCR amplification and detection were performed using 
Bio-Rad CFX96 equipment (Bio-Rad, Hercules, CA), and the data were analyzed 
with the PCR Array Data Analysis protocol (SA Biosciences). The threshold cycle 
(Ct) values for each gene were normalized using the average of the five 
housekeeping genes on the same array. 
16. Statistical analyses (I-III) 
Mann–Whitney test was utilized to compare the medians of the test and control 
groups in all functional assays (I, III). Statistical analyses for the TMA (II) were 
performed using JMP™ software (SAS Institute Inc. Cary, NC, USA). All tested P-
values were two sided, and a P-value of less than 0.05 was considered significant. 
The Pearson Chi-square test was used to assess the relationship between 19q13 copy 
number changes and the clinicopathologic parameters (tumor stage, nodal stage, and 
tumor grade). Association of 19q13 copy number changes with cancer-specific 
survival was studied using the Kaplan-Meier method, and the log rank test was 
applied to test the significance between stratified groups. The statistical methods 
used in the microarray data analysis are described above (12.2. Microarray data 
analysis). 
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RESULTS 
1. Characterization of the 19q13 amplicon and 
identification of putative target genes (I) 
A previous genome-wide aCGH profiling identified a ~2.9-Mb region of 
amplification in pancreatic cancer (Mahlamäki et al., 2004) that was here 
systematically characterized in 16 pancreatic cancer cell lines using fluorescence in 
situ hybridization (FISH). Fifteen evenly distributed BAC clones across the 
amplicon were selected for DNA copy number analysis, which revealed copy 
number increases (relative copy number > 2) in three cell lines: PANC-1, SU.86.86, 
and HPAC. Up to 20-fold amplification was detected in PANC-1 cells, whereas 
SU.86.86 and HPAC cells harbored lower-level gains (up to 5.3- and 2.6-fold). The 
copy number profile of PANC-1 cells was used to define the minimal amplified 
region, and in this way, the original amplicon of approximately 2.9 Mb could be 
outlined to 1.1 Mb. Within this 1.1 Mb minimal amplified region, defined by six 
overlapping BAC clones from RP11-67A5 to CTC-425O23, a 660-kb core region 
(from RP11-67A5 to CTC-488F21) of high-level (over 10-fold) amplification was 
identified.  
Next, the effects of amplification on gene expression were explored. With the 
help of public genomic databases (UCSC Genome Browser 
http://www.genome.ucsc.adu and NCBI Genome http://www.ncbi.nlm.nih.gov), 39 
transcripts were identified within the 1.1 Mb amplicon. Of these transcripts, 27 were 
known genes and 12 were hypothetical or predicted proteins (Table 5). Careful 
examination, including bioinformatics and gene expression analyses of PANC-1 
cells, revealed appropriate genes for comprehensive quantitative RT-PCR analysis. 
Sixteen genes were excluded as putative candidates according the following criteria: 
they represented (a) obvious pseudogenes, (b) predicted transcripts with no mRNA 
or expressed sequence tag (EST) evidence in the databases, or (c) transcripts with no 
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or low expression in PANC-1 cells. The last criterion was based on the concept that 
a putative target gene should be expressed in cells with high-level amplification.  
 
Table 5. List of the 39 genes within the 1.1Mb amplicon at 19q13. 
Gene  Description 
IL29 Interleukin 29 
LRFN1 Leucine rich repeat and fibronectin type III domain containing 1 
GMFG Glia maturation factor gamma 
SAMD4B Sterile alpha motif domain containing 4B 
PAF1 RNA polymerase II associated factor, homolog (S. cerevisiae) 
MED29 Mediator subunit 29 
ZFP36 Zinc finger protein 36, C3H type, homolog (mouse) 
PLEKHG2 Pleckstrin homology domain containing family G member 2 
RPS16 Ribosomal protein S16 
SUPT5H Suppressor of Ty 5 homolog (S. cerevisiae) 
TIMM50 Translocase of inner mitochondrial membrane 50 homolog (yeast) 
DLL3 Delta-like 3 (Drosophila) 
SELV Selenoprotein V 
EID-3  EID-2-like inhibitor of differentiation-3 
CRI2 CREBBP/EP300 inhibitor 2 
LOC390930 Similar to Eosinophil lysophospholipase (Charcot-Leyden crystal protein) 
LGALS13 Lectin, galactoside-binding, soluble, 13 (galectin 13) 
LOC441850 Similar to Eosinophil lysophospholipase (Charcot-Leyden crystal protein) 
LOC148003 Similar to Placental tissue protein 13 (Placenta protein 13) (Galectin-13) 
LOC400696 Eosinophil lysophospholipase-like 
LGALS14 Lectin, galactoside-binding, soluble, 14 
CLC Charcot-Leyden crystal protein 
LOC342900 Hypothetical protein LOC342900 
DYRK1B Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B 
FBL Fibrillarin 
FCGBP Fc fragment of IgG binding protein 
LOC440525 Proline rich 13 pseudogene 
PSMC4 Proteasome (prosome, macropain) 26S subunit, ATPase, 4 
ZNF546 Zinc finger protein 546 
LOC390933 Similar to hypothetical protein 
LOC163131 Hypothetical protein LOC163131 
LOC284323 Hypothetical protein LOC284323 
MAP3K10 Mitogen-activated protein kinase kinase kinase 10 
TTC9B Tetratricopeptide repeat domain 9B 
FLJ13265 Hypothetical protein FLJ13265 
LOC440526 Hypothetical protein LOC440526 
AKT2 v-akt murine thymoma viral oncogene homolog 2 
FLJ36888 Hypothetical protein FLJ36888 
PLD3 Phospholipase D family, member 3 
 
The remaining 23 genes were included in the quantitative RT-PCR analysis of 
16 pancreatic cancer cell lines. Most of the genes (22 of the 23) were overexpressed 
in PANC-1 cells compared to other pancreatic cancer cell lines and normal 
pancreas. Only PLD3, which is located at the border of the amplicon, was not 
overexpressed in PANC-1 cells. Gene expression levels in HPAC and SU.86.86 
cells showed more variability between individual genes and were thus utilized to 
distinguish differentially expressed genes between amplified and nonamplified cell 
lines. Six known genes (GMFG, SAMD4B, IXL (MED29), SUPT5H, PSMC4, and 
MAP3K10) and one hypothetical protein (LOC284323) were consistently 
overexpressed in all three amplified cell lines. Of these, GMFG, SAMD4B, MED29, 
and SUPT5H were located in the 660 kb amplicon, making them more likely targets 
than PSMC4, MAP3K10, and LOC284323, which were located outside of this core 
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region. Interestingly, high-level expression of MED29 was almost exclusively 
detected in the amplified cells, indicating a clear distinction between the amplified 
and nonamplified cells (Figure 6). In contrast, GMFG and MAP3K10 showed high 
expression in additional non-amplified cells, indicating additional mechanisms that 
give rise to increased expression. 
 
Figure 6. Relative MED29 gene expression in the 19q13 amplified vs. non-amplified 
pancreatic cancer cell lines.  
 
To identify functionally important candidates, a targeted high-throughput RNAi 
screen across the 1.1 Mb amplicon was applied (Ngo et al., 2006). Four siRNAs 
were designed for each of the 19 known genes (only those that were known genes at 
the time of selection and were expressed in PANC-1 cells were included), and their 
effect on cell viability was examined in PANC-1 and MIA PaCa-2 cells at 96 h after 
transfection. Cell viability was significantly reduced (i.e., viability less than 50%) 
through downregulation of MED29 in the amplified PANC-1 cells but not in the 
nonamplified MIA PaCa-2 cells. This effect was shown with two independent 
siRNAs in three repeated experiments (Table 6). Reduced cell viability (i.e., 
viability less than 50%) was also observed after LRFN1 and PLEKHG2 silencing 
but only with a single siRNA in repeated experiments (Table 6). Down-regulation of 
GMFG and SUPT5H showed a slight reduction in cell viability but no other 
examined genes had a statistically significant effect on cell viability when silenced. 
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Table 6. Results from the cell viability screen. 
siRNA PANC-1 (I)  PANC-1 (II) PANC-1 (III)     MIAPaCa-2 (I)     MIAPaCa-2 (II) 
AKT2 1012 0.83 0.84 0.93 0.75 0.56 
AKT2 1511 1.07 1.05 1.01 1.10 0.65 
AKT2 459 1.10 1.06 0.96 1.09 0.57 
CRI2 621 0.69 0.79 0.98 0.95 0.94 
CRI2 685 0.61 0.69 1.02 0.88 0.99 
CRI2 780 0.71 0.78 1.02 0.69 1.01 
CRI2 796 1.13 1.10 1.00 1.14 1.22 
DLL3 117 0.86 0.95 0.96 1.14 1.16 
DLL3 1862 0.99 1.02 0.92 1.05 1.16 
DLL3 1968 0.56 0.55 0.41 0.71 0.76 
DLL3 2302 0.52 0.49 0.83 0.85 0.93 
DYRK1B 1345 0.76 0.80 0.98 0.85 1.01 
DYRK1B 1607 1.10 1.10 0.96 1.14 1.18 
DYRK1B 599 0.67 0.69 0.43 0.86 0.83 
DYRK1B 778 0.80 0.77 0.85 0.86 0.63 
FBL 644 0.51 0.42 0.47 0.23 0.41 
FBL 807 1.00 0.99 0.93 1.01 1.05 
FBL 819 0.77 0.76 0.84 0.67 0.83 
FBL 948 0.96 0.91 0.89 0.87 1.01 
FCGBP 12000 0.80 0.87 0.95 1.04 0.75 
FCGBP 5974 1.08 1.04 0.99 1.08 0.98 
FCGBP 6395 0.65 0.70 0.66 0.74 0.67 
FCGBP 780 0.80 0.73 0.90 0.75 0.76 
LRFN1 188 0.45 0.57 0.71 0.94 1.00 
LRFN1 2069 0.34 0.63 0.83 0.97 1.04 
LRFN1 754 0.57 0.68 0.84 0.94 1.06 
LRFN1 762 0.31 0.36 0.45 0.81 0.94 
MED29 144 0.16 0.37 0.62 1.04 1.13 
MED29 261 0.81 1.01 0.91 1.05 1.14 
MED29 264 0.71 0.80 0.85 0.94 0.99 
MED29 584 0.30 0.28 0.13 0.92 1.11 
GMFG 198 0.65 0.69 0.91 0.93 1.06 
GMFG 207 0.67 0.83 0.92 0.97 1.08 
GMFG 243 0.46 0.70 0.81 1.03 1.09 
GMFG 27 0.51 0.58 0.58 0.99 1.03 
MAP3K10 1326 1.05 1.10 0.97 1.00 0.77 
MAP3K10 1351 1.12 1.19 1.05 1.13 0.94 
MAP3K10 1719 0.85 0.98 1.03 0.89 0.79 
MAP3K10 2401 1.19 1.16 1.02 1.14 1.05 
MAP3K10 631 1.14 1.12 1.00 1.11 0.66 
PAF1 1051 0.58 0.87 0.73 1.13 1.20 
PAF1 267 0.96 1.06 0.82 1.12 1.19 
PAF1 555 0.79 0.70 0.91 1.02 1.08 
PAF1 587 0.60 0.97 0.71 1.08 1.16 
PLD3 1051 1.14 1.08 1.00 1.14 0.89 
PLD3 1279 1.13 1.15 1.03 1.14 0.85 
PLD3 512 1.13 1.07 1.01 0.95 0.84 
PLD3 706 0.81 1.01 1.00 0.92 0.97 
PLEKHG2 1677 0.30 0.33 0.58 0.86 0.88 
PLEKHG2 1774 0.65 0.83 0.84 1.10 1.17 
PLEKHG2 3219 0.55 0.70 0.85 1.15 1.13 
PLEKHG2 3463 0.55 0.65 0.61 1.12 1.16 
PSMC4 200 0.73 0.74 0.69 0.34 0.58 
PSMC4 260 0.72 0.83 0.87 0.53 0.50 
PSMC4 596 0.96 0.90 0.83 0.64 0.78 
PSMC4 752 1.04 0.97 0.94 1.02 0.92 
RPS16 161 0.75 0.75 0.46 0.85 1.11 
RPS16 308 0.73 0.74 0.47 0.80 1.05 
RPS16 313 0.82 0.89 0.43 0.73 1.02 
RPS16 360 0.55 0.72 0.57 0.82 1.04 
SUPT5H 2304 0.57 0.68 0.36 1.02 1.08 
SUPT5H 2694 0.74 0.87 0.56 1.02 0.98 
SUPT5H 3363 0.55 0.64 0.52 0.83 0.77 
SUPT5H 525 0.61 0.83 0.72 1.04 1.02 
TIMM50 1099 0.50 0.82 0.83 0.99 1.10 
TIMM50 1123 0.57 0.69 0.75 0.89 1.19 
TIMM50 676 0.68 0.87 0.89 1.00 1.20 
TIMM50 964 0.57 0.58 0.47 0.57 0.98 
ZFP36 1524 0.75 0.80 0.97 1.04 1.10 
ZFP36 376 0.86 1.01 0.95 1.15 1.19 
ZFP36 488 0.68 0.80 0.67 1.12 0.98 
ZFP36 890 1.00 1.04 0.85 1.20 1.19 
ZNF546 192 0.99 1.04 1.00 1.08 0.97 
ZNF546 2279 0.89 0.90 0.98 0.77 0.83 
ZNF546 2656 1.00 0.95 0.94 0.96 0.50 
ZNF546 743 1.00 1.04 0.96 0.90 0.60 
 
Each experiment lists the average viability of siRNA-treated cells relative to non-silencing siRNA-
treated cells. Viability less than 0.50 in repeated experiments was considered as a significant change. 
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2. Clinical significance of the 19q13 amplification 
in pancreatic cancer (I, II) 
After identification of the 19q13 amplification in pancreatic cancer cell lines, we 
investigated whether the same change was present in cancers of other tissues, and 
most importantly, in primary pancreatic tumors. The amplification status of the core 
region of the 19q13 amplicon was evaluated in a broad collection of 120 cell lines 
derived from multiple tumor types, in a panel of 31 primary tumors of the pancreas, 
and in a large panel of over 500 pancreatic tumor specimens.  
In the first experiment we determined the amplification status of the 19q13 core 
amplicon in 120 cancer cell lines representing nearly 20 different tumor types. Ten 
(9.3%) of the 107 cell lines with successful hybridizations had an increased copy 
number. Six of these were amplifications (relative copy number over 2), and four 
were gains (relative copy number >1.5 but <2). Amplifications were detected in one 
(OVCAR-3) of four ovarian cancer cell lines, three (RT-112, KU-19-19, CRL-7930) 
of six bladder cell lines, one (SW-48) of twelve colorectal cell lines, and one 
(ONCO-DG-1) of four thyroid carcinoma cell lines. 
In the smaller set of primary tumors, 19q13 amplification was observed in three 
(9.7%) of the 31 analyzable cases. All of these amplified tumors were moderately to 
poorly differentiated (grade 2 or 3) pancreatic adenocarcinomas with lymph node 
metastases. In addition, two of the three amplified cases had extensions to 
peripancreatic soft tissue with perineural invasion. The metastatic status of the third 
amplified case was not available. Although the sample set was small, it provided a 
promising starting point with an amplification frequency of almost 10% and an 
indication of possible association of amplification to higher tumor grade.  
The frequency of the 19q13 copy number changes was then explored in 357 
primary pancreatic tumors, 151 metastatic lesions, and 24 local recurrences. Copy 
number increases were detected in 12.2% of the 303 analyzable cases. Changes in 
copy number were most frequent in ductal adenocarcinomas and pancreatic 
endocrine tumors (Table 7). One of 15 IPMNs showed increased copy number. 
Amplification typically manifested as a tight cluster of signals with an average 3.4-
fold copy number increase, but a few cases with up to 10-fold amplification were 
also observed. The average copy number of the 19q13 locus per cell in polysomic 
samples was between five and ten, but it ranged up to twenty. Copy number 
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increases were detected in 7 (5.8%) of the 121 successfully hybridized metastases, 
of which 3 were amplifications and 4 were gains. Copy number data from the 
primary tumors matched well with the metastases, showing an overall concordance 
of 99% (90/91). Copy number changes were not detected in the local recurrences 
(total of 18 analyzable cases).  
 
Table 7. Primary pancreatic cancer subtypes and their copy number status. 
    n analyzable 
(n) 
  normal 
(%) 
   CNI 
(%) All samples   357 303 87.8 12.2 
Ductal adenocarcinomas   213 197 86.3 13.7 
Intraductal papillary mucinous 
neoplasms  
   33 15 93.3 6.7 
Endocrine tumors    40 35 88.6 11.4 
Cystic/benign tumors    15 6 100 0.0 
Cystic/malignant tumors     1 1 100 0.0 
Acinar cell cancers     1 0 - - 
Adenocarcinomas of the ampulla of 
Vater 
    54 49 89.8 10.2 
Metastases    151 121 95.0 5.0 
Lymph node metastases    129 100 96.0 4.0 
Distant metastases     22 21 90.4 9.6 
Local recurrences     24 18 100 0.0 
 
CNI = copy number increases (amplifications, polysomy, gains) 
 
 
To evaluate the possible clinical importance of the 19q13 amplification, we 
examined associations between the copy number status and clinicopathological 
characteristics among the ductal adenocarcinomas, the most common histological 
subtype of pancreatic cancer. To this end, tumors confined to the pancreas (pT1 and 
pT2) were compared to tumors that had spread beyond the pancreas (pT3 and pT4). 
Likewise, moderately and well-differentiated tumors (G1 and G2) were compared to 
poorly differentiated tumors (G3). Copy number increases (including gains, 
amplifications, and polysomy) showed association with both tumor grade and stage 
(P=0.044 and P=0.025, respectively). In addition, the frequency of copy number 
changes increased from low- and moderate- (G1-G2) to high-grade (G3) tumors and 
from early- (pT1-pT2) to late- (pT3-pT4) stage tumors. Copy number changes were 
not detected in any of the low-grade (G1) tumors, whereas 11% of grade 2 tumors 
and 16.8% of grade 3 tumors harbored an increased copy number. High-level 
amplifications were exclusively observed in grade 3 tumors (Table 8).  
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Table 8. Relationship between the 19q13 copy number changes and the cancer 
phenotype in pancreatic ductal adenocarcinomas. 
 
  n normal (%)   CNI (%) P 
pT stage  pT1 6 83.3 16.7 0.025 
 pT2 53 92.5 7.5  
 pT3 125 84.8 15.2  
 pT4 9 66.7 33.3  
pN stage pN0 68 83.8 16.2 0.826 
 pN1 124 87.1 12.9  
Grade G1 8 100 0.0 0.044 
 G2 91 89.0 11.0  
 G3 95 83.2 16.8  
 
CNI = copy number increases (amplifications, polysomy, gains) 
 
 
At last, we performed Kaplan-Meier survival analysis on the ductal 
adenocarcinomas, which showed slightly worse survival in patients having high 
level copy number changes (amplifications and polysomy) compared to those not 
having 19q13 copy number changes, but the difference was not statistically 
significant. However, the average survival time for the patient group without a 
19q13 change was 26 months, whereas patients with amplification or polysomy 
survived an average of only 16 and 17 months, respectively. Taken together, 
association of the 19q13 amplification with tumor stage and grade and shorter 
survival time among patients with the aforementioned amplification indicates a 
trend towards a worse prognosis.  
3. Functional characterization of MED29 (I, III) 
After fine-mapping of the 19q13 amplicon, comprehensive gene expression analysis 
and subsequent first-line functional screening, we aimed to perform functional 
validation of the candidate target genes. To select the most promising target gene for 
further functional characterization, we combined the results of the gene expression 
survey and the RNAi-based loss-of-function screen. MED29 was the most attractive 
target because it was located within the 660 kb amplicon and was implicated in both 
screens. MED29 was downregulated by siRNA transfection of amplified PANC-1 
cells, and the effects of silencing were explored in multiple functional assays, 
including proliferation, cell cycle, apoptosis, soft agar colony formation, migration, 
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and invasion assays. Cell cycle and apoptosis were assessed at 48 h after siRNA 
transfection by flow cytometry. An increased fraction of G0-G1 phase cells after 
MED29 siRNA (66%) transfection compared with nontransfected cells (37%) or 
cells transfected with a control siRNA (39%) was detected in cell cycle analysis. 
Similarly, the percentage of apoptotic cells increased after MED29 siRNA 
transfection (8%) compared to cells transfected with control siRNA (1.6%) or 
untreated cells (2.5%). However, similar phenotypic changes were not observed in 
non-amplified MIA PaCa-2 cells when transfected with MED29 siRNAs. In 
addition, we observed an average of 18% reduction in cell number at 24-96 h after 
MED29 siRNA transfection in PANC-1 cells. Similarly, a 26% growth reduction 
was observed in SU.86.86 cells, another MED29-amplified pancreatic cancer cell 
line, following MED29 silencing. Colony formation was assessed by growing cells 
in soft agar. MED29-silenced PANC-1 cells were found to grow more slowly 
compared to control cells. Both the size and the number of colonies were smaller in 
the MED29-silenced cells. Furthermore, cell migration (47% reduction) and 
invasion (43% reduction) were also considerably compromised after MED29 
silencing. In parallel with all siRNA experiments, sufficient gene silencing was 
verified by qRT-PCR. MED29 protein levels were likewise notably reduced by 
siRNA transfection. Taken together, MED29 silencing in pancreatic cancer cells 
with high endogenous expression seems to diminish several cancer-associated 
phenotypic characteristics. 
To study the effects of forced MED29 expression in cells with no or low 
endogenous expression, we used a lentiviral-based method to generate cells with 
stable MED29 overexpression. MED29 was transduced into NIH/3T3, Hs 700T, and 
MIA PaCa-2 cells. NIH/3T3 is a mouse fibroblast cell line, and Hs 700T and MIA 
PaCa-2 are pancreatic cancer cell lines. Significant increases in MED29 mRNA and 
protein expression were achieved in all cell lines compared to their empty vector 
controls. Decreased cell number was observed in MED29-transduced NIH/3T3 cells 
when followed for four days. Similarly, up to a 30% growth reduction compared to 
the mock cells was observed for MIAPaCa2/MED29 cells when synchronized to 
G1-phase of the cell cycle prior to growth analysis. Unfortunately, we were unable 
to synchronize the Hs700T/MED29 cells and did not see any consistent growth 
affect in these cells in vitro.  
65 
We continued to explore the possible role of MED29 in in vivo tumor 
formation. MED29-transduced Hs 700T and MIAPaCa-2 cells, and their 
corresponding empty vector cells were subcutaneously inoculated into nude mice 
and allowed to grow for seven (Hs 700T) or eight (MIA PaCa-2) weeks. A striking 
difference in tumor growth and incidence was observed between 
MIAPaCa2/MED29 and MIAPaCa2/mock mice (Figure 7). The MIAPaCa2/mock 
tumors showed a clear exponential growth pattern from day 20 of the experiment 
onward, whereas MIAPaCa2/MED29 tumors remained small throughout the entire 
observation period. At the end of the experiment, the average volume of the 
MIAPaCa2/mock tumors was 13-fold greater than that of MIAPaCa2/MED29 
tumors. A comparable but less dramatic decrease in tumor growth was also seen in 
the Hs700T/MED29 mice. The average size of the Hs700T/mock tumors at the end 
of the study was 1.3-fold compared to Hs700T/MED29 tumors. All tumors 
displayed a vascularized morphology, implying sustained functional angiogenesis. 
MED29 mRNA levels were verified in the MED29 tumors after the experiment. 
These data clearly indicate that MED29 expression leads to tumor suppression in 
vivo. 
 
 
 
 
 
 
 
Figure 7. MED29 expression inhibits tumor growth in vivo. Fluorescence-imaged 
MIAPaCa2/mock (left) and MIAPaCa2/MED29 (right) mice. 
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4. Transcriptional effects of MED29 expression 
(III) 
To conceptualize the mechanism of MED29 action and to better understand the 
causes of the observed in vitro and in vivo growth differences, a genome-wide 
microarray gene expression analysis between the MED29- and mock-transduced Hs 
700T and MIA PaCa-2 cells was performed. A total of 463 differentially expressed 
genes (≥1.5-fold change with adjusted P-value <0.05) were recognized between the 
MED29-overexpressing and the corresponding mock cells in these two pancreatic 
cancer cell lines. On the whole, downregulation was more prevalent than 
upregulation (65% vs. 35%) among the differentially expressed genes, and the 
fraction of differentially expressed genes was greater in MIA PaCa-2 than Hs 700T 
cells. Hierarchical clustering of the differentially expressed genes identified 
common up- and down-regulated gene clusters between MIAPaCa2/MED29 and 
Hs700T/MED29 cells. Biological and technical replicates clustered together as 
expected.  
Gene ontology data for these 463 differentially expressed genes revealed 
several key biological processes implicated in the cell cycle, cell division, mitosis, 
and chromosome segregation to be enriched in MED29-transduced cells (Figure 8). 
Concomitant cellular component analysis showed enrichment in condensed 
chromosomes, kinetochore, spindle, and microtubule cytoskeleton, indicating a 
central role in cell division. Many well-known cell cycle regulatory genes, such as 
CCNA2, CCNB2, CDK1, GTSE1, and CDKN2B, were identified among the enriched 
categories. Cell cycle-promoting genes (CCNA2, CCNB2, CDK1, and GTSE1) were 
downregulated in MED29-expressing cells, whereas CDKN2B, an inhibitory 
regulator of the cell cycle, was upregulated. 
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Figure 8.	   Enriched gene ontologies among the differentially expressed genes 
(MED29 vs. mock cells) involving (a) biological processes and (b) cellular 
components are illustrated here. The main category is shown at the top of the figure 
and white boxes represent enriched gene categories. The number of enriched genes 
(n) in each category is shown in the box with the adjusted P-value for enrichment. 
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To gain insight into the functional role of the genes with altered expression after 
MED29 overexpression, Ingenuity Pathway Analysis was performed on the 
differentially expressed genes. This pathway analysis identified a network that 
associates with the cell cycle, cancer, and genetic disorders. The highest enrichment 
among molecular and cellular functions included the cell cycle, cell death, and 
cellular growth and proliferation. The most affected canonical pathways involved 
the cell cycle. To conclude, enrichment of cell cycle-associated cellular networks 
and functions was observed in the pathway analysis of differentially expressed 
genes.  
A qRT-PCR-based method was applied to verify the microarray data and to 
systematically characterize the role of cell cycle regulators as transcriptional targets 
of MED29. Gene expression levels of 84 known cell cycle genes were 
simultaneously validated in MIAPaCa2/MED29 and Hs700T/MED29 cells by qRT-
PCR. The obtained results correlated well with the microarray data, identifying the 
same cell cycle regulators (e.g., BAX, CCNF, CDC34, CDK2, CDK6, CDKN1A, 
GADD45, and GTF2H1) as being differentially expressed. In addition, we explored 
whether alterations in these cell cycle regulators were present in the xenograft 
tumors derived from these cell lines. A total of 12 cell cycle genes were found to be 
differentially expressed (fold change greater than 1.5) in MIAPaCa2/MED29 
xenografts compared to MIAPaCa2/mock xenografts, of which 92% (11 out of 12) 
were downregulated. Common cell cycle-promoting genes, including CCND2, 
CDC16, CDK6, HERC5, and RBBP8, were downregulated in both 
MIAPaCa2/MED29 xenografts and parental MIAPaCa2/MED29 cells. CDKN2B, a 
negative regulator of the cell cycle, was the only upregulated gene in the 
MIAPaCa2/MED29 xenografts, also showing elevated expression in the parental 
MIAPaCa2/MED29 cells. In Hs 700T cells and xenografts, we did not notice any 
dramatic differences in cell cycle gene expression levels between the MED29 and 
mock cells. Only five differentially expressed genes were identified in 
Hs700T/MED29 tumors compared to mock tumors. Of these, ANAPC4, ATR, 
CDK4, and SUMO1 were downregulated, whereas HERC5 was upregulated. To 
summarize, this PCR-based method enabled us to validate the microarray data and 
highlighted some MED29-induced changes that are essential for the expression of 
cell cycle-related genes. 
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DISCUSSION 
1. Amplification of the 19q13 locus associates 
with tumor grade and stage (I, II) 
Gene amplification is a typical mechanism employed by solid tumors to activate 
growth-promoting oncogenes (Albertson et al., 2003) and a frequent phenomenon in 
pancreatic cancer (Hansel et al., 2003). Multiple amplified regions have been 
documented in carcinomas of the pancreas (Harada et al., 2008; Jones et al., 2008), 
but few target genes have been functionally characterized (Santarius et al., 2010), 
and minimal progress has been made in early diagnosis or treatment (Hidalgo, 
2010). Detailed analysis of amplified regions and extensive functional validation 
may bring out novel targets for diagnostic and therapeutic purposes. To this end, we 
performed a comprehensive copy number analysis of the amplified 19q13 locus in 
pancreatic cancer cell lines, delineating the amplicon to 1.1 Mb, with a 660-kb core 
region of extremely high amplification. This 660-kb core region was of particular 
interest because amplification target genes are likely to be located at or near the 
center of the amplification maximum (Albertson, 2006).  
In addition to pancreatic cancer, 19q13 amplification has been reported in e.g., 
ovarian (Cheng et al., 1992; Bellacosa et al., 1995; Thompson et al., 1996; Tang et 
al., 2002), breast (Bellacosa et al., 1995; Yu et al., 2009), colorectal (Knösel et al., 
2004), and urinary bladder (Richter et al., 2000) cancers. Nevertheless, this study 
was the first to characterize this specific core region of amplification in a systematic 
manner across a wide range of tumor types. Our cell line panel contained over 100 
samples derived from nearly 20 tumor types. Amplification of the 19q13 core region 
was identified in ovarian, colorectal, urinary bladder, and thyroid cancer cell lines, 
confirming previous findings for these tissues (Cheng et al., 1992; Bellacosa et al., 
1995; Thompson et al., 1996; Richter et al., 2000; Knösel et al., 2004; Tang et al., 
2002) with an exception of thyroid cancer, in which the 19q13 amplification had not 
been identified previously. Furthermore, these data provide valuable information on 
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suitable cell lines for functional analysis of putative 19q13 target genes for multiple 
tumor types.  
The presence of this core region of amplification was analyzed in primary 
pancreatic tumors using FISH to TMAs. Evaluation was first accomplished in a 
small set of 31 pancreatic tumors, which showed an amplification frequency of 
approximately 10%. The amplified cases were moderately to poorly differentiated 
tumors with nodal metastases, two of which had additional local metastases 
indicative of advanced disease. A similar copy number analysis was carried out in 
an extensive collection of over 500 pancreatic tumors to establish possible 
clinicopathological correlations. Copy number increases were detected in 12.2% of 
the samples, showing good concordance with the smaller sample set. In addition, 
copy numbers of primary tumors and their corresponding metastases correlated well 
with one another.  
Gene amplification has been linked to tumor progression, drug resistance, and 
poor clinical outcome in multiple cancers (Seeger et al., 1985; Slamon et al., 1987; 
Savelyeva and Schwab, 2001). For example, amplifications of CCND1, EGFR, 
ERBB2, MDM2, and MYC are associated with high tumor grade, and amplifications 
of MYC and ERBB2 correlate with shortened survival in breast cancer (Al-Kuraya et 
al., 2004). In addition, amplification of MYCN is a prognostic factor in 
neuroblastoma, and amplifications of DHFR and BCR-ABL1 are associated with 
resistance to therapies (Albertson, 2006). We therefore explored whether the 19q13 
amplification is associated with clinicopathological characteristics and patient 
survival in pancreatic cancer. We found that the 19q13 copy number increases were 
linked to both advanced tumor stage and grade. This is a novel and important 
finding given that only a few amplified genes have been linked to advanced disease 
in pancreatic cancer (Friess et al, 1995; Gansauge et al., 1997). In ovarian 
carcinoma, the 19q13 amplification has previously been reported to associate with 
less differentiated and more aggressive tumors (Bellacosa et al., 1995), supporting 
our finding. To further strengthen our data, we sought to examine MED29 protein 
expression in the same panel of samples by immunohistochemistry. Unfortunately, 
the custom-made antibody that we had successfully used in western blot analysis 
failed to show specific staining of the tissues despite numerous trials.  
Kaplan-Meier survival analysis was used to evaluate the effect of the 19q13 
amplification on patient survival. Although the analysis did not provide statistically 
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significant evidence of shorter survival, the average survival time of patients with 
high-level amplification was notably shorter than the survival of patients with 
normal copy number status. The lack of statistical power in the analysis might be a 
consequence of the fairly small number of tumors with copy number aberrations or 
it may be due to the overall dismal prognosis of pancreatic cancer. In any case, our 
data are concordant with the conception that high level amplifications typically have 
a greater impact on tumor development than low-level aberrations (Hodgson et al., 
2003). Furthermore, amplification of the 19q13 locus has been previously associated 
with poor survival of patients with non-small cell lung cancer (Kim et al., 2005). 
Taken together, these studies provide a wealth of new information. A distinct 
amplicon core was delineated in pancreatic cancer cell lines and validated in 
primary pancreatic tumors, its association with high tumor grade and stage was 
revealed, and a tendency towards shorter patient survival was demonstrated. 
2. MED29 functions as a cancer promoting gene 
when endogenously amplified and 
overexpressed (I, III) 
Comprehensive gene expression analysis across the amplified region revealed 
several putative target genes. Given that all overexpessed genes within an amplicon 
theoretically represent putative candidate genes (Albertson, 2006), we chose to 
perform a targeted high-throughput RNAi screen to identify functionally relevant 
genes (Santarius et al., 2010; Ngo et al., 2006). Combination of data from the 
expression analysis and the RNAi screen enabled us to systematically recognize 
genes with increased expression levels due to amplification and for which down-
regulation resulted in phenotypic change. This strategy identified MED29 as the 
most promising target because it was overexpressed in the cells with amplification 
of the locus and showed the most dramatic reduction in cell viability in amplified 
PANC-1 but not in non-amplified MIA PaCa-2 cells when silenced. Silencing of 
other genes, including LRFN1, PLEKH2G, SUPT5H, and GMFG, decreased cell 
viability, but the change was not as clear or consistent as that observed for MED29. 
Based on these data, MED29 seems to be the strongest candidate target for the 
19q13 amplification, although we cannot exclude the involvement of other 
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overexpressed genes in the region. It is noteworthy that the RNAi screen was solely 
based on cell viability. Selection of another phenotypic endpoint might have yielded 
different results. Another issue concerning large-scale screens is that individual 
siRNAs can not be validated individually, meaning that specific and efficient 
silencing is not always obtained. To avoid biased results, four distinct siRNA 
molecules were used for each gene in repeated experiments.  
MED29 silencing experiments revealed increased apoptosis and G0-G1 arrest in 
19q13-amplified PANC-1 cells but not in the non-amplified MIA PaCa-2 cells. 
Similarly, reduced cell growth was obtained in MED29-silenced 19q13-amplified 
SU.86.86 cells. Soft agar colony formation, cell migration, and invasion, which are 
typical tumorigenic characteristics (Hanahan & Weinberg, 2000), were significantly 
compromised in PANC-1 cells after silencing of MED29. These data suggest that 
MED29 provides cancer cells with multiple beneficial oncogenic properties when 
amplified and overexpressed. Furthermore, decreased cell growth and survival after 
MED29 downregulation suggests that cells with amplified MED29 become 
dependent on it, a phenomenon known as oncogene addiction (reviewed by 
Weinstein & Joe, 2008).  
Other suggested targets for the 19q13 amplification in pancreatic cancer include 
ACTN4 (Kikuchi et al., 2008), AKT2 (Cheng et al., 1992), DYRK1B (Deng et al., 
2006), PAF1 (Moniaux et al., 2006), and PAK4 (Chen et al., 2008). AKT2 is a 
human homolog of the viral v-akt oncogene, which causes leukemia in mice (Staal 
et al., 1987). Amplification of AKT2 has been reported in ovarian carcinoma (Cheng 
et al., 1992) and in other cancers (Bellacosa et al., 1995). Our data show 
amplification of AKT2, but it was not consistently overexpressed in all amplified 
cell lines, and the silencing of AKT2 did not reduce cell viability. ACTN4 encodes 
an actin-binding protein that is involved in cell motility and invasion and has been 
shown to be amplified and overexpressed in pancreatic cancer (Kikuchi et al., 2008). 
However, ACTN4 was not within the minimal region delineated here and is likely 
located in a separate amplicon. DYRK1B is a serine/threonine kinase that mediates 
survival and is overexpressed in pancreatic cancer (Deng et al., 2006). DYRK1B was 
considerably overexpressed in two of our amplified cell lines and is a possible target 
in the region, although the viability screen did not support this finding. PAF1 is a 
human homologue of the RNA polymerase II-associated factor that is reported to 
promote tumor growth (Moniaux et al., 2006), but it was only moderately expressed 
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in the amplified cell lines in our analysis. PAK4 is a member of the p21-activated 
kinase family that was recognized as a putative 19q13 target along with MED29 and 
PAF1 in the representational oligonucleotide microarray analysis (Chen et al., 
2008). Unfortunately PAK4 was located outside of the amplified region delineated 
in this study and was thus not included in our expression analysis. Based on these 
reports, it is likely that this amplicon contains several target genes. 
3. Forced MED29 expression leads to 
attenuated tumor growth and downregulation 
of cell cycle genes (III) 
To gain a more thorough insight into the role of MED29 in pancreatic cancer, 
MED29 was overexpressed in three models: NIH/3T3, Hs 700T, and MIA PaCa-2 
cells. NIH/3T3 is s mouse fibroblast cell line commonly used in gene transfer 
experiments because it is easy to handle and transfect. Hs 700T and MIA PaCa-2 
pancreatic cancer cells served as suitable models due to their low endogenous 
MED29 expression levels. MED29 expression resulted in the reduced proliferation 
of NIH/3T3 and synchronized MIA PaCa-2 cells. This finding was unexpected 
because we had previously observed decreased cell growth after MED29 silencing 
in PANC-1 and SU.86.86 cells. However, different cell types and different genetic 
backgrounds may explain the opposite effects (Deer et al., 2010). Decreased cell 
growth in non-cancerous fibroblasts could also be explained by the induction of 
senescence, similar to what has been reported with KRAS and RAF oncogenes 
(Serrano et al., 1997; Zhu et al., 1998). In contrast, MED29 expression had no 
consistent effect on Hs 700T cell growth in vitro, which might be a consequence of 
differences in MED29 expression levels between the cells or the fact that we could 
not synchronize cell growth as we did with MIA PaCa-2 cells.  
Most importantly, MED29 led to significantly decreased tumor formation in 
mice xenografts of MIA PaCa-2 and Hs 700T cells. Mock-transfected xenografts 
formed large tumors, whereas MED29-transfected xenografts developed much more 
slowly, forming considerably smaller tumors. MED29-expressing MIA PaCa-2 
xenografts showed greatly reduced tumor incidence and a minimal growth increase 
during the observation period in contrast to MIA PaCa-2 mock tumors, which 
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exhibited exponential growth and a 100% tumor incidence. The effects of MED29 
on Hs 700T xenografts were similar to those on MIA PaCa-2 xenografts, but they 
were not as dramatic. These in vivo data firmly suggest that MED29 also possesses 
some tumor-suppressive properties.  
The opposing phenotypic characteristics revealed by MED29 silencing and 
overexpression experiments could reflect the differences between in vitro and in 
vivo assays. Alternatively, the differences in results could be attributed to the 
divergent genetic backgrounds of the cell lines. The cell lines are all highly evolved 
cancer cell lines carrying numerous genetic and epigenetic aberrations (Mahlamäki 
et al., 2002; Sato et al., 2003a; Deer et al., 2010) that are likely to influence their 
behavior. A third possibility is that MED29 possesses a dual role in cancer, with 
both oncogenic and tumor-suppressive characteristics depending on the surrounding 
milieu. There are a few examples of other proteins with such a dualistic role in 
cancer, of which transforming growth factor beta (TGFβ) is perhaps the best known. 
TGFβ is frequently overexpressed in breast carcinomas, and its expression is 
associated with poor prognosis and metastasis (Ivanovic et al., 2003; Desruisseau et 
al., 2006; Ivanovic et al., 2006). TGFβ predominantly exerts tumor-suppressive 
properties that cancer cells must evade for malignant transformation; however, it 
can initiate immune evasion, angiogenesis and metastatic dissemination during 
tumor progression (Massague, 2008). Other examples of such dualistic proteins in 
cancer include the macrophage migration inhibitory factor (MIF) in breast cancer 
(Verjans et al., 2009) and the v-ski sarcoma viral oncogene homolog in pancreatic 
cancer (Wang et al., 2009). Also the Notch developmental signaling pathway has 
been implicated in several malignancies, acting in oncogenic or tumor suppressive 
fashion depending on the cellular context (reviewed by Yin et al., 2010). 
Finally, genome-wide microarrays were utilized to explore MED29-induced 
differences in gene expression in MIA PaCa-2 and Hs 700T cells to clarify the 
underlying mechanisms and the role of MED29 in the regulation of growth and 
survival. Downregulation was more prevalent than upregulation among the 
differentially expressed genes, suggesting that MED29 functions mainly as a 
transcriptional repressor. Gene ontology and pathway analyses clearly indicated that 
the proteins encoded by the differentially expressed genes are involved in processes 
such as the cell cycle, cell division, cellular growth and proliferation, and cell death. 
Association with cell cycle regulation was most prominent, showing downregulation 
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of cell cycle promoting genes and upregulation of cell cycle regulatory genes. The 
microarray data were validated by a qRT-PCR-based method that confirmed the 
central role of MED29 in cell cycle regulation, with an overall inhibitory effect on 
cell cycle progression. This conclusion is in excellent concordance with our in vivo 
data demonstrating reduced tumor formation after MED29 induction.  
4. The role of Mediator in cancer (III) 
Gene transcription is a complex process regulating fundamental biological 
processes, such as growth and differentiation. It involves a myriad of specialized 
proteins and protein complexes that need to co-operate in a well-organized manner 
to express a given gene at a given time (Taatjes et al., 2004). Mediator acts in this 
process as a global transcriptional regulator mediating regulatory information from 
specific activators to the general transcription machinery; however, there is still lack 
of understanding regarding its function (Kornberg, 2005; Casamassimi & Napoli, 
2007; Lewis, 2010). A large body of work has concentrated on determination of the 
structural composition of Mediator, which is now fairly well established 
(Casamassimi & Napoli., 2007). Further studies are needed to elucidate its mode of 
action. Recently, a multiple allosteric networks model (MANM) was applied to gain 
better insight into the function of Mediator (Lewis, 2010). According to this model, 
Mediator is suggested to exist not only as a physical but also as a functional network 
of interconnected proteins through which information is mediated from subunit to 
subunit by the propagation of a specific allosteric state. In addition, several distinct 
sub-networks within the Mediator complex defined by their intern connections were 
found to have discrete functions that were activated through interactions with 
different activator proteins (Lewis, 2010).   
MED29 is a component of this large, multi-subunit complex, but its exact role 
remains elusive (Conaway et al., 2005b; Malik & Roeder, 2005). Based upon the 
roles of MED29 revealed by in vivo tumor formation, functional in vitro assays, and 
transcriptional regulation of several cell cycle- and cell division-related genes, it is 
reasonable to assume that it is involved in cancer pathogenesis. MED29 has been 
previously implicated as a transcriptional suppressor of SRE and AP-1, which are 
components of the MAPK signaling pathway, a cascade that is involved in multiple 
76 
cellular processes from growth to differentiation and apoptosis (Wang et al., 2004). 
The involvement of MED29 in the MAPK signaling cascade suggests a fundamental 
role for this protein in the regulation of growth and differentiation. Furthermore, the 
proposed suppressive role supports our findings from MED29 overexpression 
experiments, in which MED29 induction led to decreased cell growth and tumor 
formation as well as downregulation of several growth promoting genes. 
MED29 has not been previously linked to any malignancies, but accumulating 
evidence indicates multiple subunits of Mediator in the development of various 
cancers. For example, CDK8 has been implicated as an oncogene and has a putative 
role in transcriptional regulation of key pathways in colon cancer (Firestein et al., 
2008). In addition, CDK8 has been shown to have increased expression in colorectal 
tumors and a significant correlation with carcinogenesis, tumor progression and 
patient survival (Seo et al., 2010). Similarly, MED28 is upregulated in several 
cancers (Zhang et al., 2004; Yoon et al., 2010) and associated with a poor outcome 
in breast cancer (Yoon et al., 2010). Moreover, the inhibition of MED28 expression 
decreases cellular proliferation in vitro and in vivo (Lu et al., 2007). MED1 is 
amplified in breast and ovarian cancers (Zhu et al., 1999) and overexpressed in 
prostate cancer (Vijayvargia et al., 2007). Furthermore, the silencing of MED1 and 
MED17 inhibits the expression of androgen receptor target genes, decreases cellular 
proliferation, inhibits cell cycle progression, and increases apoptosis in prostate 
cancer (Vijayvargia et al., 2007). Moreover, Mediator has been reported to be a key 
transducer in several signaling pathways that are often affected in cancer, including 
Ras/MAP kinase (Stevens et al., 2002; Mo et al., 2004), Wnt/β-catenin (Kim et al., 
2006), and TGFβ pathways (Kato et al., 2002). All of these observations 
substantiate the involvement of Mediator in cancer, which is not surprising in the 
context of transcriptional regulation.  
5.  Future prospects  
This study was the first to characterize the 19q13 amplicon in pancreatic cancer in 
detail and to identify MED29 as the most promising target gene. Using a large 
collection of primary tumors, a correlation between this amplicon and poor tumor 
phenotype in pancreatic cancer was also demonstrated for the first time. This 
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association is an important finding and the subsequent logical step would now be to 
evaluate MED29 protein levels in the same set of primary tumors. These analyses 
would reveal the direct clinical significance of MED29 in pancreatic cancer. 
A dramatic phenotypic effect was observed in the subcutaneous mouse 
xenograft model using MED29-expressing pancreatic cancer cells. The next step 
could be the use of an orthotopic or genetically engineered mouse model to study 
the impact of MED29 manipulation in a more appropriate cellular environment. In 
addition, the in vivo effects of MED29 silencing could be examined using pancreatic 
cancer cell lines with high endogenous expression. In such studies, both 
subcutaneous and orthotopic mouse models could be utilized in a similarly as in the 
overexpression analyses. 
Considering the exciting novel findings in this study, it would be interesting to 
evaluate the role of down-stream effectors of MED29 in pancreatic cancer 
pathogenesis. The microarray data already pinpointed a range of interesting genes 
and pathways with MED29-regulated expression. Some of these have a known 
function in e.g. cell cycle regulation and thus are likely to have a relevant role in 
cancer, but others have not been previously linked to tumorigenesis and should thus 
be investigated in greater detail. Finally, given the central role of Mediator in 
transcriptional regulation, it would be appealing to study the possible role of other 
components of the Mediator in cancer pathogenesis.  
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CONCLUSIONS 
The main aim of this study was to perform a detailed molecular characterization of 
the 19q13 amplification in pancreatic cancer, and more precisely, to elucidate the 
biological significance of this amplification and the role of individual genes that are 
activated through this amplification during tumor development.  
Thorough amplicon mapping of the 19q13 locus revealed a minimal amplified 
region of 1.1 Mb and a highly amplified core region of 660 kb. The clinical 
significance of this amplicon core was evaluated in two sets of primary pancreatic 
tumors, both of which revealed 19q13 amplification to be a frequent event in 
pancreatic cancer, affecting more than 10% of patients. Importantly, the 19q13 copy 
number increases correlated with both tumor stage and grade. This is a new and 
important finding in pancreatic cancer. Patient survival was not significantly 
affected by this amplification, although the average survival time of patients with 
high-level amplification was notably shorter than the survival time of patients with 
normal copy number status. 
Comprehensive expression analysis of putative amplification targets disclosed 
several overexpressed genes. However, the combined data from the expression 
survey and the RNAi-based viability screen for functional targets revealed MED29, 
a novel cancer-associated gene, to be the most promising target gene. It was 
consistently overexpressed, and its downregulation led to significant phenotypic 
changes in amplified pancreatic cancer cells. Further functional studies of MED29 
revealed both oncogenic and tumor-suppressive characteristics. RNAi-based 
downregulation of high endogenous MED29 expression led to the inhibition of 
several tumor cell-associated phenotypes, including cell growth, migration, 
invasion, and colony formation, substantiating the oncogenic role of MED29 in 
pancreatic cancer. In contrast, the in vivo xenograft data from nude mice injected 
with pancreatic cancer cells with induced MED29 expression showed a dramatic 
reduction in tumor formation, thus providing a strong indication of a tumor 
suppressive role of MED29. Finally, systematic genome-wide expression analysis 
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indicated that these phenotypic effects are largely mediated by alterations in cell 
cycle regulation. 
Taken together, this study provides new exciting information on molecular 
events in pancreatic cancer and serves as a valuable reminder of the contextual 
concept of cancer. The study accomplished detailed characterization of the 19q13 
amplification in pancreatic cancer, including determination of its frequency and 
clinical significance, as well as the identification of a novel cancer-associated gene, 
MED29. It is fascinating that MED29 seems to possess a dual role in pancreatic 
cancer, having both oncogenic and tumor-suppressive properties. However, the 
further functional characterization of MED29 and its interacting partners are needed 
to elucidate its role in cancer more precisely. A deeper understanding of the 
Mediator complex and its individual components in transcriptional regulation might 
help to build a more comprehensive view of the functional role and mechanisms of 
action of MED29 in cancer pathogenesis. 
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Abstract
Pancreatic cancer is a highly aggressive disease characterized
by poor prognosis and vast genetic instability. Recent micro-
array-based, genome-wide surveys have identified multiple
recurrent copy number aberrations in pancreatic cancer;
however, the target genes are, for the most part, unknown.
Here, we characterized the 19q13 amplicon in pancreatic
cancer to identify putative new drug targets. Copy number
increases at 19q13 were quantitated in 16 pancreatic cancer
cell lines and 31 primary tumors by fluorescence in situ
hybridization. Cell line copy number data delineated a 1.1 Mb
amplicon, the presence of which was also validated in 10% of
primary pancreatic tumors. Comprehensive expression anal-
ysis by quantitative real-time reverse transcription-PCR
indicated that seven transcripts within this region had
consistently elevated expression levels in the amplified versus
nonamplified cell lines. High-throughput loss-of-function
screen by RNA interference was applied across the amplicon
to identify genes whose down-regulation affected cell viability.
This screen revealed five genes whose down-regulation led to
significantly decreased cell viability in the amplified PANC-1
cells but not in the nonamplified MiaPaca-2 cells, suggesting
the presence of multiple biologically interesting genes in this
region. Of these, the transcriptional regulator intersex-like
(IXL) was consistently overexpressed in amplified cells and
had the most dramatic effect on cell viability. IXL silencing
also resulted in G0-G1 cell cycle arrest and increased apoptosis
in PANC-1 cells. These findings implicate IXL as a novel
amplification target gene in pancreatic cancer and suggest
that IXL is required for cancer cell survival in 19q13-amplified
tumors. [Cancer Res 2007;67(5):1943–9]
Introduction
Pancreatic adenocarcinoma is a highly aggressive malignancy
with extremely poor prognosis. In the United States, pancreatic
cancer is the fifth leading cause of cancer death, accounting for
f30,000 deaths per year (1). Pancreatic cancer is characterized
by rapid progression, invasiveness, and profound resistance to
treatment (2). Apart from surgery, there is practically no effective
therapy; typically, the disease is diagnosed at an advanced stage
when surgical resection is no longer possible. Consequently, the
5-year survival rate for pancreatic cancer is <5% and the median
survival is <6 months (2, 3). Even for patients who undergo
potentially curative resection, the 5-year survival rate is only
f20% (2).
Aneuploidy and increased genetic instability manifesting as
complex genetic aberrations, such as losses, gains, and amplifica-
tions, are common features of pancreatic cancer (4, 5). These
genetic alterations are likely to conceal genes involved in disease
pathogenesis, and uncovering such genes might thus provide
targets for the development of new diagnostic and therapeutic
tools. In particular, gene amplification is a common mechanism for
activating oncogenes, and other growth-promoting genes in cancer
and amplification of target genes, such as ERBB2 in breast cancer
and MYCN in neuroblastomas, have been shown to have clinical
significance as diagnostic and prognostic markers as well as
therapeutic targets (6). We recently did a microarray-based copy
number analysis in pancreatic cancer cell lines and identified an
f2.9 Mb amplicon at 19q13 (7). This result has since been
confirmed in multiple subsequent studies (8–12) and the same
amplicon has also been observed in other tumor types, including
ovarian, breast, cervical, gastric, and small-cell lung cancer (13–20).
Unfortunately, the microarray used in our previous study did not
provide a complete coverage of the 19q13 region and thus did not
allow direct elucidation of putative target genes. Here, we present
results from the comprehensive evaluation of the 19q13 amplicon
in pancreatic cancer, including detailed copy number and
expression analyses as well as high-throughput loss-of-function
screen using the RNA interference (RNAi) technology.
Materials and Methods
Cell lines and tissue samples. Thirteen pancreatic cancer cell lines,
AsPC-1, BxPC-3, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF-II, Hs 700T, Hs
766T, MiaPaCa-2, PANC-1, SU.86.86, and SW1990, were obtained from the
American Type Culture Collection (Manassas, VA). Three additional cell
lines, DAN-G, HUP-T3, and HUP-T4, were acquired from the German
Collection of Microorganisms and Cell Cultures (Brunswick, Germany). The
cell lines were cultured under recommended conditions. Commercially
available pancreatic cancer tissue microarray (AccuMaxTM Arrays) was
obtained from Petagen Incorporation (Seoul, Korea). The tissue microarray
contained four nonneoplastic pancreatic tissue specimens and 33
pancreatic cancer cases. Detailed clinicopathologic information on the
tumor specimens is shown in Supplementary Table S1.
Genomic clones. Public genome databases (National Center for
Biotechnology Information3 and University of California Santa Cruz
Genome Bioinformatics4) were used to select 15 bacterial artificial
chromosome (BAC) clones evenly distributed over the 2.9 Mb amplicon
at 19q13. These BAC clones were obtained from Invitrogen (Carlsbad, CA).
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
Requests for reprints: Anne Kallioniemi, Institute of Medical Technology, Biokatu
6, 33014 University of Tampere, Tampere, Finland. Phone: 358-3-3551-8833; Fax: 358-3-
3117-4168; E-mail: anne.kallioniemi@uta.fi.
I2007 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-06-3387
3 http://www.ncbi.nlm.nih.gov/
4 http://www.genome.ucsc.edu/
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In addition, a BAC clone (RP11-345J21, a kind gift from Mariano Rocchi,
University of Bari, Bari, Italy) adjacent to the chromosome 19 centromere
on 19q was used as a control. The list of all BAC clones is shown in
Supplementary Table S2.
Fluorescence in situ hybridization. BAC clone DNA was labeled with
SpectrumOrange-dUTP (Vysis, Downers Grove, IL) using random priming.
Chromosome 19 reference probe (RP11-345J21) was labeled with fluores-
cein-12-dUTP (Perkin-Elmer, Boston, MA). Dual-color interphase fluores-
cence in situ hybridization (FISH) to pancreatic cancer cell lines was done
as described (21). Hybridization signals were evaluated using Olympus BX50
fluorescence microscope (Olympus, Tokyo, Japan). Forty intact nuclei were
scored for each probe, and relative copy numbers were calculated as ratios
of mean absolute copy number of the test probe versus reference probe.
FISH on tissue microarray was carried out as described (22). Three adjacent,
partly overlapping BAC clones (RP11-67A5, RP11-256O9, and CTC-488F21)
were combined to increase signal intensity and hybridization efficiency.
Control experiments on normal lymphocytes verified that this probe
combination gave a single hybridization signal. The RP11-345J21 probe was
again used as a reference. Hybridization signals were scored and evaluated
as described above.
Quantitative real-time reverse transcription-PCR. Gene expression
analyses were done using either the Light Cycler equipment (Roche,
Mannheim, Germany) or the ABI 7900HT Fast Sequence Detection System
(Applied Biosystems, Foster City, CA). Total RNA was isolated from cell lines
using RNeasy Mini total RNA extraction kit (Qiagen, Valencia, CA) and
reverse transcribed into first-strand cDNA using Superscript III reverse
transcriptase (Invitrogen) and random hexamers or iScript cDNA synthesis
kit (Bio-Rad, Inc., Hercules, CA). Normal human pancreatic RNA was
obtained from Ambion (Cambridgeshire, United Kingdom). For the Light
Cycler analyses, primers and probe sets were obtained from TIB MolBiol
(Berlin, Germany), and Light Cycler software (Roche) was used for data
analysis as described (23). Expression levels of the target genes were
normalized against a housekeeping gene TBP (TATA box binding protein;
ref. 23). For the ABI system, TaqMan Gene Expression Assays were obtained
from Applied Biosystems and ABI 7900HT software (Applied Biosystems)
was used for data analyses. Expression levels of the target genes were
normalized against an endogenous reference gene GAPDH (glyceraldehyde-
3-phosphate dehydrogenase). Primer and probe sequences are shown in
Supplementary Table S3.
Loss-of-function RNAi screen. Loss of function screening was done by
high-throughput RNAi using a focused small interfering RNA (siRNA) library
targeting all 19 known genes within the amplicon that were expressed in
PANC-1 cells (Supplementary Table S4). Two genes, SAMD4B and EID2B ,
were hypothetical proteins at the time of the experiment and were thus not
included. Four siRNAs were designed for each gene using previously
described criteria (24, 25) and were obtained from Qiagen. A nonsilencing
siRNA (Qiagen) was used as a negative control. High-throughput RNAi was
done using siRNA reverse transfection of cells. Briefly, siRNAs were printed
in quadruplicate wells of a 384-well Costar microtiter plate (Fisher
Scientific, Hampton, NH). Diluted Oligofectamine (Invitrogen) was added
to the wells to allow for the complexing of siRNA and transfection reagent.
After a 30-min incubation period, cell suspensions of either MiaPaca-2 or
PANC-1 cells were added to give a final concentration of 1,000 per well. Cells
were grown at 37jC with 5% CO2 for 96 h. Total cell number was analyzed
using Cell Titer Blue (Promega, Madison WI), and the plate was read at
excitation 544 nm/emission 560 nm using a EnVision plate reader (Perkin-
Elmer, Wellesley, MA). Reduced cell viability to 50% or less compared with
nonsilencing siRNA-treated cells was considered a significant change.
Cell cycle and apoptosis analyses. Oligofectamine reagent (Invitrogen)
was used to transfect siRNAs in a final concentration of 100 nmol/L into
PANC-1 cells according to the manufacturer’s protocol. IXL 144 siRNA was
used to determine the effect of inhibition of IXL expression; luciferase
control siRNA, which targets the firefly luciferase gene (Genbank accession
no. M15077), was used as a control (Supplementary Table S4). Experiments
were done in triplicates using 24-well plates. After a 48-h transfection, cells
were collected for cell cycle and apoptosis analyses as well as for parallel
mRNA expression analyses (see above) to verify that efficient silencing was
obtained. For the cell cycle analysis, trypsinized cells were centrifuged and
suspended to 500 AL hypotonic staining buffer (0.1 mg/mL sodium citrate
tribasic dehydrate, 0.03% Triton X-100, 50 Ag/mL propidium iodide,
2 Ag/mL RNase A) and the amount of propidium iodide incorporated was
determined using flow cytometry (Coulter EPICS XL-MCL, Beckman
Coulter, Inc., Fullerton, CA). Cell cycle distribution was analyzed using
the Cylchred program.5 Annexin V FITC Apoptosis Detection Kit
(Calbiochem) was used to detect apoptotic cells by flow cytometry
(Beckman Coulter, San Diego, CA).
Results
We first did a systematic characterization of the extent of the
19q13 amplicon in a panel of 16 pancreatic cancer cell lines. To this
end, FISH, using 15 BAC clones evenly distributed across the
2.9 Mb region (Supplementary Table S1), was applied. Greater than
2-fold copy number increases were observed in 3 of 16 (19%) cell
lines, PANC-1, Su.86.86, and HPAC (Fig. 1). The PANC-1 cell line
harbored massive amplification (up to 20-fold) that on metaphase
chromosomes manifested as homogeneously staining region–like
structures (Fig. 1E), whereas lower-level copy number increases
(up to 5.3- and 2.6-fold, respectively) were observed in SU.86.86 and
HPAC cells (Fig. 2). The relative copy numbers of PANC-1 cells
varied considerably across the 2.9 Mb region (Fig. 1A–D), whereas
SU.86.86 and HPAC cells showed essentially uniform copy number
levels across the entire amplicon. Based on the PANC-1 copy
number profile, we were able to delineate a 1.1 Mb amplicon core
defined by six partly overlapping BAC clones from RP11-67A5 to
CTC-425O23 (Fig. 2). Furthermore, three BAC clones within this 1.1
Mb amplicon core, RP11-67A5, RP11-256O9, and CTC-488F21,
displayed 14- to 20-fold copy number increase in PANC-1 cells
(Fig. 2), thus defining an 660 kb subregion of extremely high level
amplification.
We also examined the presence of this amplicon in primary
tumors using FISH to a tissue microarray containing 33 pancreatic
cancer specimens. High-level amplification (relative copy number
z5) was observed in 3 of 31 tumors (9.7%) with successful
hybridizations (Fig. 3). All three tumors with amplification were
moderately to poorly differentiated (grades 2–3) ductal adenocar-
cinomas and showed lymph node metastases (Supplementary
Table S2). Two of the tumor samples also had extensions to
peripancreatic soft tissue with perineural invasion. The metastasis
status of the third tumor was not available.
To explore the consequences of amplification on gene expres-
sion, we first used public genome databases6 to retrieve all
transcribed sequences within the core 1.1 Mb amplicon. A total of
39 transcripts, including 27 known genes and 12 hypothetical or
predicted proteins, were identified (Table 1). Sixteen of these were
excluded as possible candidate genes because they represented (a)
obvious pseudogenes, (b) predicted transcripts with no mRNA
and expressed sequence tag evidence in public databases, or (c)
transcripts with no or very low level expression in PANC-1
(Table 1). The last criterion was based on the expectation that any
putative amplification target gene should be highly expressed in
PANC-1 cells that show high-level amplification. The expression
levels of the remaining 23 transcripts were then assessed in all 16
pancreatic cancer cell lines using quantitative real-time RT-PCR.
Interestingly, 22 of the 23 genes were highly overexpressed in
5 http://www.cardiff.ac.uk/medicine/haematology/cytonetuk/documents/
software.htm
6 http://www.genome.ucsc.edu and http://www.ncbi.nlm.nih.gov
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PANC-1 cells compared with the other pancreatic cancer cell lines
(Fig. 4) and normal pancreas (data not shown). Only PLD3 , located
at the distal-most end of the amplicon, was not overexpressed in
PANC-1. In contrast, HPAC and Su.86.86 cells showed variable
expression levels from one gene to another (Fig. 4) thus allowing us
to distinguish genes differentially expressed between amplified and
nonamplified cell lines. Six known genes (GMFG, SAMD4B, IXL,
SUPT5H, PSMC4 , and MAP3K10) and one hypothetical protein
(LOC284323) showed consistent overexpression in all three
amplified cell lines (Fig. 4). Of these, IXL showed the most distinct
differential expression pattern between the amplified and non-
amplified cell line groups, with high-level expression occurring
almost exclusively in the amplified cell lines. In contrast,
GMFG and MAP3K10 were also highly expressed in additional cell
lines with no copy number increase, indicating other activating
mechanisms besides amplification. Interestingly, three of the
overexpressed genes, PSMC4, MAP3K10 , and LOC284323 , are
located outside the 660 kb amplicon maximum, thus making them
less likely to be the main targets of the amplification.
To identify which of the amplified targets are functionally
important, we did a targeted high-throughput RNAi screen across
the defined 1.1 Mb amplicon. This loss-of-function survey was
applied to study the effect of silencing of 19 known genes from the
amplified region. Four different siRNAs were designed for each
gene (Supplementary Table S4), and their effect on cell viability was
examined in PANC-1 and MiaPaCa-2 cells 96 h after transfection.
Down-regulation of IXL resulted in statistically highly significant
reduction in cell viability (P < 0.001) in the amplified PANC-1 cells
but not in the nonamplified MiaPaCa-2 cells (Fig. 5A ; Supplemen-
tary Table S5). This effect was observed with two independent
siRNAs in three repeated experiments. Similar reduction in cell
viability was detected after LRFN1 and PLEKHG2 silencing as well
but only with a single siRNA. Finally, down-regulation of GMFG and
SUPT5H also led to reduction in cell viability but to a lesser extent
(Fig. 5A). Other genes examined did not have a statistically
significant effect on cell viability.
Further functional characterization concentrated on IXL be-
cause it was located within the 660 kb amplicon maximum and was
implicated in both the expression survey and the RNAi viability
Figure 1. Copy number increases at 19q13 in pancreatic cancer cell lines. A to D, FISH signals in PANC-1 cells across the amplicon using BAC clones
(red signals ) CTC-218B8 (A ), CTC-488F21 (B ), RP11-246P10 (C ), and CTC-492K19 (D ), with a chromosome 19 pericentromeric reference probe (green signals ).
E, amplification manifesting as homogenously staining regions on PANC-1 metaphase chromosome (arrows ). Two apparently normal copies of chromosome 19
are seen in the same metaphase. Low-level copy number increases in SU.86.86 (F ) and HPAC (G ) as well as no copy number change in Capan-1 cells (H ). Nuclei were
counterstained with 4¶,6-diamidino-2-phenylindole (blue ). Bar (in A ), 10 Am, for all panels.
Figure 2. Amplicon mapping at 19q13 in pancreatic cancer cell lines.
Relative copy number ratios for eight BAC clones around the minimal amplified
region are shown for the three amplified cell lines, PANC-1, SU.86.86, and
HPAC, as well as a representative nonamplified cell line, Capan-1. Vertical
dashed lines, the 1.1 Mb core region of amplification (defined by clones
RP11-67A5 and CTC-425O23) as well as the 660 kb subregion (defined by
clones RP11-67A5 and CTC-488F21).
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screen. To explore the functional role of IXL overexpression, we
transfected siRNAs targeting IXL into amplified PANC-1 cells and
assessed the effects on cell cycle and apoptosis 48 h after
transfection. A parallel mRNA expression analysis was done to
verify that sufficient silencing was obtained (Fig. 5B). All
functional experiments were done in triplicates and repeated
twice. Cell cycle analysis using flow cytometry showed an
increased fraction of G0-G1 phase cells after IXL siRNA (66%)
transfection compared with nontransfected cells (37%) or cells
transfected with a control siRNA (39%; Fig. 5C). Also, the
percentage of apoptotic cells was increased in IXL siRNA–treated
cells (8%) compared with control siRNA (1.6%) or untreated cells
(2.5%; Fig. 5D). Similar phenotypic changes were not observed
after IXL siRNA transfection to nonamplified MiaPaCa-2 cells
(data not shown).
Discussion
Gross chromosomal aberrations, including losses, gains, and
amplifications, are frequent in pancreatic cancer (3). Gene
amplification is a common mechanism for solid tumors to up-
regulate the expression of genes involved in tumor progression
(26, 27). Although multiple amplified regions have been docu-
mented in pancreatic carcinoma, the putative target genes
activated by these aberrations are largely unknown. Identification
of novel amplification target genes is extremely important because
it will not only advance our knowledge on pancreatic cancer
pathogenesis but it might also provide new tools for the clinical
management of this highly aggressive disease.
Previously, we did a genome-wide cDNA microarray-based copy
number analysis to identify localized DNA amplifications in
pancreatic cancer and recognized a novel amplified region at
19q13 spanning 2.9 Mb (7). However, due to incomplete clone
coverage on the microarray used, this previous study did not
permit exact definition of the amplicon boundaries or direct
identification of possible amplification target genes. Therefore,
we now carried out a systematic evaluation of this amplified region
to achieve these objectives. Three cell lines, PANC-1, SU86.86, and
HPAC, harbored the 19q13 amplification, with PANC-1 cells
demonstrating a massive, up to 20-fold, amplification. In addition,
the copy number profile of PANC-1 allowed us to narrow down the
amplicon core to 1.1 Mb, which also contained a 660 kb subregion
of extremely high level amplification. Previous studies have
indicated that amplification target genes are likely to be located
at or near the center of the amplification maximum; that is, the
region with highest copy number increase (28, 29). We thus believe
this 660 kb subregion to be of particular interest in pinpointing the
actual target genes of this amplicon.
Because the delineation of the amplicon core was accomplished
using established pancreatic cancer cell lines, we next sought to
validate the presence of the 19q13 amplicon in primary pancreatic
tumors. Evaluation of a set of 31 pancreatic tumors revealed
amplification in a f10% of the cases, thus confirming that this
aberration is also present in actual human tumors and is not a cell
culture–derived artifact. In general, oncogene amplification has
been shown to be linked to advanced disease (30, 31), and, in
ovarian carcinoma, 19q13 amplification has been associated with
less differentiated and more aggressive tumors (14). In our series,
all three tumors with amplification were moderately to poorly
differentiated. All three patients had nodal metastases and two of
them also had local metastases, whereas this information was
missing from the third patient. Based on these tumor character-
istics, the 19q13 amplification seems to be associated with
advanced disease in pancreatic cancer as well. However, the
number of analyzed tumors was limited; therefore, the amplifica-
tion frequency as well as the possible clinicopathologic associa-
tions need to be confirmed.
A comprehensive expression analysis was subsequently done
across the 1.1 Mb region to identify genes whose expression levels
are elevated through 19q13 amplification. This approach was based
on the well-established concept that amplification leads to
increased expression of the putative target gene. Our data revealed
a very distinct expression profile in PANC-1 cells demonstrating
high-level expression of all but one gene throughout the entire
amplicon. We hypothesize that the extremely high-level amplifica-
tion in PANC-1 cells leads to complete deregulation of transcrip-
tional control across the amplicon and thereby increased
expression of all genes within this region. In contrast, SU.86.86
and HPAC cells displayed more variable expression patterns with
consistent overexpression in a subset of seven genes compared
with nonamplified cells, with IXL having the strongest association
with amplification. Four of these seven genes, GMFG, SAMD4B, IXL ,
and SUPT5H , are located within the 660 kb amplicon maximum
and were therefore considered the most likely targets.
Because the expression analysis did not explicitly pinpoint a
single putative amplification target gene, we chose to perform a
targeted high-throughput RNAi screen across the entire amplicon
to identify functionally relevant genes. Combination of data
from the expression analysis and the RNAi screen allowed us to
rapidly and systematically identify genes whose expression levels
were elevated through amplification, and, at the same time, whose
down-regulation resulted in phenotypic changes. This strategy
highlighted IXL as a gene that is activated by the 19q13
amplification and whose down-regulation resulted in most
dramatic reduction in cell viability in amplified PANC-1 but not
in nonamplified MiaPaCa-2 cells. LRFN1 and PLEKH2G knock-
downs also affected cell viability but not as consistently as IXL .
However, these genes were not systematically overexpressed in all
amplified cell lines. Down-regulation of SUPT5H and GMFG also
depressed cell viability; however, the decrease was not as
significant as for IXL . Based on these data, IXL seems to be the
strongest candidate for the amplification target gene; however, we
cannot exclude the involvement of some of the other genes in the
region.
Further functional assays showed that IXL silencing resulted in
increased apoptosis and G0-G1 arrest again in PANC-1 cells but not
in MiaPaCa-2 cells, suggesting that IXL affects cell cycle regulatory
Figure 3. Copy number analysis in primary pancreatic tumors by FISH. A contig
of three adjacent probes (RP11-67A5, RP11-256O9, CTC-488F21; red signals )
was hybridized together with the chromosome 19 pericentromeric control
probe (green signals ) to a tissue microarray containing 33 pancreatic tumor
samples. Examples of tumors with (A–B ) and without (C) amplification.
Cancer Research
Cancer Res 2007; 67: (5). March 1, 2007 1946 www.aacrjournals.org
mechanisms that control the G1-S transition as well as induction of
apoptosis. These data implicate that IXL is required for cell cycle
progression and cell survival in 19q13-amplified pancreatic cancer
cells. IXL is a homologue to Drosophila melanogaster intersex , a
transcriptional regulator involved in female somatic sex determi-
nation (32). The protein is broadly conserved during evolution (33),
suggesting its importance in transcriptional regulation also in
other species. Indeed, mammalian IXL has been recognized as a
subunit of Mediator, a multiprotein complex that transduces
regulatory signals from DNA-binding transcription factors to RNA
polymerase II and thereby regulates mRNA synthesis (33, 34). The
Mediator complex is required for transcriptional activation and
thus controls key cellular processes. The exact function of human
IXL remains elusive, although it was recently proposed to be
involved in mitogen-activated protein kinase signaling pathway
(33). The overexpression of IXL in pancreatic cancer may thus lead
to inappropriate activation of several critical cellular processes,
such as those regulating cell growth.
The AKT2 gene has previously been suggested as the target for
the 19q13 amplification (15). AKT2 is the human homologue of the
viral v-akt oncogene, which is responsible for leukemia in mice (19).
Amplification of AKT2 was originally discovered in ovarian cancer
(15) but has been later observed also in other cancer types (14). Our
data show that AKT2 is indeed amplified in pancreatic cancer,
although it is located at the distal-most end of the 19q13 amplicon.
However, AKT2 was not consistently overexpressed in all amplified
cell lines and its down-regulation did not affect cell viability. These
findings indicate that AKT2 is clearly not the main target of the
19q13 amplification in pancreatic cancer although it cannot be
ruled out that simultaneous activation of AKT2 with other
Table 1. List of genes in the 19q13 amplicon
Gene name Start Stop Description Comment
IL29 44,478,805 44,481,152 Interleukin 29 Not expressed*
LRFN1 44,489,048 44,503,338 Leucine-rich repeat and fibronectin type III domain containing 1
GMFG 44,510,839 44,518,460 Glia maturation factor g
SAMD4B 44,539,246 44,568,186 Sterile a motif domain containing 4B
PAF1 44,568,112 44,573,519 Paf1, RNA polymerase II associated factor, homologue (S. cerevisiae)
IXL 44,573,840 44,583,048 Intersex-like (Drosophila)
ZFP36 44,589,327 44,591,885 Zinc finger protein 36, C3H type, homologue (mouse)
PLEKHG2 44,595,590 44,607,994 Pleckstrin homology domain containing family G member 2
RPS16 44,615,692 44,618,478 Ribosomal protein S16
SUPT5H 44,628,164 44,659,150 Suppressor of Ty 5 homologue (S. cerevisiae)
TIMM50 44,663,316 44,674,306 Translocase of inner mitochondrial membrane 50 homologue (yeast)
DLL3 44,681,427 44,690,949 Delta-like 3 (Drosophila)
SELV 44,539,246 44,568,186 Selenoprotein V Not expressed*
EID-3 44,715,334 44,713,470 EID-2-like inhibitor of differentiation-3
CRI2 44,721,289 44,722,664 CREBBP/EP300 inhibitor 2
LOC390930 44,735,501 44,738,032 Similar to Eosinophil lysophospholipase (Charcot-Leyden crystal protein) Pseudogene
LGALS13 44,785,004 44,789,955 Lectin, galactoside-binding, soluble, 13 (galectin 13) Not expressed*
LOC441850 44,820,643 44,824,298 Similar to eosinophil lysophospholipase (Charcot-Leyden crystal protein) Pseudogene
LOC148003 44,838,415 44,843,127 Similar to placental tissue protein 13 (placenta protein 13; galectin-13) No mRNA/EST evidence
LOC400696 44,861,854 44,868,848 Eosinophil lysophospholipase-like Not expressed*
LGALS14 44,877,533 44,891,927 Lectin, galactoside-binding, soluble, 14 Not expressed*
CLC 44,913,736 44,934,546 Charcot-Leyden crystal protein Not expressed*
LOC342900 44,959,075 44,968,615 Hypothetical protein LOC342900 No mRNA/EST evidence
DYRK1B 45,007,831 45,016,681 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B
FBL 45,016,938 45,028,813 Fibrillarin
FCGBP 45,045,811 45,132,373 Fc fragment of IgG binding protein
LOC440525 45,140,982 45,141,428 Proline-rich 13 pseudogene Pseudogene
PSMC4 45,168,913 45,179,193 Proteasome (prosome, macropain) 26S subunit, ATPase, 4
ZNF546 45,194,869 45,215,354 Zinc finger protein 546
LOC390933 45,221,651 45,222,297 Similar to hypothetical protein Pseudogene
LOC163131 45,248,079 45,232,104 Hypothetical protein LOC163131 Not evaluated
LOC284323 45,270,739 45,288,649 Hypothetical protein LOC284323
MAP3K10 45,389,491 45,413,314 Mitogen-activated protein kinase kinase kinase 10
TTC9B 45,413,805 45,416,138 Tetratricopeptide repeat domain 9B Not expressed*
FLJ13265 45,419,955 45,424,404 Hypothetical protein FLJ13265 Not expressed*
LOC440526 45,429,392 45,430,177 Hypothetical protein LOC440526
AKT2 45,431,556 45,483,036 v-akt murine thymoma viral oncogene homologue 2
FLJ36888 45,518,813 45,546,262 Hypothetical protein FLJ36888 Not expressed*
PLD3 45,557,389 45,576,230 Phospholipase D family, member 3
Abbreviation: EST, expressed sequence tag.
*Not expressed in PANC-1.
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candidate genes from this region might provide a growth
advantage for the cancer cells. Recently, two other genes from this
region, PAF1 and DYRK1B , were proposed to associate with
pancreatic cancer development and cell survival, respectively
(35, 36). Yet, again, our data do not show evidence that these
genes would be the key targets of 19q13 amplicon.
In summary, our detailed characterization of the 19q13 amplicon
in pancreatic cancer cell lines delineated a minimal region of
amplification to a 1.1 Mb segment and further pinpointed a 660-kb
amplification maximum. This amplicon was recognized in 19% of
cell lines and 10% of primary pancreatic tumors. Expression
profiling of genes residing in the amplicon revealed seven
biologically interesting genes that were more strongly expressed
in the amplified cell lines compared with the nonamplified ones.
High-throughput loss-of-function screen by RNAi technology
showed that down-regulation of IXL , and, to a lesser extent,
GMFG and SUPT5H , resulted in decreased cell viability in the
amplified PANC-1 but not in the nonamplified cells. Additionally,
IXL knockdown was found to associate with G0-G1 arrest and
increased apoptosis. Our results reveal IXL as a novel amplification
Figure 4. Schematic representation of
mRNA expression levels of 23 genes
within the 1.1 Mb amplicon at 19q13 in
16 pancreatic cancer cell lines. The
expression levels were determined using
quantitative real-time RT-PCR and were
normalized against a housekeeping gene
TBP . The relative expression levels for
each gene were median centered and
displayed as a pseudocolor gradient. The
genes are arranged according to their
chromosomal position (from centromere to
telomere). Bottom, key to the color coding.
Horizontal line above the figure, 660 kb
amplicon core.
Figure 5. Functional evaluation of
RNAi-based gene silencing in the PANC-1
cells. A, summary of data from the
high-throughput RNAi viability screen. The
number of cells were determined 96 h
after siRNA transfection and compared
with that of untreated control (UT ).
Columns, mean of four independent wells
shown for selected genes as well as
nonsilencing control siRNA; bars, SD.
*, P < 0.01; **, P < 0.001, statistically
significant reduction in cell viability. The
experiment was repeated thrice with similar
results. Raw data from the entire viability
screen are shown in Supplementary
Table S5. B, quantitative real-time
RT-PCR analysis of IXL mRNA expression
levels in PANC-1 cells 48 h after
transfection of luciferase control siRNA
(siLUC) or IXL 144 siRNA. Results were
normalized against untreated cells.
Columns, mean of triplicate experiments;
bars, SD. C, IXL down-regulation results in
G0-G1 arrest. Cell cycle analysis of
untreated, luciferase siRNA–treated and
IXL 144 siRNA–treated PANC-1 cells
48 h after transfection. Columns, mean
of triplicate experiments; bars, SD.
D, induction of apoptosis after IXL
silencing. Percentage of early apoptotic,
late apoptotic, and total apoptotic cells are
shown for untreated, luciferase siRNA–
treated, and IXL 144 siRNA–treated
PANC-1 cells 48 h after transfection.
Columns, mean of triplicate experiments;
bars, SD.
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target gene that is essential for the growth and survival of a subset
of pancreatic carcinomas with 19q13 amplification. Thereby, IXL
has a critical role in pancreatic cancer development and growth
regulation and represents an ideal therapeutic target. However, it is
possible that other genes in this region might also contribute to
pancreatic cancer pathogenesis. Finally, this study shows that the
combination of copy number and expression analysis together with
targeted RNAi screen provides an efficient method for rapid
identification of putative amplification target genes in cancer.
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Pancreatic cancer is a devastating disease with an extremely poor prognosis, and thus, there is a great need for better
diagnostic and therapeutic tools. The 19q13 chromosomal locus is amplified in several cancer types, including pancreatic
cancer, but the possible clinical significance of this aberration remains unclear. We used fluorescence in situ hybridization
on tissue microarrays containing 357 primary pancreatic tumors, 151 metastases, and 24 local recurrences as well as 120
cancer cell lines from various tissues to establish the frequency of the 19q13 amplification and to find potential correla-
tions to clinical parameters including patient survival. Copy number increases were found in 12.2% of the primary pancre-
atic tumors and 9.3% of the cell lines, including those derived from bladder, colorectal, ovarian, and thyroid carcinomas.
Copy number changes were linked to high grade (P ¼ 0.044) and stage (P ¼ 0.025) tumors, and the average survival time
of patients with 19q13 amplification was shorter than that of those without this aberration. Our findings revealed recur-
rent 19q13 amplification in pancreatic cancer and involvement of the same locus as in bladder, colorectal, ovarian, and thy-
roid carcinomas. More importantly, the 19q13 amplifications were associated with poor tumor phenotype and showed a
trend toward shorter survival. VC 2010 Wiley-Liss, Inc.
INTRODUCTION
Pancreatic cancer is a lethal disease, which is
typically diagnosed at an advanced stage when
patients are no more eligible for curative surgery.
Therefore, novel methods for early detection and
better treatment of pancreatic cancer are urgently
needed. Because the molecular mechanisms con-
tributing to the development of pancreatic cancer
are still not fully understood, additional informa-
tion about the biology of pancreatic cancer is
highly valuable and might eventually lead to the
generation of novel tools for the clinical manage-
ment of this disease.
Gene amplification, defined as a copy number
increase of a restricted chromosomal region, is a
typical mechanism for solid tumors to activate
oncogenes and thereby amplified genomic regions
are likely to harbor genes of importance for tumor
development and progression. Excessive dosage
of such genes may provide tumor cells a growth
advantage or confer resistance to various thera-
pies (Albertson, 2006). Identification of amplifica-
tion target genes may offer better diagnostic and
prognostic tools and even better treatment strat-
egies. The ERBB2 oncogene is an excellent
example of an amplification target gene with
well-established clinical significance as a prognos-
tic and predictive marker and a therapeutic target
in breast cancer (Carter et al., 1992). Other well-
documented oncogenes that are activated via
amplification and serve as prognostic markers or
therapeutic targets include MYCN in neuroblasto-
mas (Savelyeva and Schwab, 2001) and EGFR in
gliomas (Etienne et al., 1998). Gene amplification
has been studied widely also in pancreatic cancer,
and a number of presumptive oncogenes have
been pinpointed, such as ARPC1A (Laurila et al.,
2009), EMSY (van Hattem et al., 2008), GATA6
(Kwei et al., 2008), ERBB2, and MYC (Mahla-
ma¨ki et al., 2002).
Genomewide comparative genomic hybridiza-
tion (CGH) surveys have identified multiple
regions of copy number changes in several can-
cers, including pancreatic cancer. They provide a
powerful approach for identifying novel cancer
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genes when combined with further genetic and
functional studies. Our previous array CGH
screen (Mahlama¨ki et al., 2004) revealed a 2.9-
Mb region at 19q13 that is recurrently amplified
in pancreatic cancer. This finding has been sub-
sequently confirmed by several other microarray-
based copy number surveys (Aguirre et al., 2004;
Holzmann et al., 2004; Bashyam et al., 2005;
Gysin et al., 2005; Heidenblad et al., 2005).
Recently, we characterized the structure and
boundaries of the 19q13 amplicon in detail in
pancreatic cancer cell lines and defined a 660-kb
amplicon core region with exceptionally high
level copy number increase (Kuuselo et al.,
2007). This chromosomal region is extremely
gene-rich (Supporting Information Fig. 1). Only a
subset of the genes within this region, such as
MED29 (previously known as IXL), PAF1,
DYRK1B, and PAK4, have been functionally vali-
dated and suggested to represent putative ampli-
con targets (Kuuselo et al., 2007; Moniaux et al.,
2006; Deng et al., 2006; Chen et al., 2008).
In addition to pancreatic cancer, amplification
of the 19q13 chromosomal region has also been
reported in other tumor types, such as ovarian
(Cheng et al., 1992; Bellacosa et al., 1995;
Thompson et al., 1996; Tang et al., 2002), breast
(Kallioniemi et al., 1994; Bellacosa et al., 1995),
cervical (Rao et al., 2004), gastric (Staal, 1987),
and lung cancer (Ried et al., 1994; Kim et al.,
2005). However, these studies have been per-
formed using a variety of technologies, ranging
from chromosomal CGH to different array CGH
platforms, and thus, it is difficult to know
Figure 1. Analysis of 19q13 copy number levels in primary pancreatic tumors by FISH. Examples of
tumors with (A) no copy number increase, (B) gain, (C) polysomy, and (D) amplification are shown. Red
signals correspond to the 19q13 core region and green signals represent the Chromosome 19 centro-
mere probe. Nuclei were counterstained with DAPI (blue). [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
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whether they pinpoint a single common amplicon
or correspond to multiple separate regions of
copy number increase at 19q13. Here, we exam-
ined for the first time the presence of copy num-
ber aberrations at the 660-kb amplicon core
(Kuuselo et al., 2007) in 120 cancer cell lines
originating from various tissues.
In a previous study, we demonstrated using a
small set of 31 tumors that the 19q13 amplifica-
tion is present in about 10% of the primary pan-
creatic cancer cases (Kuuselo et al., 2007). Now,
we evaluated the clinical significance of the
19q13 amplicon core in an extensive sample set
containing more than 500 pancreatic tumors. We
applied fluorescence in situ hybridization (FISH)
to a tissue microarray (TMA) containing 357 pri-
mary tumors of the pancreas, 151 metastases, and
24 local recurrences to determine the 19q13 copy
number levels and to reveal their possible associ-
ation with clinicopathological parameters and
patient survival.
MATERIALS AND METHODS
Patients with Pancreatic Cancer
Primary pancreatic tumor samples and corre-
sponding metastases were obtained from 356
patients who underwent pancreatic surgery at the
Department of General, Visceral and Thoracic
Surgery, University Medical Center Hamburg-
Eppendorf, during the years 1993–2005. Forma-
lin-fixed (buffered neutral aqueous 4% solution)
paraffin-embedded material was used. All slides
from all tumors were reviewed by two patholo-
gists determining the histological type and grade
of the samples (G1 ¼ highly differentiated, G2 ¼
moderately differentiated, and G3 ¼ poorly dif-
ferentiated). The pathologic stage, nodal status,
and metastasis information were obtained from
the primary reports of the Department of Pathol-
ogy, University Medical Center Hamburg-Eppen-
dorf. Follow-up and survival data were collected
by the Department of General, Visceral and Tho-
racic Surgery. The following TNM classification
was used: pT stage, T1 ¼ tumor size " 2 cm,
T2 ¼ tumor size > 2 cm, T3 ¼ tumor growth
into surrounding tissues, T4 ¼ tumor growth into
the stomach, spleen, large bowel, or nearby large
blood vessels; pN stage, N0 ¼ no lymph node
metastases, N1 ¼ metastases in local lymph
nodes; and pM stage, M0 ¼ no distant metasta-
ses, M1 ¼ distant metastases. Median age of the
patients was 62.8 years (range 21–88 years). The
mean follow-up time for ductal adenocarcinomas
was 18.52 months (range 1–74 month). Informed
consent had been obtained from all patients upon
admission to hospital.
Tissue Microarrays
The pancreatic cancer tissue microarray (TMA)
contained a total of 600 samples. These included
357 primary tumors of the pancreas [213 ductal
adenocarcinomas, 54 adenocarcinomas of the
ampulla of Vater, 40 pancreatic endocrine tumors,
33 intraductal papillary mucinous neoplasms
(IPMNs), 15 benign cystic tumors, 1 malignant
cystic tumor, and 1 acinar cell carcinoma], 129
corresponding lymph node metastases, 22 distant
metastases, 24 local recurrences, and a standard
control area containing 40 tumors from other
organs, 10 healthy pancreatic tissues, and 18
healthy tissues from other sites. The cell line
TMA had 120 cancer cell lines representing vari-
ous tissue types and nine cell lines of non-neo-
plastic origin (Supporting Information Table 1).
Fluorescence In Situ Hybridization
To determine the 19q13 copy number levels,
we used a contig of three partly overlapping
locus-specific BAC probes (RP11-67A5, RP11-
256O9, and CTC-488F21) that were previously
shown to correspond to the 660-kb core region of
the amplicon (Supporting Information Fig. 1) and
verified to give a single signal on normal lympho-
cytes (Kuuselo et al., 2007). The BAC clone
DNA was isolated using standard alkaline lysis
method and labeled with Spectrum Orange
dUTP (Vysis, Downers Grove, IL) using random
priming. A chromosome 19 pericentromere-spe-
cific reference probe (RP11-345J21) was labeled
with fluorescein-12-dUTP (PerkinElmer Life
Sciences, Boston, MA) and used as a control.
FISH on TMA was carried out as described
(Andersen et al., 2001) with some modifications.
Briefly, the slides were deparaffinized in three
changes of hexane for 10 min each, dipped twice
in 100% ethanol, treated for 30 min with 0.3%
NaBH4, and rinsed with PBS. Then the slides
were treated for 40 min with Vysis Pretreatment
Solution (Vysis, Downers Grove, IL) at 80#C,
rinsed with H2O, and treated for 20 min with
Vysis Protease at 37#C, followed by Proteinase K
treatment for 10 min at 37#C. Finally, the slides
were washed in increasing series of ethanol (70,
85, and 100%), dehydrated, denatured for 3 min
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at 70#C in 70% formamide/2$ SSC, washed again
in ethanol series, dehydrated, and hybridized
with denatured probes in a humidified chamber
at 37#C for 24 hr. The nuclei were counterstained
with DAPI in Vectashield antifade solution.
Hybridization signals were evaluated using
Olympus BX50 fluorescence microscope (Olym-
pus, Tokyo, Japan), and relative copy numbers
were calculated for each sample as ratios of mean
absolute copy number of the locus-specific probe
versus the reference probe. Forty intact nuclei
were scored per sample. Relative copy numbers
over 1.5 but less than 2 were considered as gains,
whereas relative copy numbers greater than or
equal to 2 were considered as amplifications. Pol-
ysomy was defined as samples with absolute copy
number of the 19q13 locus over five but relative
copy number less than two.
Statistical Analyses
Statistical analyses were done using JMPTM
software (SAS Institute, Cary, NC). All P values
tested were two-sided and P < 0.05 was consid-
ered significant. The Pearson v2 test was used to
assess the relationship between 19q13 copy num-
ber changes (categorized as normal, gain, amplifi-
cation, and polysomy) and the clinicopathologic
parameters T stage, n stage, and tumor grade.
The Kaplan–Meier method was used to visualize
association of 19q13 copy number changes with
cancer-specific survival, and the log rank test was
applied to test the significance between stratified
groups.
RESULTS
The presence of copy number changes at the
19q13 amplicon core was first screened in a set of
120 cancer cell lines representing various tumor
types (Supporting Information Table 1). Ten
(9.3%) of the 107 cell lines with successful
hybridizations displayed increased copy number.
Six of these were amplifications (relative copy
number % 2) and four were gains (relative copy
number >1.5 but <2). Amplifications were
detected in one (OVCAR-3) of four ovarian can-
cer cell lines, three (RT-112, KU-19-19, CRL-
7930) of six bladder, one (SW-48) of twelve colo-
rectal cell lines, and one (ONCO-DG-1) of four
thyroid carcinoma cell lines.
We then determined the frequency of the
19q13 copy number changes in 357 primary pan-
creatic tumors, 151 metastatic lesions (including
both lymph node and distant metastases), and 24
local recurrences. Among the primary tumors,
copy number data were obtained in 303 cases and
12.2% of them had copy number increases (Fig.
1). Gains were detected in 7.3%, amplifications in
3.3%, and polysomy in 1.7% of the cases. Copy
number changes were most frequently observed
in ductal adenocarcinomas and pancreatic endo-
crine tumors (Table 1). In addition, copy number
increase was also detected in one of 15 IPMNs.
Tumor samples with amplification typically
showed a tight cluster of signals with an average
of 3.4-fold copy number increase, but a few cases
with up to 10-fold amplification levels were
observed. The polysomic samples had an average
of five to ten copies of the 19q13 locus per cell,
ranging up to twenty copies.
A total of seven (5.8%) of the 121 metastases
with successful hybridizations showed copy num-
ber increase (Table 1). Of these, three were
amplifications and four cases had gains. Copy
number data were available on a subset of 91
cases where both the primary tumor and a
TABLE 1. Primary Pancreatic Cancer Subtypes and Their Copy Number Status
n
19q13 FISH result
Analyzable (n) Normal (%) Gain (%) Amplification (%) Polysomy (%)
All samples 357 303 87.8 7.3 3.3 1.7
Ductal adenocarcinomas 213 197 86.3 8.1 3.6 2.0
Intraductal papillary mucinous neoplasms 33 15 93.3 0.0 6.7 0.0
Endocrine tumors 40 35 88.6 8.6 0.0 2.9
Cystic/benign tumors 15 6 100 0.0 0.0 0.0
Cystic/malignant tumors 1 1 100 0.0 0.0 0.0
Acinar cell cancers 1 0 – – – –
Adenocarcinomas of the ampulla of Vater 54 49 89.8 6.1 4.1 0.0
Metastases 151 121 94.2 3.3 2.5 0.0
Lymph node metastases 129 100 95.0 3.0 2.0 0.0
Distant metastases 22 21 90.4 4.8 4.8 0.0
Local recurrences 24 18 100 0.0 0.0 0.0
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matching lymph node metastasis were studied.
Among this subset of cases, increased copy num-
ber was detected in four primary tumors and
three corresponding metastases thus showing an
overall concordance of 99% (90/91). Finally, none
of the local recurrences (of a total of 18 analyz-
able cases) showed copy number increases (Table
1). However, 17 of the 18 corresponding primary
tumors also had no copy number change, while
the one remaining case did show copy number
gain.
To evaluate the possible clinical significance
of the 19q13 amplification, the relationships
between copy number data and clinicopathologi-
cal characteristics were examined among the
ductal adenocarcinomas, the most common histo-
logical subtype of pancreatic cancer (Table 2).
Because of the small number of samples, tumors
confined to pancreas (pT1 and pT2) were com-
pared to those that had spread beyond the pan-
creas (pT3 and pT4). Similarly, moderately and
well-differentiated tumors (G1 and G2) were
combined and compared to poorly differentiated
tumors (G3). Copy number increases (including
gains, amplifications, and polysomy) were linked
to both tumor grade and stage (P ¼ 0.044 and P
¼ 0.025, respectively, Table 2). The frequency of
gains and amplifications increased from low/mod-
erate (G1–G2) to high grade (G3) tumors and
from early (pT1–pT2) to late (pT3–pT4) stage
tumors. Actually none of the low-grade (G1)
tumors harbored copy number changes, whereas
11% of Grade 2 tumors and 16.8% of Grade 3
tumors had increased copy number. All of the
tumors with amplification were of Grade 3.
Finally, the Kaplan–Meier analysis among the
ductal adenocarcinomas showed that the survival
of patients having high level copy number
changes (amplifications and polysomy) was some-
what worse than those without 19q13 copy num-
ber changes, but this difference was not
statistically significant (data not shown). Nonethe-
less, the average survival time for the normal
copy number patient group was 26 months,
whereas it was only 16 and 17 months for the
patients with amplification and polysomy,
respectively.
DISCUSSION
Pancreatic cancer is a highly devastating dis-
ease with exceptionally poor prognosis. Conse-
quently, there is a huge need for better
understanding of the biology of this disease and
for identification of novel diagnostic and prognos-
tic markers as well as molecular targets for ther-
apy. Every piece of knowledge about the
mechanisms behind pancreatic cancer develop-
ment may shift us toward novel strategies for
improved clinical applications. To this end, we
evaluated the clinical significance of the 19q13
amplification that was initially discovered by us
and others using genomewide copy number
screens of pancreatic cancer (Mahlama¨ki et al.,
2004; Aguirre et al., 2004; Holzmann et al., 2004;
Bashyam et al., 2005; Gysin et al., 2005; Heiden-
blad et al., 2005). Recently, we characterized this
amplicon in detail in pancreatic cancer cell lines
and in a small set of primary pancreatic tumors
and defined a 660-kb amplicon core region (Kuu-
selo et al., 2007). Here, we studied the clinical
significance of the 19q13 amplification in a large
collection of over 500 clinical pancreatic tumor
samples using FISH to TMAs. We also examined
whether this specific amplicon is present in other
tumor types using more than 100 different cancer
cell lines. The FISH technique is perhaps the
most reliable and accurate method to detect
TABLE 2. Relationship Between the 19q13 Copy Number Changes and the Cancer Phenotype in Pancreatic
Ductal Adenocarcinomas
n Normal (%) Gain (%) Amplification (%) Polysomy (%) P
pT stage pT1 6 83.3 0.0 0.0 16.7 0.025a
pT2 53 92.5 1.9 1.9 3.8
pT3 125 84.8 10.4 4.0 0.8
pT4 9 66.7 22.2 11.1 0.0
pN stage pN0 68 83.8 10.3 4.4 1.5 0.826
pN1 124 87.1 7.3 3.2 2.4
Grade G1 8 100 0.0 0.0 0.0 0.044b
G2 91 89.0 9.9 0.0 1.1
G3 95 83.2 7.4 7.4 2.1
a(T1 þ T2 vs. T3 þ T4).
b(G1 þ G2 vs. G3).
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different types of copy number changes from
chromosomal rearrangements to amplifications
and deletions (Fletcher, 1999). It now represents
a standard diagnostic tool in the classification of
hematological malignancies and in detecting clini-
cally relevant gene amplification events, such as
those involving the ERBB2 oncogene in breast
cancer (Spiridon et al., 2002).
Copy number analysis in an extensive collec-
tion of over 500 pancreatic tumors revealed that
12.2% of the primary cancers had 19q13 copy
number increases. This frequency is in good con-
cordance with our preliminary data from a small
set of 31 tumors (Kuuselo et al., 2007). The copy
number aberrations were divided into three cate-
gories: gains were detectable in 7.3% of the cases,
amplification in 3.3%, and 1.7% of the tumors
were polysomic. Moreover, a concordant copy
number result between a primary tumor and a
corresponding lymph node metastasis was
obtained in 99% of the samples. Surprisingly,
none of the local recurrences showed copy num-
ber changes. However, the number of samples
analyzed was small and more importantly the cor-
responding primaries did not show copy number
aberrations either. Thus, these data do not allow
us to draw conclusions on the possible genetic
differences between the primaries and local
recurrences.
Although amplification of the 19q13 chromo-
somal locus has been previously reported in a
subset of other cancer types, here we character-
ized for the first time the presence of this specific
amplicon core in a large number of cell lines rep-
resenting various tumor types. In addition to pan-
creatic tumors, we found amplification of the
19q13 core region in ovarian, colorectal, urinary
bladder, and thyroid cancer cell lines. These data
now confirm previous studies in ovarian (Bella-
cosa et al., 1995; Cheng et al., 1992; Thompson
et al., 1996; Tang et al., 2002), colorectal (Bardi
et al., 1993), and urinary bladder (Richter et al.,
2000) cancer. However, 19q13 amplification has
not been previously reported in thyroid cancer.
The cell line TMA data now allow rapid identifi-
cation of numerous cell lines that are suitable for
further functional analyses of putative target
genes within the 19q13 amplicon.
Gene amplification has been shown to fre-
quently associate with tumor progression, drug re-
sistance, and poor clinical outcome in a variety of
tumor types (Savelyeva and Schwab, 2001). For
example, amplification of oncogenes, such as
CCND1, EGFR, ERBB2, MDM2, and MYC, has
been associated with high grade breast tumors
(Al-Kuraya et al., 2004), MYCN amplification is a
prognostic factor for patients with neuroblastoma
(Savelyeva and Schwab, 2001), and amplification
of genes such as DHFR and BCR-ABL1 has been
reported to be associated with resistance to anti-
cancer drugs (Albertson, 2006). Now we found
that the 19q13 copy number increases were
linked to both advanced tumor stage and grade in
pancreatic cancer. Similarly, 19q13 amplification
has been previously shown to associate with less
differentiated and more aggressive tumors in
ovarian carcinoma (Bellacosa et al., 1995).
Our results suggest a trend toward shorter sur-
vival time in patients with 19q13 amplification.
The average survival time of patients with high
level copy number increases (amplification or pol-
ysomy) was shorter than the survival time of
patients with normal copy number status,
although this difference was not statistically sig-
nificant. The lack of statistical significance may
be due to the rather small number of tumors with
copy number changes but also on the overall poor
prognosis of pancreatic cancer. In any case, our
data are in concordance with the finding that
high level copy number increases have a greater
impact on tumor development than low level
aberrations (Hodgson et al., 2003). Previously, the
19q13 amplification has been associated with
poor survival of patients with non-small cell lung
cancers (Kim et al., 2005), but there are no other
studies reporting associations of this specific
amplification locus with patient survival. How-
ever, the connection of the 19q13 amplification to
more aggressive and less differentiated tumors
(Bellacosa et al., 1995; Tang et al., 2002) could
support the hypothesis that this amplicon is
indeed associated with poor prognosis.
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